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Abstract
Cell cycle perturbation is a common event in tumorigenesis and the development o f anticancer drug 
resistance. Acquired drug resistance is a significant hindrance in achieving effective cancer 
treatm ent. Thus, understanding o f mechanisms underlying acquired drug resistance is vital to  
develop strategies to  overcome those processes and to improve the survival rates o f cancer patients. 
Moreover, understanding drug resistance can lead to  the discovery o f potential druggable targets 
tha t can contribute towards increasing success o f cancer intervention. In this study, molecular 
mechanisms leading to  acquired drug resistance in various cancer cell lines were investigated. 
Informed by cDNA micro array screens, the cell cycle regulators p57’^ ''^  ^W e e l and Stratifin (SFN) 
were shown to be frequently deregulated in drug resistance. Using Western blotting and qPCR, 
pSy'^ 'P^  was shown to  be downregulated in platinum-resistant ovarian cancer cell lines PEOlCarbR 
and PEOlCisR in comparison w ith  the platinum-sensitive counterpart. downregulation was
due to  epigenetic silencing (hypermethylation o f gene promoter region).Thus, silencing w ith  
siRNA in otherwise drug sensitive cells recapitulated platinum resistance. Interestingly, p57’^ ''^  ^
downregulation conferred collateral sensitivity towards the synthetic CDK inh ibitor drug Seliciclib 
(CYC202). A similar approach was adopted in the study o f W e e l and SFN in taxane resistance. W e e l 
and SFN were downregulated in Taxol-resistant SK-OV-3 and A2780 cell lines compared to  drug- 
sensitive counterparts. Silencing o f Weel in Taxol-sensitive SK-OV-3 decreased the apoptotic 
response to  Taxol treatm ent, but this effect was not seen using SFA/ silencing. I conclude that W e e l 
plays an im portant role in response to  Taxol. However, p53 status is also associated w ith  this 
response. Additionally, examination o f several drug resistant and sensitive pairs o f cancer cell lines 
indicated tha t DNA damage checkpoint and cell cycle regulation are significant factors in mediating 
anticancer drug resistance. Based on the results, the ATR-Chkl-W eel pathway was shown to  be the 
most deregulated pathway in drug-resistant cancer cells. I conclude tha t deregulation o f cell cycle is
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essential to  the adaptive responses and enabling characteristics that result in the drug resistant 
phenotype.
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Introduction
1. Cell cycle and its components
Cells are the building blocks o f every living organism. Cells undergo division and most o f them 
differentiate into specialized cells, which have a specific function. Cell cycle is utilised by the cell to 
divide into tw o daughter cells. This is a highly coordinated and regulated series which becomes 
imbalanced and leads to  either cell death or tum our occurrence. Malfunctions w ith in  cell cycle 
regulation lead to  survival o f damaged or mutated cells resulting in cancer.
1.1 Cell cycle phases
The eukaryotic cell cycle is divided into four non-overlapping phases: Gi, S, G2 and M (Figure 1-1). In 
the Gi phase, cells grow and prepare fo r DNA synthesis. In this phase, diploid cells contain 2n 
chromosomes. Alternatively, cells may stop tem porarily from  dividing and stay in the Go phase, 
which is also referred to  as quiescence state. A fter passing the restriction point at the end o f the Gi 
phase, cells enter the S phase in which DNA duplication occurs. DNA content in diploid cells w ill be 
4n by the end o f this phase. Following S phase, cells w ill enter another gap, G2 which is essential fo r 
the cell as a preparation stage before mitosis. The M phase is the m itotic phase, during which cell 
separate into tw o daughter cells (Foster 2008; Maddika et al. 2007). From here, cells tha t are 
committed to  divide w ill enter cell cycle through Gi while others might d ifferentiate into specialized 
cells.
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Figure 1-1: Cell cycle stages.
1.2 CDKs
Transition of cells from one phase to  another is mediated by the expression of regulatory proteins, 
including cyclin-dependent kinases (CDKs). CDKs are a group o f key regulator proteins, a family o f 
heterodimeric serine/threonine protein kinases (Barbacid et al. 2005). Activation o f CDKs takes place 
through association w ith its partner, the cyclins and phosphorylation o f its T-loop threonine by CDK- 
activating kinase (CAK). Levels o f CDK proteins remain stable throughout the cell cycle while cyclin 
expression fluctuates at different stages of the cycle (Barbacid et al. 2005; Maddika et al. 2007). 
Cyclins shared a conserved 150 amino acid residues termed 'cyclin box', formed by 5 helical regions 
which is responsible fo r binding to  CDKs (Barbacid et al. 2005).
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CDKs have diverse cellular functions. Several important CDKs in the cell cycle are CDKl, 2, 3, 4, 6 , 7, 
10 and 11, which associates w ith  d ifferent cyclins and functions on d ifferent cell cycle stages. In 
proliferating cells, CDK4-cyclinD, CDK6 -cyclinD and CDKS-cyclInC complexes play an im portant role in 
Gi phase by phosphorylating retinoblastoma protein (Rbp). CDK2-cyclinE completes Rbp 
phosphorylation and is im portant in transition from Gi to  5 phase. CDK2 then associates w ith  cyclinA 
throughout S phase progression. CyclinA binds to CDKl in the Gz phase followed by binding o f CDKl 
to  cyclinB in G2 to  M phase transition. CDKIO and C D K ll m ight play a role in mitosis but the ir 
importance is not clearly understood. CDK7 binds to  cyclinH and M a tl to  form  CAK, which binds and 
activates all cell cycle CDKs (Barbacid et al. 2005; Maddika et al. 2007).
1.3 Cyclins
Cyclins as the name implies are proteins w ith  cyclic expression i.e. differentia lly expressed w ith in  the 
specific cell cycle phases, contrary w ith  CDKs whose expression levels are relatively constant (Figure 
1-2). Evans et al. firs t describe them as proteins w ith in embryonic cell cycle which levels rise and fall 
(Evans et al. 1983; Hartley 2008). Further research revealed tha t cyclins are activating partner o f 
CDKs, form ing complexes and acts as regulatory subunits w ith in  the complex. Each specific CDK- 
Cyclin complex corresponds w ith  certain cell cycle phases and promotes cell cycle progression via 
substrate phosphorylation (Golias et al. 2004; Hartley 2008; Stamatakos et al. 2010). Cyclical level o f 
cyclins is a result o f periodic transcription together w ith  rapid protein turnover (Hartley 2008). 
Mitogenic signal received prompts the cell to  synthesize CyclinD, which forms a complex w ith  
CDK4/CDK6 and this correspond w ith Gi cell cycle phase. This CDK-Cyclin complex phosphorylates 
Rbp, which releases transcription factor E2F. Genes transcribed by E2F are im portant in cell cycle 
progression. These genes include CyclinE, which couples w ith  CDK2 and promotes cell cycle 
transition from  Gi to  S phase. CDK2 then forms complex w ith CyclinA fo r S phase progression. CDKl- 
CyclinA/B complex is essential fo r entry into M phase (Hartley 2008; Stamatakos et al. 2010).
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Figure 1-2: Oscillating expression of Cyclins corresponds to cell cycle phase.
Some Cyclins play a vital role in carcinogenesis. Upregulation of CyclinD isoform, CyclinDl is found in 
human oesophageal cancer while CyclinD2 is downregulated in tumours such as sporadic and 
familial breast cancers (Golias et al. 2004). Overexpression of CyclinDl is due to chromosomal 
translocations, gene amplification, disruption o f normal intracellular localization and proteolysis. 
CyclinD also inactivates negative regulators of CDK2-CyclinE, promoting CDK2-CyclinE activity. 
Additionally, CyclinDl is able to  promote gene silencing via recruitment of histone deacetylases and 
histone methyltrasferases which alters chromatin structure. Deregulation o f cyclinD is found in 
parathyroid adenomas, papillary thyroid carcinoma, mantle cell lymphoma and breast cancer which 
is associated w ith metastasis, worse survival and tamoxifen resistance among others (Stamatakos et 
al. 2010). Apart from CyclinD, CyclinA is also found to be overexpressed in several cases of 
hepatocellular carcinoma (Golias et al. 2004). CyclinE overexpression is related w ith carcinogenesis 
and is found to be overexpressed in number of cancers which w ill be explained further in another 
chapter.
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1.4 CKls
Another regulatory proteins expressed during cell cycle are negative regulator o f CDKs, termed 
cyclin-dependent kinases inhibitors (CKls). CKls are im portant signalling pathway components, which 
control cell cycle exit and essential fo r cell d ifferentiation (Zhang et al. 1998). CKls are divided into 2 
families, inh ib itor o f protein kinase 4 (INK4) fam ily and Cip/Kip (CDK inhib itor protein/kinase 
inh ib itor protein) fam ily (Collins and Garrett 2005). The characteristic o f protein sequence 
homologies and putative CDK targets have been considered in arranging CKls into the d ifferent 
families (Nam and Kim 2008). INK4 fam ily includes p lS , p l 6 , p l 8  and p l9  while Cip/Kip fam ily 
consists o f p21^'’’\  p27" '^^  ^and p57' '^^^. INK4 fam ily members inh ibit CDK4 and CDK6  while Cip/Kip 
fam ily members have w ider action by inhibiting CDK/cyclin complexes formed at later stages o f the 
cell cycle (Foster 2008; Nam and Kim 2008) (Figure 1-3). Due to  the ir function as inhibitors to  the cell 
cycle progression, CKls have been proposed to  be tum our suppressors (Kim et al. 2005). Besides 
CKls, CDK kinase activities are also regulated by phosphorylation-déphosphorylation. W e e l and 
M y t l phosphorylate adjacent threonine and tyrosine residues to  inhibit CDK activity while CDC25 
phosphatases reverse this process. Other regulations include folding and subcellular localization 
(Barbacid et al. 2005; Maddika et al. 2007).
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Figure 1-3: CDK-Cyclin complexes in mammalian cell cycle. CDK-Cyclin complexes were regulated by CKls which can be 
grouped into two families: broader-acting CIP/KIP family and more specifically acting INK4 family.
1.5 Cip/Kip family of CKls
Cip/Kip family consists o f p27' '^^  ^and p57'^'’^ .^ p57 '^'^^ is the least studied member of Cip/Kip
family of CKls. Each family member has a conserved domain at the amino-terminal o f the protein 
termed CDK binding-inhibitory domain. The Cip/Kip family has a broader spectrum of action by 
inhibiting w ider range of cyclin/CDK complexes compared to  INK4 family which is restricted to 
inhibition o f CDK4 and CDK6  activities (Beretta et al. 2005; Zhang et al. 1998). INK4 family members 
exhibit their inhibitory effects at the early phase o f the cell cycle, while Cip/Kip fam ily members 
inhibit cell cycle progression at several cell cycle checkpoints (Kim et al. 2005). However, the ir 
inhibitory actions are dose-dependent since at a low level, they bind to  and promote the assembly of 
CDK-Cyclin heterodimer complexes (Pateras et al. 2009).
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p27'^'‘^  ^is expressed in a wide variety o f d ifferent epithelial and non-epithelial tissues. Its expression 
usually correlates w ith poor cancer prognosis. p57'^"’  ^on the other hand is more tissue-specific 
(Rosenberg et al. 2001). The importance o f Cip/Kip fam ily actions in controlling proliferation during 
development, d ifferentiation and response to  cellular stresses has been widely described. Biological 
functions o f each fam ily member are d ifferent from  each other, thus d ifferent anti-proliferative 
signals tend to  cause elevated level o f only some o f them. p21^'^^ responds to  DNA damage in Gi and 
Gz, causing cells to  arrest as it is an im portant target o f p53. Expression level o f p27' '^'^  ^is usually 
elevated in mitogen-starved cells and other quiescent cells. As cells enter the cell cycle, p27" '^^  ^
protein level is quickly downregulated. p57'^'’’  ^have the weakest CKI activity o f the Cip-Kip family 
members. p57'^ ''^  ^has a significant role in regulation o f the cell cycle during embryonic development 
and have been shown to  be indispensable fo r embryonic development (Beretta et al. 2005; Besson 
et al. 2008).
1.6 Regulation of Cyclins and CKls
Periodic degradation o f Cyclins and CKls is im portant in controlling the tim ing o f CDK activation. This 
mechanism is promoted by the ubiquitin-proteosome system (Rodier et al. 2008). Selective 
recognition and degradation o f protein by the 26S proteosome begins w ith  enzymatic tagging of 
protein w ith  a polyubiquitin chain. The tagging is a collaborative result o f ubiquitin-activation 
enzyme (El), ubiquitin-conjugation enzyme (E2) and ubiquitin ligase (E3). E3 provides specificity o f 
target proteins (Kamura et al. 2003; Kitagawa et al. 2009). E3 ubiquitin ligases associated w ith  
tumours are categorized into several groups: - HECT, single RING, Skp l/C ull/F -box (SCF), ECV and 
Cul-4. Two major E3 types involved in cell cycle control are SCF complexes and the anaphase- 
promoting complex/cyclosome (APC/C), the first is involved in Gi-S progression while the la tter plays 
an im portant role in the anaphase and cell cycle exit from  M phase into Gi (Kamura et al. 2003; 
Kitagawa et al. 2009; Rodier et al. 2008).
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Another mechanism o f Cyclin and CDK regulation comes from  MicroRNAs (miRNA/miR). miRNAs are 
recently discovered as the regulators o f gene expression and is classified as an epigenetic event that 
helps in controlling gene expression. miRNAs are noncoding single-stranded RNAs w ith  the ir ability 
to  bind to  the 3' untranslated region o f target mRNAs resulted in mRNA cleavage or translation 
inhibition. Due to  its ability to  bind both complimentary and imperfect complimentary sequences, 
miRNA can regulate multiple targets. miRNAs is thought to  regulate approximately more than 30% o f 
human genes and is essential in regulating normal and pathological phenotypes (Borriello et al.
2011; Lopez et al. 2009).
2. Restriction point
Mitogenic signals are required fo r the cell to  undergo cell division. There is a stage in the cell cycle 
where these signals are no longer required fo r the cell to  divide, called the restriction point and 
begins at late Gi phase. Cells tha t have passed this point w ill progress into S phase. Rbp in 
combination w ith  the transcription factor E2F plays a role in restriction point; thus completion o f the 
Gi phase. E2F is a transcription factor crucial fo r expression o f genes and the ir corresponding 
proteins needed fo r cell cycle progression from Gi to  S phase, such as cyclinE and DNA polymerase 
subunits. In its hypophosphorylated state, Rbp binds to E2F and renders it inactive. M itogenic signals 
received by the cell at early Gi phase w ill increase production o f cyclinD. CyclinD activates CDK4 and 
CDK6 by binding to these CDKs and forms complex w ith them. This CDK activation promotes 
phosphorylation o f Rbp. Hyperphosphorylated Rbp releases E2F, which in turn  activates 
transcription o f genes needed to  enter S phase, including CyclinE by binding to  the promoter region 
o f those genes. In turn, irreversible inactivation o f Rbp is carried out by CyclinE, which forms a 
complex w ith  CDK2. This event corresponds to the restriction point (Foster 2008; Malumbres and 
Barbacid 2005; Sun et al. 2007) (Figure 1-4).
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Figure 1-4: Restriction point between and S phase of the cell cycle. Phosphorylation of Rbp by CDK4/6-Cyc!inD and 
CDK2-CyclinE release E2F1 transcription factor subsequently results in S phase progression from  G .^
3. Cell cycle checkpoints
There are several checkpoints w ithin the cell cycle in which the cell cycle progression may arrest in 
response to stress, fo r example DNA damage. These checkpoints enable DNA repair or activation of 
cell death mechanism if the damage cannot be repaired. Cell cycle checkpoints also prevent 
daughter cell from inheriting faulty DNA copies. These checkpoints exist at Gi to  control entry into S 
phase, inter-S phase (halts S phase progression) and G2M phase (to control entry into mitosis) (Curtin 
2012) (Figure 1-5). Gi checkpoint exists in order to  ensure tha t DNA synthesis machinery is ready to 
enter S phase and the DNA template is undamaged (Gatti and Zunino 2005). DNA damage that leads 
to  stalled replication forks or depletion of nucleotides leads to inter-S phase checkpoint activation 
while G2 M phase checkpoint is activated if cell suffered DNA damage that threatens DNA integrity 
(Gatti and Zunino 2005).
1 0
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The main player regulating Gi checkpoint is ATM(ATR)/Chk2(Chkl)-p53/MDM2-p21 pathway. p53 is 
directly phosphorylated by ATM/ATR upon DNA damage and can be additionally phosphorylated by 
Chk2/Chkl. Apart from  p53, these proteins also targets MDM2, a ubiquitin ligase targeting p53 for 
degradation. These events result in accumulation, stabilization and increase in transcriptional 
activity o f p53. p53 promotes transcription o f CKI p21^'’’  ^thus causing Gi arrest via inhibition o f 
CDK2-CyclinE activity. CDK2-CyclinE inhibition also prevents cell from  passing through restriction 
point and results in a sustained Gi blockade (Kastan and Bartek 2004).
Contrary to  ATM and Chk2 expression which are relatively constant throughout cell cycle 
progression, ATR and Chkl expression and activities reaches peak nearing the end Gi to  S phase 
transition as a result o f E2F activity (Kastan and Bartek 2004). E2F also induces CDC25A, a specialized 
phosphatase essential in controlling S phase progression and also entry into mitosis by removing 
inhibitory phosphorylation o f CDK2-CyclinE, CDK2-CyclinA and CDK2-CyclinB (Karlsson-Rosenthal and 
M illar 2006). Regulation o f CDC25A by Chkl and Chk2 ensures appropriate level o f CDC25A during 
cell cycle progression. DNA damage sustained during late Gi leads to  increased activity o f Chkl and 
Chk2, leading to  downregulation o f CDC25A activity which halts cell cycle progression during Gi to  S 
phase transition, S and Gi phases (Kastan and Bartek 2004).
DNA polymerase a initiates DNA replication during S phase. Its recruitment onto chromatin is 
promoted by CDC45 protein, which is activated by CDK2. DNA damage during S phase downregulates 
CDK2 activity and subsequently blocks the loading o f CDC45 onto chromatin, resulting in the 
inhibition o f a new DNA synthesis complex. ATM-mediated phosphorylation o f several other target 
proteins also leads to  S phase checkpoint activation. Apart from  preventing new DNA synthesis, S
1 1
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phase checkpoint is im portant in the prevention o f DNA breaks resulting from  DNA adducts 
form ation by protecting the integrity o f the stalled replication forks (Kastan and Bartek 2004).
DNA damage 
/ \
y
CyclinD CyclinE CyclinE/A CyclinB
Figure 1-5: DNA damage causes activation of cell cycle checkpoints via cell cycle regulators (after Curtin 2012).
The main target o f G2 M phase checkpoint is CDKl-CyclinB complex. By inhibiting CDKl-CyclinB 
activity, G2 M phase checkpoint prevents mitosis initiation of a cell suffering from  DNA damage either 
during G2 phase or during DNA damage carried over from previous S or G% phase. CDKl-CyclinB, 
which is also known as mitosis-promoting factor (MPF) promotes cell cycle progression from G2 to  M 
phase. Various proteins regulate MPF, including ATM/ATR-Chk2/Chkl-Weel/SFN pathway (as 
negative regulators) and CDC25 phosphatases as positive regulators (Figure 1-6). Apart from  these 
proteins, DNA-damage induced mechanisms also targets polo-like kinases (PLK) 3 and 1, which are 
an upstream regulators of CDC25 and/or MPF. S phase checkpoint regulators such as 53bp l and
1 2
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BRCAl also play a role in G2 M checkpoint. This checkpoint serves as an interesting target for 
development o f cell cycle inhibitors, since most cancers are known to  have faulty GiS checkpoint. 
Inhibition o f G2M checkpoint in cancer cells might sensitize them to the DNA damaging agents while 
sparing normal cells w ith  an intact GiS checkpoint (Kastan and Bartek 2004).
DNA
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Nuclear
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Figure 1-6: Regulation of CDKl-CyclinB (MPF) at G^M cell cycle checkpoint. DNA damage causes activation of DNA damage 
signalling pathway and results in cell cycle arrest via downregulation of MPF activity. MPF is also regulated by CKls.
4. Hallmarks of cancer
Hallmarks of cancer encompass several biological changes acquired during cancer development. Six 
o f the well-known hallmarks of cancers are sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, inducing angiogenesis, enabling replicative im m ortality and 
activating invasion and metastasis (Hanahan and Weinberg 2011; Schulz 2007). These hallmarks of 
cancer provide foundation fo r understanding the cancer biology. Information about the causes of 
cancer increases w ith research over time thus fu rther provide us w ith new emerging hallmarks of
13
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cancer. Two o f these emerging hallmarks are deregulating cellular energetic and avoiding immune 
destruction. Tumour-promoting inflammation, genome instability and mutation are classified as 
enabling characteristics o f neoplasia (Hanahan and Weinberg 2011).
Of all hallmarks mentioned previously, evading growth suppressors have a direct link to  cell cycle 
deregulation. Two bona fide  tum our suppressors are Rbp and TP53 (tum our protein 53, p53). Both 
control a diverse amount o f cell cycle regulations. Whereas Rbp transduces signals originating from 
outside the cell, p53 is an intracellular stress and abnormality sensor. p53 activation can results in 
e ither cell cycle arrest or apoptotic cell death. It is a highly regulated event tha t depends on the 
severity o f damage and the level o f various vital components o f cell growth including nucleotide 
pools, growth promoting signals, glucose and oxygenation. There is an underlying redundancy 
mechanism exists in the cell tha t enables compensation fo r the loss o f p53 and Rbp function as cell 
proliferation regulators. Experiments in chimeric mice reveal tha t p53 and Rbp null mice undergo 
normal development and do not have abnormalities until later in life. This mechanism is im portant in 
preventing abnormal cell replication in the absence of these critical key regulators (Hanahan and 
Weinberg 2011).
Evading growth suppressors is also closely related w ith  resisting cell death. This is shown by p53 role 
in orchestrating apoptosis. p53 is one o f the prominent key players in tumorigenesis. p53 promotes 
apoptosis via upregulation o f Bim, Noxa and Puma BH3-only proteins depending on the in itia tor 
events. The events tha t lead to  p53 activation are chromosomal abnormalities, inadequate level o f 
survival signals and hyperactive oncoproteins signalling which can be neutralized by antiapoptotic 
factors. In order to  lim it or evade apoptosis, cancer cells have developed several strategies w ith  loss 
o f p53 being the most common one. Others include overexpression o f antiapoptotic regulators or
14
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survival signals, downregulation o f proapoptotic signals and bypassing the extrinsic ligand-induced 
death pathway. Alternatively, these strategies reflect a myriad o f apoptosis-inducing signals 
encountered by cancer cells during the ir malignant transformation. The idea o f apoptotic machinery 
and apoptotic evasion strategies has been widely accepted starting the beginning o f the last decade. 
Since then, other forms o f cell death have been incorporated as part o f defensive mechanism against 
carcinogenesis (Hanahan and Weinberg 2011).
Genome instability has become the latest enabling characteristic o f neoplasia, paving the path fo r 
the transformations o f normal cells into malignant cancer cells. It is generally described as the 
inability o f a cell to  accurately pass on its genome to  daughter cells caused by mutations in tum our 
suppressor genes and chromosome rearrangement (chromothripsis). Three mechanisms leading to  
genome instability are microsatellite instability, nucleotide excision repair (NER)-related instability 
and chromosome instability (Coschi and Dick 2012). M icrosatellite is DNA sequences which have one 
specific base repetition in a row in a certain number o f repetitions, fo r example ten thymidines in 
one sequence (Curtin 2012). M icrosatellite instability results from  uncorrected DNA replication 
errors caused by a defective mismatch repair mechanism and produces alteration o f microsatellite 
length (Bouwman and Jonkers 2012; Curtin 2012). NER-related instability occurs w ith  a failure o f 
removal and replacement o f UV-damaged nucleotides. Finally, chromosome instability is a result o f 
gain or loss o f either a small part o f chromosome (segmental chromosome instability) or the whole 
chromosome (whole chromosome instability). Segmental chromosome instability also includes 
alteration in chromosome structure that does not change chromosome copy number, such as 
translocation and inversion. However, whole chromosome instability w ill leads to  aneuploidy if 
sustained through continual cell division (Coschi and Dick 2012).
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4.1 Cell cycle alterations in cancer
In human cancers, mutation o f CDKs is infrequent (Malumbres and Barbacid 2005). However, there 
is a case o f miscoding m utation in CDK4 leading to  its resistance towards inhibition by INK4 CKls. 
Translocation o f CDK6 gene near the immunoglobulin loci was reported in several cases o f splenic 
marginal zone lymphoma and B-cell lymphoma. However, alterations in upstream regulators o f CDKs 
(such as CKls and Cyclins) or its substrates (for examples Rbp and p53) are common. These 
alterations are the results o f mutations or epigenetic alterations (Chen et al. 2012; Malumbres and 
Barbacid 2005). The Gi checkpoint is frequently altered, thus cancer cell depends more on the S and 
Ga checkpoints to  avoid cell death caused by damaged DNA (Chen et al. 2012; Kawabe 2004). W ithin 
the Gl checkpoint, CDK4/6-CyclinD-INK4-Rbp pathway is commonly deregulated in cancer. W ild-type 
Rbp is found in most cancers, however in some drug-resistant cancers alteration in Rbp do occurs. 
M utation of one Rbp allele together w ith  somatic inactivation o f the other allele leads to  
retinoblastoma. INK4 family member pie"^”^ ®^ inactivation in cancer is associated w ith  several 
mechanisms, such as gene deletion, point mutation and transcriptional silencing via 
hypermethylation. The inactivation o f pis"^"^^^ results in upregulation o f CyclinD-associated kinases 
activity, providing escape from  senescence and growth advantage to cancer cells. Apart from  pis"^' '^*^ 
downregulation, overexpression o f CyclinD is also common (Massague 2004; Shapiro 2006). 
Mechanisms of CyclinD overexpression include gene rearrangement and amplification, alternative 
splicing and mutations. In breast cancer, CyclinD is the main mediator fo r tumorigenesis originating 
from  Ras or Neu oncogenes. In parathyroid carcinoma, CyclinD gene undergoes inversion at 
I lp l5 ;q l3  while translocation t ll;1 4 (q l3 ;q 3 2 ) o f the gene is reported in mantle-cell lymphoma and 
multiple myeloma. As a consequence o f the translocation, the coding region o f CyclinDl is 
juxtaposed to  the gene o f immunoglobin heavy chain resulting in high CyclinDl expression in 
lymphoid cells. Alternative splicing produces CyclinD variant that is unable to  be exported out from 
the nucleus and contributes to  the oncogenicity in the m ajority o f mantle-cell lymphoma. M utations 
at T286 residue o f CyclinDl prevents nuclear export and promotes stabilization o f the protein. This
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m utation is reported in endometrial carcinoma. Culmination o f downregulation and
overexpression o f CyclinD is associated w ith  higher activity o f CDK2-CyclinE and phosphorylation and 
inactivation o f Rbp (Shapiro 2006). Other cell cycle deregulations in cancers are fo r examples, 
upregulation o f CyclinE and expression o f low molecular weight CyclinE expression, downregulation 
o f CKI pS?' '^’^  ^ upregulation o f Skp2 and deregulation of effector molecules such as W e e l and 
Stratifin (14-3-3a,SFN) which w ill be discussed more in other chapters.
4.2 Conventional cancer treatment
Depending on the classification o f cancers, cancer treatm ent w ill include surgery, irradiation, drug 
treatm ent or a combination o f the stated treatments. For localized cancers, surgery and irradiation is 
the treatm ent o f choice while fo r leukaemias, lymphomas, locally advanced carcinomas, soft tissue 
cancers and metastatic cancers, drug treatm ent is preferable. In cancer treatm ent, adjuvant therapy 
refers to  chemotherapy or irradiation follow ing tum our removal via surgery, aimed to  attack residual 
tumours. Alternatively, neo-adjuvant is chemotherapy given before surgery to  reduce tum our size 
and assist in complete tum our removal. First line therapy is a standard chemotherapy regime given 
to  cancer patients, and in case o f relapse, second line therapy is given. Some cancers have high 
susceptibility to  drugs used in chemotherapy or irradiation, however others do not respond well. 
Some cancers such as ovarian cancer is sensitive to  its firs t line therapy but some do relapse and 
acquire resistance towards drugs used previously to  trea t them. Some contemporary anti-cancer 
drugs frequently used can be divided into several classes: drugs tha t binds to  the DNA (for examples 
platinum compounds, alkylating agents), nucleoside analogs or nucleotide biosynthesis inhibitors (5- 
fluorouracil (5-FU), S'-aza-deoxycytidine), topoisomerase inhibitors (topotecan), m icrotubule- 
binding agents (Taxol) and biological agents (tamoxifen) (Schulz 2007) (Table 1-1).
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DNA-binding agents are fu rther classified into several types based on the ir mode o f action. They are 
radiomimetics, alkylating agents, topoisomerase inhibitors and antimetabolites (Indovina and 
Giordano 2010). Radiomimetics caused similar damage to  DNA as ionizing radiation. Alkylating 
agents or crosslinking agents such as cisplatin is a molecule w ith  tw o reactive groups that can react 
w ith  tw o groups in DNA to  cause intrastrand or interstrand crosslinks. Antimetabolites are agents 
tha t resemble a normal precursor or cofactor (usually fo r DNA synthesis) which interfere w ith  the 
normal metabolic process, examples are nucleoside and folate analogs (Curtin 2012). Although these 
agents are widely used as chemotherapeutic agents, they possess several disadvantages. They 
lacked target specificity, thus also affecting normal cells especially w ith  high proliferative nature 
(such as epithelia o f the gastrointestinal tract and hair follicle) as well as cancer cells. This nature of 
non-specific target is manifested by side effects suffering by patients receiving treatm ents w ith  
these agents, such as gastrointestinal irrita tion and baldness. In several cases, some patients do not 
respond to  treatm ent using these agents and some other develops resistance towards those agents 
after a while (Indovina and Giordano 2010).
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DNA-binding agents Cisplatin,
carboplatin
Direct binding to  the DNA, reacts w ith  DNA bases 
causing intrastrand and interstrand crosslink, 
u ltim ately blocks DNA replication
Nucleoside 
analogues/nucleotide 
biosynthesis inh ibitors
5-FU, S'-aza- 
deoxycytidine
Limiting synthesis o f deoxynucleotide 
triphosphate precursors. Additional function o f 
5'-aza-deoxycytidine is as a demethylating agent 
via interaction w ith DNA methyltransferases
Topoisomerase inh ib itors Topotecan,
etoposide
Binds to  and inhibit enzymes (topoisomerases) 
involved in DNA replication. Also part o f DNA- 
binding agents
M icrotubule-binding agents Taxol Block assembly o f or disrupt existing m icrotubuli 
or block m icrotubuli turnover, causing disruption 
in mitosis, intracellular vesicle transport and cell 
m igration
Biological agents Tamoxifen,
interferons
A diverse group o f compounds tha t do not 
directly interfere w ith  basic cellular functions; 
acts on signalling pathways controlling cell 
proliferation and differentiation
Table 1-1: Anti-cancer drugs frequently used in treating cancers (Schulz 2007).
4.3 Drug resistance
Some cancers respond well to  chemotherapy while others do not. This clinical drug resistance can be 
either de novo or acquired in origin. Primary or de novo resistance is a pre-existing condition o f 
cancer present during diagnosis that leads to  the failure to  respond towards firs t line chemotherapy. 
De novo resistance can be further divided into intrinsic and extrinsic. Intrinsic de novo resistance is 
caused by random genetic mutations already presents in the cell itself that confers survival 
advantage to  the cell upon therapy. Extrinsic de novo resistance is caused by extrinsic factors such as 
cell environment tha t offers protection to  cancer cells from  being affected by therapies. Extrinsic de 
novo resistance or environment-mediated drug resistance (EM-DR) is fu rthe r sub-divided according
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to  the type o f environmental factors involved in mediating the resistance. Soluble factor-mediated 
drug resistance (SFM-DR) is extrinsic de novo resistance facilitated by soluble factors such as 
cytokines, chemokines and growth factors. Adhesion o f cancer cells to  stromal fibroblasts or to  
components o f extracellular matrix, which results in cancer cells being protected from  therapies, is 
called cell adhesion-mediated drug resistance (CAM-DR). EM-DR is thought to  play a major role in 
minimal residual disease and providing cancer cells w ith  protective environment leading to  the 
development o f acquired resistance (Meads et al. 2009). Acquired or secondary resistance originates 
from  natural selection o f cancer cells tha t sequentially acquired advantageous (epi)genetic 
alterations which accumulates over tim e after therapy (Baird and Kaye 2003; Bouwman and Jonkers 
2012; Meads et al. 2009). These alterations result in chemoresistance to  previously utilised 
chemotherapy agents. Acquired resistance commonly occurs to  cancers which successfully 
responded to  the initial treatm ent (Baird and Kaye 2003; Bouwman and Jonkers 2012). According to  
oligonucleotide microarray analysis performed by Hazlehurst et al. (2003) on myeloma cell lines, 
acquired resistance phenotype showed higher gene expression changes in comparison w ith  CAM-DR 
phenotype albeit producing similar level o f protection against apoptosis induced by melphalan 
treatm ent (Hazlehurst e t al. 2003; Meads et al. 2009).
4.3.1 Mechanisms of drug resistance
Failure o f cancers to  respond to  a specific drug treatm ent can be attributed to  tw o  general causes: 
host factor and genetic or epigenetic alteration in cancer cells. These w ill lead to  reduced drug 
uptake or increased in drug efflux. Host factor includes poor absorption, rapid metabolism or 
increased drug excretion, sub-optimal dose o f drug, alteration in host-tumour environment and 
decreased access to  cancer site caused by bulky tumour, high molecular weight drugs or low tissue 
penetration (Baird and Kaye 2003; Gottesman 2002). Activation o f oncogenes or silencing o f tum our 
suppressor genes are among (epi)genetic alterations acquired by cancer cells, which leads to
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chemoresistance (Gottesman 2002). Additionally, tum our cells are characterized by a high degree o f 
genomic instability and may readily have genetic alterations in genes involved in drug resistance 
mechanisms (Bouwman and Jonkers 2012).
According to  Gatti and Zunino (2005), chemoresistance mechanisms can be broadly divided into 
three main groups. These mechanisms are intracellular defence mechanisms, alteration o f drug- 
target interactions and cellular response tha t mediates chemoresistance. Intracellular defence 
mechanisms that caused chemoresistance includes alteration in metabolism and/or subcellular 
d istribution, alteration to  drug transporters such as p-glycoproteins and human multidrug 
resistance-associated proteins (MRPs), and upregulation o f glutathione (GSH)-dependent system 
components. Mutations or changes in level o f target proteins contribute to  alteration o f drug-target 
interactions. Finally, cellular response tha t mediates chemoresistance includes increased DNA repair 
and tolerance towards drug treatm ent, development o f resistance towards apoptosis and cell cycle 
mediated drug resistance (reviewed by Gatti and Zunino 2005). Figure 1-7 summarize mechanisms o f 
drug resistance in cancer.
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Figure 1-7: Tumour cells treated with drugs will respond with either sensitivity or resistance. Sensitivity to  drugs used w ill 
results in cell death while resistance towards drug treatm ent can either originate de novo or acquired after several rounds 
of treatment. This chemoresistance phenotype can be due to several common mechanisms.
Taxanes and platinum compounds (for example cisplatin and carboplatin) (Figure 1-8) are the most 
commonly used chemotherapeutic agents in cancers, especially in ovarian cancer. Thus, acquired 
chemoresistance towards these agents are not unheard of. Taxol and platinum compounds d iffer in 
the ir mode o f action and resistance mechanisms that arise from these agents are d ifferent in terms 
o f targeted cell cycle phases. Taxol affects G2M phase by interfering w ith microtubule dynamics 
while platinum compounds induce DNA adducts form ation that interferes w ith  DNA replication 
machinery at Gi and S phase (Shah and Schwartz 2001). The mode o f action o f these agents and 
mechanism of resistance are fu rther detailed in the subsequent chapters.
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Figure 1-8: Chemical structure of paclitaxel (taxane) and platinum compounds used in this study. Two platinum 
compounds, cisplatin (a) and carboplatin (b) were used in the study of platinum-resistant cancer while Paclitaxel (Taxol™) 
(c) was utilized in Taxol-resistant cancer study.
4.3.2 Cell cycle-mediated drug resistance
Certain types o f chemotherapeutic agents produce a cell cycle phase-specific effect. Some examples 
o f these agents are Taxol that causes G2 M cell cycle arrest and camptothecins that maximally target 
cells in 5 phase (Gatti and Zunino 2005; Shah and Schwartz 2001). In combination therapy where tw o 
agents are utilized to  target a certain tumour, the usage o f cell cycle phase-specific agents may 
sometimes be ineffective. This is due to  the effect o f the first agent, which alters the tum our's cell 
cycle and produces a cell cycle condition tha t is not in favour o f the second, cell cycle phase-specific 
agent. This phenomenon is called cell cycle-mediated drug resistance. To put it concisely, cell cycle- 
mediated drug resistance is relative insensitivity to  phase-specific agents due to the position o f the 
cell in the cell cycle (Gatti and Zunino 2005; Shah and Schwartz 2001).
Several methods can be utilized to  study the cell cycle-mediated drug resistance. Shah and Schwartz 
(2001) have listed methods such as the isobologram, modification o f isobologram method by Steel 
and Pecham, Webb's fractional product method, surviving fraction and Chou and Talalay's 
combination index method as scientific approaches to  study drug synergy or antagonism (Shah and 
Schwartz 2001). Chou and Talalay's combination index method is employed in this study to  look at
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the combination effect o f platinum compound w ith  synthetic CKI drug seliciclib on drug-resistant 
cells. This method is fu rther explained in Chapter 2 (Materials and Methods).
5. Epigenetic mechanisms in cells
Epigenetic mechanisms can be translated as mechanisms tha t results in stable inherited patterns of 
gene expression in somatic cells w ithout changes in the content or sequence o f genomic DNA. 
Several mechanisms that are included in this category are X-inactivation in female cells, genomic 
imprinting, chromatin remodelling, post-transcriptional histone modification, DNA méthylation and 
miRNAs (Feinberg and Tycko 2004; Schulz 2007). Genomic imprinting is involved in selective 
expression o f several genes. In most cases, genes are expressed in equal strength from  both alleles 
inherited from  m other (maternal) and father (paternal). However fo r approximately 50 selected 
genes, the ir expression differs between the alleles either in every tissue or in selected tissue and 
may be qualitative or quantitative (Schulz 2007). CKI p57' '^'^  ^expression is an example o f genomic 
imprinting in action and w ill be explained fu rthe r in another chapter.
Other epigenetic mechanisms are im portant in controlling gene expression. Modification of 
chromatin in the regulatory regions o f the gene is needed in order to  allow access to  DNA sequence 
by transcription complex, which in turn  initiate gene transcription. This is regulated via concerted 
action o f DNA méthylation and histone modification (Schulz 2007; Seidel et al. 2012). DNA 
méthylation is vital in determining expression status o f a gene. Generally, the prom oter o f an 
actively transcribed gene is unmethylated. Promoter méthylation results in gene silencing and this 
phenomenon are observed in X-inactivation and in downregulation o f certain genes in cancers. DNA 
méthylation in mammals is restricted to  the 5'-position o f cytosine residues and only to  those in CpG 
dinucleotides. CpG islands are DNA sequences in which higher CG contents can be observed
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compared to  the rest o f the genome, usually around the transcriptional start site o f genes and 
associated w ith housekeeping genes (Lopez et al. 2009; Schulz 2007). Méthylation o f CpG 
dinucleotides is carried out by enzyme DNA methyltransferases (DNMTs). Four main isoform o f 
DNMT exists. DNM Tl is often known as the maintenance methyltransferase responsible fo r the 
conservation o f methyl marks during DNA replication. DNMTS A and DNMT3B are involved in 
méthylation o f new sites at the sequence previously unmethylated {de novo DNA méthylation) while 
DNMT3L is the catalytically inactive isoform. These enzymes are responsible in establishing DNA 
méthylation pattern during development (Schulz 2007; Seidel et al. 2012).
Histone modification is thought to  play an additional role in controlling transcription. Generally, 
hyperacetylation is a sign of transcriptionally active chromatin. Two opposing enzymes regulate 
acétylation status o f a chromatin: Histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) (Woo et al. 2007). HDACs remove acetyl groups from  the lysine residues o f target proteins, 
in this case, histones. Apart from  histones, HDACs also target other proteins such as nuclear 
transcription factors and cytoplasmic proteins. HDACs are classified into four classes (Class I, II, III 
and IV) based on the sequence homology, cellular localization and activity (Seidel e t al. 2012).
5.1 Epigenetic alteration in cancers
In cancers, alteration in méthylation status is commonly observed. These alterations are 
hypomethylation and hypermethylation and can occur w ith in the same cell. Hypomethylation is 
described as diminished overall DNA méthylation compared to  normal status. Frequently, 
hypomethylation occurred throughout/globally across the genome. Global hypomethylation could 
lead to  expression o f otherwise transcriptionally silenced genes. Examples o f these genes are 
oncogenic HRAS, CyclinDZ and multidrug-resistance gene MDRl (Feinberg and Tycko 2004). 
Additionally, hypomethylation has been shown to  affect chromosome instability, which is linked to
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progression of carcinogenesis. In contrast, specific hypermethylation o f several genes are common 
which results in stable silencing o f the gene (Figure 1-9). Hypermethylation was shown to be as 
effective as mutations in inactivating tum our suppressor genes (Lopez et al. 2009; Schulz 2007). 
Some cell cycle regulatory genes that are silenced due to  promoter hypermethylation include RBI 
which encodes Rbp, CDKN2A (pl6'^"^'), CDKN2B (pis""^^®), CDKNIC Weel and SFN.
Promoter hypermethylation o f CDKN2A was shown to be an early event that leads to the 
progression o f lung cancer. Other genes involved in DNA repair, apoptosis, cell adhesion and 
angiogenesis are among genes that are also affected by aberrant promoter hypermethylation in 
cancers (Feinberg and Tycko 2004; Lopez et al. 2009).
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Figure 1-9: Hypermethylated CpG islands are a common feature of cancers. Hypermethylation of prom oter sequences 
prevents expression of downstream genes.
Several properties of DNA hypermethylation make it an attractive target fo r development o f 
biomarkers. Firstly, hypermethylation o f most genes is rarely found in normal cells.
Hypermethylation o f certain genes are acquired en route to carcinogenesis, thus it is cancer-specific. 
Secondly, methylated DNA is also chemically stable and assays developed fo r its detection are highly 
sensitive and user-friendly w ith wide variety of sample types that can be used to  harvest genomic 
DNA, for example blood or small tissue biopsies. These properties also make gene hypermethylation.
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a suitable candidate fo r screening and helping in determining early treatm ent strategies. Other 
possible usage o f hypermethylation profiles are in determining tum our prognosis and cancer relapse 
(Lopez et al. 2009).
Apart from  abnormal méthylation status, alteration in acétylation pattern also contributes to  the 
development o f cancers. Several mechanisms have been identified as a contributor to  the 
deregulation o f normal acétylation status. Overexpression o f HD AC isoforms are observed in a 
certain type o f cancers. HDACl and HDACS isoforms were overexpressed in some ovarian cancers 
while HDACS and HDAC9 overexpression were found in medulloblastoma. Various cancers show 
loss-of-function mutations o f HD AC isoform genes, which leads to  the ir inactivation or abolished 
the ir cellular localization. Finally, HDAC abnormal recruitment to  gene prom oter by fusion or 
chimeric proteins frequently found in leukaemia, results in gene silencing and tumorigenesis via the 
arrest o f normal haematopoietic cell d ifferentiation (Seidel et al. 2012).
5.2 Chromatin-modifying agents
Chromatin-modifying agents (CMAs) are developed w ith  the aim to  restore normal epigenetic gene 
regulations. CMAs are used either singly or in combination w ith  other CMAs. Currently only few  
CMAs were approved to be used clinically. There are tw o groups o f CMAs, DNMT inhibitors (DNMTi) 
fo r example 5-azacytidine; and HDAC inhibitors (HDACi) such as Trichostatin A (TSA) w ith  d ifferent 
mode o f action (Figure 1-10). 5-azacytidine was approved as a treatm ent agent fo r myelodysplastic 
syndrome and currently in clinical trials fo r several other types o f leukaemias (Seidel et al. 2012). 
Contrarily, undesirable chemical properties o f TSA (instability issue and low retention level) makes it 
unsuitable fo r use in clinical settings (Seidel et al. 2012). DNMTi are incorporated into the newly 
synthesized DNA and works by trapping DNMT enzymes w ithin DNA strands, thus triggers 
proteosomal degradation of the enzyme and inhibits fu rther méthylation o f DNA (Seidel et al. 2012).
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This property o f DNMTi means that the ir effect is maximaliy expressed in celis w ith  high proliferative 
status, fo r example cancer cells. DNMTi have been shown to  effectively re-establish expression o f a 
previously silenced gene. However, DNMTi lacks specificity and is less suitable fo r solid tum our 
treatm ent (Lopez et al. 2009). Contrariwise, HDACi acts by inhibit HDACs activity resulted in the 
aiteration o f proliferation and differentiation state o f cancer ceils. HDACi can be divided into severai 
groups based on the ir chemical structure: benzamides, cyclic peptides, depsipeptides, hydroxamates 
and short-chain fa tty  acids. Some HDACi targets all isoforms o f HDACs whiie others have more 
specific action on a certain HDACs isoform only (Seidel et al. 2012). The precise mechanisms o f 
HDACi are yet to  be established. However, promoting acétylation o f chromatin through chromatin 
modification and structure changes in transcription factor compiexes has been proposed as the 
mechanisms o f action. This u ltim ately leads to  re-expression o f silenced genes (Lopez et al. 2009).
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Figure 1-10: Chemical structure of CMAs utilized in this study, a) 5-Azacytidine, a DNMT enzymes inhibitor, b) HDAC 
inhibitor Trichostatin A (TSA).
6. Targeting cell cycle components in cancer
Cells rely on checkpoints, especialiy Gi checkpoint to  avoid oncogenesis. However, cancerous cells 
often have alterations in Gi and S checkpoints. These are caused by mutations to  Rbp and p53, 
which renders them inactive and unable to  provide proper functioning checkpoints. Other 
alterations, fo r example in the ievel o f p53 negative regulator MDM2 (murine double m inute 2) also 
affects p53 activity. As a result, cancer cells bypass these checkpoints w ith  a high level o f genomic
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instability, higher mutational rate and higher possibility o f replicating damaged DNA. These events 
commonly favour carcinogenesis by overexpression o f oncogenes such as CycllnE, CycllnDl and 
silencing o f tum our suppressor genes such as CKIs apart from  p53 and Rbp. As a consequence o f Gi 
checkpoint deregulation, cancer cells rely more on G2 checkpoint to  enhance the rate o f mutation 
which might give additional survival advantages. Thus, targeting G2 checkpoint Is a sensible way o f 
sensitizing cancer cells specifically while sparing normal cells w ith  Intact Gi and S checkpoints (Chen 
et al. 2012; Kawabe 2004). Some proteins In cell cycle have overlapping functions In cell cycle 
checkpoints fo r example p53, ATM and ATR. Therefore, proteins downstream o f these sensor 
proteins are favourable targets fo r drug development, since they are more substrate-specific. These 
targets also preferably should not abundantly available throughout cell cycle or Involved In other 
cellular processes as a non-redundant components (Kawabe 2004). Based on these criteria, several 
G2 checkpoint-targeted drugs were developed. There Is a huge Interest In developing Chkl Inhibitors 
and other G2 kinase Inhibitors as well, fo r example MK1775. MK1775 Is a G2 kinase Inhibitor 
specifically Inhibiting W ee l, a negative regulator o f CDKl-CycllnB (Figure 1-11). W ee l 
overexpression Is observed In certain types o f cancers such as hepatocellular carcinoma and breast 
cancer (MasakI et al. 2003).
r ,
Figure 1-11: Chemical structure of W eel inhibitor MK1775.
Deregulation o f CKIs and CDKs are also a common feature o f cancers. Among CDKs, CDK2 Is an 
attractive target fo r drug development, since It Is vital during an early phase o f the cell cycle and Is 
often deregulated In cancer (Malumbres and Barbacid 2005). Hence, drug development aimed at
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developing small molecule inhibitors resulted in agents such as seliciclib (CYC202) and PD0332991 
(Figure 1-12). Seliciclib is a CDK inhibitor w ith  potent inhibitory action against CDK2-CyclinE, w ith 
lesser activity on CDK9-cyclinI, CDK7-cyclinH and CDKl-cyclinB. Seliciclib has been shown to have 
antitum or activity in a broad range o f cancers, e ither alone or in combination w ith  other 
chemotherapeutic agents (Aldoss et al. 2009; Coley et al. 2007). PD0332991 is another CDK inhibitor 
acting on CDK4 and CDK6, specifically on cancers w ith  Rbp-positive feature (Fry et al. 2004). 
PD0332991 sensitivity is inversely related w ith  the expression o f plO" '^ '^*  ^(Katsumi et al. 2011) while 
p57'^ ''^  ^downregulation predicts sensitivity towards seliciclib treatm ent in carboplatin-resistant 
ovarian cancer (Coley et al. 2012).
a)
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Figure 1-12: Chemical structure of CDK inhibitors used in this study, a) Seliciclib (CYC202), a CDK2 inhibitor, b) PD0332991, 
inhibitor of CDK4 and CDK6.
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Aims of study
This study is based on earlier findings tha t demonstrated drug resistant cancer cell lines show 
epigenetic silencing o f several genes, including some tha t are cell cycle associated. The overall aim is 
to  confirm specific epigenetic changes seen in the original microarray analysis and to  do a functional 
analysis on various drug resistant epithelial ovarian cancer cell lines.
Three genes were chosen from  the derived list: p57 '^^ ,^ Stratifin and Weel. The firs t part o f this 
work focused on and its association w ith  platinum resistant ovarian cancer. From here we 
have gone on to look at the effects o f the CDK inh ib itor seliciclib in cells w ith  silenced p57' '^'^^ In the 
next part o f the study, we considered other genes tha t have been identified in the initial gene list 
and the mechanism underlying the ir contribution towards drug resistance. We have chosen to  study 
Stratifin and Weel and assess the ir roles in Taxol-resistant ovarian cancer.
Looking at the broader picture, alterations in cell cycle components are a common feature o f 
cancers. Thus, we utilized western blotting as means fo r screening alterations o f cell cycle 
components particularly G2M phase in several panels o f drug-sensitive and drug-resistant cancer 
cells. This work w ill serve as a basis fo r understanding cell cycle perturbation in drug resistance.
Finally, we chose the CDK inhibitor drug PD0332991, which has shown activity versus CDK4 and 
CDK6 to  develop a drug-resistant melanoma cell line. This cell line harbours a defect in the INK4 
fam ily members i.e.
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Materials
1. Reagents
Agilent Technologies Inc., Santa Clara, CA 
Mycoplasma Plus PGR Primer Set
Bio-Rad Laboratories Inc., Hercules, CA 
BCA Protein Assay Kit
Merck & Co Inc., Whitehouse Station, NJ 
Calbiochem® Annexin V-FITC kit
New England Biolabs Inc., Ipswich, MA
ATM (D2E2) (#2873) rabbit monoclonal antibody, ATR (#2790), Chkl (#2345), Chk2 (#2662) and p53 
(#9282) rabbit polyclonal antibodies
Thermo Fisher Scientific Inc., Waltham, MA
NaCI, Tris Base, Agarose, 5X SiRNA buffer, DharmaFECT® Transfection Reagent, 2X Thermo-Start™ 
PCR Master Mix, ON-TARGET plus siRNAs (Human CDKNIC, Stratifin, W e e l and GAPDH), siGENOME 
Non-targeting siRNA Pool #1
GE Healthcare Ltd., Amersham, Herts. 
Amersham Hyperfilm™ ECL
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Life Technologies, Carlsbad, CA
4X NuPAGE® IDS Sample Buffer, lOX NuPAGE® reducing agent. No vex® Sharp Protein Standard, 
HiMark™ Pre-Stained High Molecular W eight Protein Standard, NuPAGE® Novex® Bis-Tris (4-12% 
and 10%) and 7% Tris-acetate gels, 20X NuPAGE® MES SDS, 20X MOPS SDS and 20X Novex® TA 
running buffers, Invitrolon™ PVDF membrane, 20X NuPAGE® Transfer Buffer, Novex® AP 
Chemiluminescent substrate (GDP-Star®), 2° (Secondary) Antibody Solution Alkaline-Phosphatase 
Conjugated (anti-mouse, anti-rabbit and anti-goat), TRIzol® reagent. Proteinase K (Ambion), Fetal 
Calf Serum (FCS) (Gibco), GlutaMAX™ lOOX (Gibco)
Promega Corp., Madison, Wl
ImProm-ll™ Reverse Transcription System
Qiagen, Limburg, Netherlands
QuantiTect® SYBR® Green PCR kit, QuantiTect® Primer Assay (GAPDH), EpiTect® Bisulphite Kit, RT  ^
qPCR Primer Assay fo r gene expression analysis (CDKNIC, Stratifin, W ee l)
Insight Biotechnology Inc., Dallas, TX
p57' '^P^(H-91) (SC-8298), W ee l (C-20) (SC-325) and Survivin (FL-142) (SC-10811) rabbit polyclonal 
antibodies; E2F-1 (KH-95) (SC-251), p27"^'" (F-8) (SC-1641) and Cyclin E (HE12) (SC-247) mouse 
monoclonal antibodies; XIAP (N-18) (SC-8789) and 14-3-3o (C-18) (SC-7683) goat polyclonal 
antibodies
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Selleck Chemicals, Houston, US 
MK1775, PD0332991, Seliciclib (CYC202)
Sigma Aldrich, St. Louis, MO
RPMI-1640 medium, DMEM medium, EDTA, DMSO, Trypsin, TrisHCI, Nonidet P40, SDS, Sodium 
Orthovanadate, Bovine Serum Albumin (BSA) powder, Tween20, RNase-free water, GenElute DNA 
kit, RNase-A, P-actin (Clone AC-15) and GAPDH (Clone 71.1) mouse monoclonal antibodies, MTT 
reagent, 5'-Azacytidine, Trichostatin A, carboplatin, cisplatin, Taxol
Zymo Research Corp., Irvine, CA
Universal Methylated DNA standard and primers
2. Buffers and solutions
Phosphate Bujfered Saline (PBS) IX
To prepare IL  PBS (IX), 1 PBS tablets was dissolved in lOOmL RO water as per instruction from  
manufacturer. PBS solution was autoclaved if necessary to  make it sterile. Typical form ulation o f PBS 
is as follows: NaCI 8g/L, Potassium Chloride 0.2g/L, Di-sodium hydrogen phosphate 1.15g/L, 
Potassium dihydrogen phosphate 0.2g/L w ith  pH o f 7.3 ± 0.2 at 25°C.
MTT solution
5 mg/mL3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide was dissolved in a sterile 
IXPBS solution and filtered prior to  usage if necessary. Solution was kept in cold room away from  
light.
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Lysis buffer
To prepare lysis buffer, ice-cold Tris buffer containing 50mM TrisHCI and 150mM NaCI w ith  pH 
adjusted to  7.5 was used as the basis and 1% Nonidet P-40, 0.2% sodium dodecyl sulphate (SDS), 
Im M  phenylmethanesulphonylfluoride (PMSF), lOpg/mL aprotinin, lOpg/mL leupeptin and Im M  of 
sodium orthovanadate (NasV0 4 ) were added and mixed thoroughly. Lysis buffer was kept on ice.
70% ethanol in PBS
To prepare SOOmL 70% ethanol in PBS, 350mL absolute ethanol was mixed w ith  ISOmL IXPBS 
solution and agitated thoroughly. Solution was kept in cold room.
SDS-PAGE Running buffer
To prepare IL  o f SDS-PAGE running buffer, 50mL 20X running buffer stock was diluted w ith  950mL 
RO water and mixed thoroughly. Buffer was immediately used and discarded accordingly.
SDS-PAGE Transfer buffer
To prepare IL  o f SDS-PAGE transfer buffer containing 10% methanol (per gel), 50mL20X transfer 
buffer stock and measured amount o f methanol was diluted w ith  RO water to  make up to  IL  and 
mixed thoroughly. Buffer was immediately used and discarded accordingly.
Tris buffer
To prepare 200mLTris buffer containing ISOmM NaCI and 50mM Tris-HCI fo r protein extraction, 
1.75g NaCI (FW 58.44) and 1.58g Trizma-HCI (FW 157.6) were weighed and dissolved in RO water. pH 
was adjusted to  7.5 and solution was sent fo r autoclaving. Solution was stored in cold room.
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lOX TRIS Buffered Saline (TBS)
To prepare SOOmL lOX TBS stock solution, 12.Ig  Tris base and 40g NaCI were weighed and dissolved 
in RO water. pH o f the solution was adjusted to  7.6 w ith  HCI. To make SOOmL IX  TBS working 
solution, SOmL o f stock solution was diluted in 450mL RO water. Solutions were stored at room 
temperature.
PBS-/TBS-Tween20
To prepare SOOmL PBS-/TBS-Tween20, 500pLTween20 (final concentration 0.1% v/v) was dissolved 
in SOOmL IXPBS/IXTBS. Solution was kept on room temperature.
Blocking/primary antibody buffer
To prepare lOmL blocking/primary antibody buffer, O.Sg o f nonfat dry milk/BSA or 0.25g dry m ilk 
and 0.25g BSA together were weighed and dissolved in IXPBS/IXTBS per recommendation from  the 
datasheet. lOpL Tween20 was added and mixed thoroughly. For primary antibody solution, a 
calculated amount o f antibody preparation (e.g. 1 :2 0 0 , 1 : 1 0 0 0 ) was added into the buffer and 
mixed thoroughly. A fter initial use, primary antibody solution can be kept in 4°C or -20°C accordingly.
lOX TAE
To prepare IL  lOX TAE, mixed together 48.4g Tris base, 11.42mL acetic acid glacial, 3.7g EDTA and 
RO water to  top up to  IL. Solution was used at IX  by diluting w ith  RO water. Solutions were kept at 
room temperature.
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Drug solutions
Seliciclib, PD0332991, MK1775, Taxol, and TSA were diluted in sterile DMSO. Carboplatin and 
cisplatin were diluted in 0.9% saline. S'-azacytidine was diluted in sterile distilled water. Drug stocks 
were stored in -20°C and thawed prior to  use.
siRNA resuspension
SiRNAs purchased were obtained in lyophilised form  and resuspended prior usage. SiRNA 
resuspension was carried out according to  manufacturer's recommendations. SiRNA vial was briefly 
centrifuged to collect pellet at the bottom. To prepare 20pM siRNA stock, 5X siRNA buffer (300mM 
KCI, 30mM HEPES pH 7.5, Im M  MgCb) diluted w ith  sterile RNase-free water to  IX  concentration was 
used. IX  siRNA buffer consists o f 20mM KCI, 6 nM HEPES (pH 7.5) and 0.2mM MgCb as stated in the 
product datasheet. Buffer was added into the vial and solution was resuspended several times. The 
vial was then placed on the orbital mixer at room temperature fo r 30 minutes before being briefly 
centrifuged again. siRNA was aliquoted into small volumes and stored at -20°C until use.
BSA protein standard
BSA stock solution was prepared by dissolving 25g BSA in 5mL water and stock was aliquoted into 
smaller tube. To make a set o f BSA protein standards, stock solution (5mg/mL) was diluted 
accordingly using sterile RO water. Range used was 0.2, 0.5, 0 .7 ,1 .0 ,1 .2  and 1.5mg/mL BSA. 
Solutions were stored in -20°C.
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Methods
1. Cultured Cancer Cell lines
Several cell lines were utilised throughout the study and were not lim ited to  a certain lineage. PEOl 
is the parental cell line w ith  modal chromosome number o f 41, originates from  a poorly 
d ifferentiated ovarian serous adenocarcinoma (Langdon et al. 1988). Two drug-resistant cell lines, 
PEOlCarbR (carboplatin-resistant) and PEOlCisR (cisplatin-resistant) were derived from  the parental 
cell line by step-wise incubation w ith  carboplatin and cisplatin until a stable resistance phenotype 
was acquired. Maintenance o f resistance phenotype was achieved by an addition o f 2pM carboplatin 
and Ip M  cisplatin respectively (Coley et al. 2006). A2780 is a cell line derived from  a human ovarian 
carcinoma and SK-OV-3, which is a cell line derived from  an ovarian adenocarcinoma. Taxane- 
resistant cell lines were established from these tw o parental cell lines utilising similar drug-resistant 
development protocol as platinum-resistant PEOl. A2780TaxR is a taxane-resistant counterpart fo r 
A2780 w ith  a lower resistance level developed based on a previous study (Syed et al. 2011). Two 
variants o f taxane-resistant SK-OV-3 w ith  differing levels o f drug resistance, SKOV3T6 and 
SK0V3TaxR were established from  the SK-OV-3 parental cell line. The maintenance dose fo r 
A2780TaxR was SOOnM Taxol, 6 nM Taxol fo r SKOV3T6 and lOnM Taxol fo r SK0V3TaxR. Several cell 
line pairs o f drug sensitive and drug-resistant counterparts were used in the other part o f the study. 
Cell lines of ovarian cancer lineage consist o f PEOl and its drug-resistant variants PEOlCarbR, 
PEOlCisR and PEOlTaxR (taxane-resistant); SK-OV-3 w ith  its drug-resistant counterparts SK0V3TaxR 
and SK0V3CR (carboplatin-resistant). Cell lines o f breast cancer lineage were MCF7 derived from 
breast adenocarcinoma and its taxane-resistant MCF7TaxR (Ajabnoor e t al. 2012) and T47D o f ductal 
carcinoma w ith  its taxane-resistant T47DTaxR (four-fold resistance to  paclitaxel). Other cell lines 
used in this study were head and neck cancer cell line HN5 and its cisplatin-resistant HNSCisR and a 
cell line o f melanoma origin, A375. A375 was also being used in developing a new drug-resistant cell
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line using an experimental drug PD0332991 in the final part o f the study (Chapter 7) and were 
subsequently named as A375PdR.
All drug-resistant cell lines mentioned above were established by Dr Helen M Coley, University o f 
Surrey, Guildford apart from  A375PDR, which is jo in tly  established as part o f the study. All parental 
cell lines utilised were purchased from  American Type Culture Collection (ATCC) apart from  A2780 
and HN5. A2780 was purchased from  European Collection of Cell Cultures (ECACC) while HN5 was 
kindly donated by Dr H. Modjtahedi (Institute o f Cancer Research, Sutton, UK).
Cell line Description Drug-resistant 
counterpart (agent)
Chapter Reference
(where applicable)
PEOl Ovarian serous 
adenocarcinoma
PEOlCarbR (Carboplatin) « 3, 4 .
-
PEOlCisR (Cisplatin)
PEOlTaxR (Paclitaxel)
Langdon et al. 1988 
Coley et al. 2006
A2780
ISK-QV-3
MCF7
J47D
HN5
A375
.  .  -  '
Ovarian carcinoma A2780TaxR (Paclitaxel) 4, 5, 6  Syed et al. 2011
Ovarian SKOV3T6 (Paclitaxel) 3 ,4 ,5 , 6  Syed et al. 201 Ï
SK0V3TaxR (Paclitaxel)
SK0V3CR (Carboplatin) .
MCF7TaxR (Paclitaxel) 4
adenocarcinoma
Breast
adenocarcinoma 
Ductal carcinoma 
Head and neck 
cancer 
Melanoma
Ajabnoor et al. 2012
T47DTaxR (Paclitaxel)
' -----A:_____
HNSCisR (Cisplatin)
A375PDR (PD0332991)
Table 2-1: Summary of cell lines utilised in this study together with the associated chapter.
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2. Cell cryopreservation and resuscitation
Cells were cryopreserved in liquid nitrogen as a long-term storage and essential especially fo r a 
precious cell lines and cell lines tha t were still developing a drug-resistant phenotype. In order to  
cryopreserve a cell line, cells were seeded in a T25 flask until near confluence. Complete medium 
containing 10% FCS, IX  Glutamax and 10% DMSO was prepared prior to  the procedure. Cells were 
trypsinized and pelleted before an addition o f a DMSO-containing media. Cells were slowly 
resuspended and aliquoted into cryopreserve vials. Vials were labelled and put into an isopropyl 
alcohol container. The container was then left at -80°C fo r at least 24 hours before transferred into a 
long-term storage containing liquid nitrogen.
To resuscitate cells from  liquid nitrogen storage, vial containing cells was quickly thawed in a 
waterbath. Thawed cells were then pipetted into a T25 flask containing complete medium and left 
inside the incubator. The medium was changed the next day if necessary to  aid in recovery o f the 
cells.
3. Viability assay
•■ p
Figure 2-1: MTT chemical structure.
Cytotoxicity testing using MTT has been commonly employed to estimate cellular viability. MTT (3- 
(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) (Figure 2-1) is a hydrogen acceptor, 
which react w ith  oxidized substrates or appropriate coenzymes including NADH and NADPH. This 
assay was utilised to  assess cellular reductive capacity (due to  mitochondrial activity), which 
correlates w ith  cell viability (Vistica et al., 1991). MTT, a water-soluble yellow tétrazolium  dye is
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reduced by live cells to  a purple formazan product, which is insoluble in aqueous solution. This 
product can be resolubilized in a suitable solvent (e.g. dimethyl sulfoxide (DMSO)) and its absorption 
can be read using spectrophotometry at X540nm (Mosmann 1983). Viability assay using MTT was 
used as a way to  look at the cell's viability after the drug treatments, and to estimate IC50 values. The 
IC50 value is a drug dose needed to  cause a 50% reduction in cell viability relative to  untreated 
control cells, obtained from  the dose response curve (Twentyman and Luscombe 1987).
The MTT reagent was prepared by dissolving 5mg/mL MTT in sterile PBS, stored at 4°G. 200pL o f cell 
suspension were seeded in flat-bottom ed 96-well m icrotitre plates using a density o f 2x10"^ cells/mL 
up to  4x10'* cells/mL (according to  doubling times o f the particular cell line in question) and left 
overnight in standard cell culture incubation conditions (with humidity). The follow ing day, drug 
dilutions were prepared w ith  RPMI-1640 medium containing 10% FCS. Drugs were dispensed at the 
appropriate concentrations. Untreated cells in the plate acted as a control and medium w ithou t any 
drug dilution was dispensed into the control wells accordingly. The drug-treated plates o f cells were 
incubated fo r 72 hours (to allow fo r approximately three cell doublings to  take place) followed by 
the addition o f 25pL MTT reagent into each well. An incubation period o f three to  four hours was 
necessary fo r the form ation o f formazan crystals before the media containing MTT reagent was 
aspirated. 200pL o f DMSO was dispensed into the wells to  solubilise the purple formazan crystal 
product. Absorbance of the colour produced was read at 540nm using Multiskan RC microplate 
reader (Thermo Electron Corp., Finland) w ithin 30 minutes after DMSO addition. The dose-response 
curves were plotted using percentage o f cell viability compared to  control (y-axis) versus log drug 
concentration (x-axis). From these plots, the IC5 0 value was calculated, which is referred to  as the 
concentration o f drug that causes 50% cell death relative to  untreated controls.
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4. Isobologram analysis
Isobologram analysis was selected as a method to  assess interaction between tw o d ifferent drugs. In 
this study, isobologram analysis was carried out to  assess the effect o f seliciclib in combination w ith 
carboplatin, a drug commonly utilised in ovarian cancer treatm ent on PEOl parental and its 
carboplatin-resistant variant PEOlCarbR cell lines. Interaction between the drugs was calculated 
w ith  the aid o f CalcuSyn software program (Cambridge Biosoft, Cambridge, UK). This program 
utilizes Combination Index (Cl) described by Chou and Talalay, based on the m ultiple drug-effect 
equation derived from  enzyme kinetic models. Cl values o f <1.0 indicate synergism. Cl equals to  1 
indicate additive effect, and Cl >1 indicates antagonism (Chou and Hayball, 1996, Coley et al., 2007).
200pL per well cell suspension were seeded into the flat-bottom ed 96-well plate at the density of 
3x10^ cells/mL and left fo r 24 hours before the drug treatm ent. Duplicate plates were seeded fo r 
each cell line used fo r single drug and combination treatm ent each d ifferent plate. Six dilutions o f 
each drug w ith  constant ratio design were prepared in the drug dilution medium and dispensed into 
the wells. For the single drug treatm ent plate, additional media w ithou t drug were dispensed into 
the wells to  enable equal comparison to  the combination drug treatm ent plate. Plates were 
incubated fo r 72 hours before being subjected to  the cytotoxicity assay as described previously. 
Viability fraction o f control and drug-treated cells were calculated fo r each drug concentration. 
Fraction o f cells affected (FA) value fo r each drug dose was then calculated using the formula 1- 
viability fraction. FA values were subsequently used as an input to  calculate Cl. The fo llow ing table 
(Table 2-) contains recommended symbols to  fu rther explain the extent o f synergism or antagonism 
in Cl analysis o f drug combination experiment:
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Range of Cl Symbol Description
<0.1 % +++++ Very strong synergism
0.1-0.3 ++++ Strong synergism
w  '-"' . ..... . iimu-ngmir"",!
0.3-0.7 ^ +++ Synergism
0.7-0.85 ++ Moderate synergism
j 0.85-0.90 + Slight synergism
0.90-1.10 ± Nearly additive
1.10-1.20 - Slight antagonism . ;
1.20-1.45 - Moderate antagonism
1.45-3.3 — Antagonism
3.3-10 — Strong antagonism
>10 Very strong antagonism
Table 2-2: Range of Cl, symbols and description suggested for Cl analysis of combination drug treatment.
5. Preparation of whole cell lysate
This method was employed to harvest protein from  cells, untreated and drug-treated at a particular 
dose. Floating cells in the media were also collected. Cells were grown in T25 flask, T75 flask or a 6- 
well plate according to  the experimental settings and needs. Generally, cells were harvested by the 
time the untreated controls reached approximately 80-90% confluence. By the end o f the incubation 
period, cells were washed w ith PBS, trypsin was added (or cells subjected to harvesting using a 
sterile plastic scraper) and the flask incubated at 37°C to dissociate cells. The harvested cells were 
then pelleted via centrifugation at 600g fo r 5 minutes. The cell pellet was then washed tw ice w ith  
ice-cold PBS. Lysis buffer was prepared as described before. The buffer should be freshly prepared 
each time and used w ithin approximately half an hour. This is because of a PMSF short half-life at 
room temperature. Lysis buffer was added to the pellet while disaggregating it w ith a pipette tip.
The disaggregated pellet was left on ice for 10 minutes before being transferred into a microfuge 
tube. The cells were fu rther lysed using a 23-gauge needle before being left on ice again fo r 20 to 30 
minutes. Following incubation the tube then centrifuged at lOOOg fo r 10 minutes at 4°C to  remove
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nuclei and unbroken cells. The supernatant was transferred into a new tube, labelled and stored at - 
70°C.
BCA protein assay kit was used in order to  determine the protein concentration in the sample. This 
assay was based on Bradford protein assay principle. In this assay, BSA protein standards were 
prepared beforehand ranging from  0.2mg/mL to  1.5mg/mL. Protein samples were diluted either 
w ith  1/10 or 1/20 dilution w ith  deionised w ater in duplicate w ith  a to ta l o f 50pL per well in a 96-well 
plate. Working solution consisting o f a m ixture o f Reagent S (contains SDS) and Reagent A (20pL 
reagent S per Im L Reagent A) was made and added to  the standards and samples. Addition o f 
Reagent B to  the m ixture triggered a colorimetric reaction that was quantified by using plate a 
reader at 690nm after a brief incubation time. Measurement o f protein standards was translated 
into a standard curve which was then utilised to  determine the concentration (pg/mL) fo r each 
whole cell lysate sample.
6. SDS-PAGE
SDS-PAGE (Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis) is an electrophoresis 
procedure using polyacrylamide gel. Electrophoresis is a way o f separating small-sized biological 
samples (protein, DNA and mRNA) and PCR amplicons based on the ir molecular weight w ith  the aid 
o f electric current. To assist in visualising protein size, a marker is placed and ran alongside protein 
samples. The distance the protein travelled was tracked w ith  the aid o f a dye marker. The 
polyacrylamide percentage can be modified to  optim ize visualisation o f the protein o f interest. 
Before preparing samples, a known amount o f protein samples were calculated so that each well 
contained the same amount o f protein. The amount o f protein per well (pg/well) was calculated 
from  protein concentration derived using the BCA protein assay. Between 20pg to  50pg o f protein
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per well was sufficient fo r the majority o f western blotting analyses. This was determined based on 
the performance o f primary antibody and the amount o f protein o f interest in the sample. To 
prepare a sample, protein lysate was mixed w ith  4X NuPAGE® LDS Sample Buffer at IX  concentration 
which also acts as a tracking dye, lOX NuPAGE® reducing agent (IX  concentration) and deionised 
water to  top up to  the final volume. Protein m ixture was then heat-denatured at 70°C fo r 10 
minutes, cooled on ice and loaded into the well o f the gel. To help determine molecular weight o f 
protein o f interest, the Novex® Sharp Protein Standard or HiMark™ Pre-Stained High Molecular 
Weight Protein Standard was loaded in a separate well and ran together w ith  protein samples. 
NuPAGE® Novex® Bis-Tris (4-12% or 10%) or 7% Tris-acetate gels combined w ith  either IX  NuPAGE® 
MES SDS or IX  MOPS SDS or IX  Novex® TA running buffer were employed based on molecular 
weight o f the protein o f interest. Novex® Mini Cell (XCell SureLock™ Electrophoresis Cell) 
electrophoresis apparatus was employed to  run electrophoresis at 150V constant fo r 90 minutes or 
until the dye was on the edge o f the gel.
7. Western Blotting
Western blotting is a procedure o f transferring the protein from a gel onto a membrane. A fter the 
transfer process, the membrane was incubated w ith  antibodies and developed w ith  a film  to 
visualise band o f the desired protein. Membranes o f choice were either Polyvinylidene Fluoride 
(PVDF) or nitrocellulose (NC) membrane. Both membranes have d ifferent properties and pore size. 
The choice o f membrane depends on the properties o f desired protein. Protein on the gel was 
transferred onto the membrane facilitated by electrical current. A sandwich o f gel, membrane, 
b lotting papers and sponges were set in a transfer device XCell II™ Blot Module and ran at 35V 
constant fo r 2 hours in IX  NuPAGE® Transfer Buffer. The membrane was then washed using IX  TBS- 
or IX  PBS-Tween20 (0.1%) (TBS-/PBS-T) washing solution and transferred into blocking solution 
consists o f 5% milk or BSA or the m ixture o f the tw o in TBS-/PBS-T to  block non-specific binding o f
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antibodies. Membrane blocking was done w ith  agitation at room temperature fo r m inimum o f 1 
hour or overnight in the cold room. Following blocking, the membrane was washed and incubated 
w ith  primary antibody, which w ill specifically bind to  the protein o f interest. Primary antibody 
solution was prepared similarly as the blocking solution. The primary antibody dilution and 
incubation tim e were determined based on optim ization. A fter a certain period o f tim e, membrane 
was washed trice, 5 minutes each w ith washing solution and incubated w ith  secondary antibody 
solution available commercially fo r 1 hour. The secondary antibody that w ill bind to  the primary 
antibody was tagged w ith  molecules such as alkaline-phosphatase (ALP) to  allow visualisation on 
film . Following incubation, membrane was washed as before and Novex® AP Chemiluminescent 
substrate (CDP-Star®) was added onto the membrane fo r at least 3 minutes before being exposed to 
the hyperfilm. Chemical reaction between ALP and the substrate produces a signal tha t can be 
captured on film . Intensity o f the signal was proportional to  the level o f targeted protein in the 
protein mixture. A fter exposure, the developed film  was labelled and stored at room temperature.
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Figure 2-2: Schematic diagram of SDS-PAGE and Western blotting procedures. 1) Samples are separated using SDS-PAGE 
along w ith a marker. 2) Proteins are then transferred to the membrane from the gel w ith an aid of an electrical current. 3) 
After the transfer procedure, the membrane is blocked w ith a blocking agent to prevent non-specific binding o f the 
antibody. 4) After a period o f time, the membrane is subjected to incubation w ith the primary and secondary (5) 
antibodies. The secondary antibody is tagged w ith an enzyme. 6) The substrate is later added to the membrane after the 
end of the antibody incubation period. The substrate reacts w ith  the enzyme tag producing a chemiluminescent signal that 
is captured on the hyperfilm (7). The signal on the film  corresponds w ith the position of the target protein on the 
membrane.
Stripping is a process to  remove an antibody's signal attached to  the protein on the membrane (blot) 
in order to  enable re-probing w ith different antibodies. This method is done by using heat and 
detergent, or by using a low pH solution. After stripping procedure, the blot can be reused again fo r 
detection o f another protein o f interest. The blot was washed w ith PBS once fo r 5 minutes and 
incubated w ith  Im M  sodium azide in PBS for a m inimum o f 2 hours at room temperature or
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overnight in the cold room w ith  gentle agitation. The blot was subsequently washed as before and 
can be used again fo r another round o f antibody incubation.
8. Densitometry
Densitometric analysis was utilised to  make a quantitative analysis o f selected western blotting 
results. The chemiluminescent signals seen on the hyperfilm obtained from Western blotting 
experiments were scanned and analysed w ith  QuantiScan software (Version 3.0) (BioSoft, 
Cambridge, UK). The data obtained were presented as bar charts on the appropriate figures.
9. Alcohol fixation for DNA analysis
Cells were grown in T25 flask at a density o f 3 to  4x10"^ cells/mL. Cells in an early exponential phase 
o f growth (approximately 12 hours after seeding) then were treated w ith  predetermined 
concentration o f drug fo r a set o f tim e (24 hours and/or 48 hours). For drug-treated cells, floating 
cells in the media were also collected. By the end o f incubation time, cells were dissociated using 
trypsin; media was added and centrifuged at 600g fo r 4 minutes to  get the cell pellet. Pellet was 
washed w ith  PBS once before being resuspended in a new PBS solution. 70% ethanol in PBS was 
then added to the resuspended cells slowly whilst vortex-mixing. The cell suspension was left at 4°C 
fo r at least 24 hours fo r fixation. Cell suspension was washed post-fixation w ith  PBS and centrifuged 
as before. Cell pellet was then resuspended in PBS followed by staining process. To stain the cells, 
5pg/mL propidium iodide (PI) and Im g/m L Ribonuclease A were used followed by incubation at 37°C 
fo r at least 30 minutes in the dark. Ribonuclease A aids in the removal o f unwanted RNA and PI 
intercalates w ith DNA in the sample. A fter staining, the cells were subjected to  flow  cytometry 
analysis using Beckman Coulter Epics XL flow  cytometer (Beckman Coulter (UK) Ltd., High Wycombe, 
UK).
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10. RNA isolation
RNA isolation was carried out using TRIzol® reagent and phase-separation technique. Similarly w ith  
the cell lysate procedure, cells can be grown in T25 or 6-well plate accordingly. Medium was 
aspirated and cells were lysed directly in the flask using Im L o f TRIzol® per 1x10^ cells. The lysate 
was passed through a pipette several times before being transferred into 2mL microfuge tube. The 
homogenised samples were then incubated fo r 2 to  3 minutes at room temperature to  complete 
dissociation o f nucleoprotein complexes. 0.3mL o f chloroform was added to  the sample and tube 
was vigorously shaken fo r 15 seconds. The lysate was left at room temperature fo r 2 to  3 minutes 
before centrifugation at 10,000g fo r 10 minutes at 10°C. A fter centrifugation, the aqueous solution 
should separate into 3 phases; the bottom red phase, th in  white intermediate layer and upper clear 
phase, which contains RNA. The upper clear phase was transferred carefully into a new tube and 
isopropanol was added to  the solution (O.SmL per Im L  TRIzol® used) and mixed by inversion before 
being left fo r 10 minutes at room temperature. A fter incubation, the lysate was centrifuged at 
8,000g fo r 10 minutes at 4°C. W hite pellet may appear if the RNA concentration was high in the 
sample. The supernatant was removed into waste and the pellet washed w ith  75% ethanol w ith  
vortex mixing. Resuspended pellet was centrifuged again at 8,000g fo r 5 minutes, supernatant 
removed and the pellet was dried by opening the tube cap. Precaution should be taken as excess 
drying o f pellet w ill result in d ifficulty in dissolving the pellet. The RNA pellet was then dissolved in 
RNAse-free water by mixing gently w ith  pipette. The solution was incubated at 55 to  60“C fo r 10 
minutes before being stored at -80°C. Total RNA yields (ng/pL) and purity was verified using 
Nanodrop NP-lOO spectrophotometer (Labtech International Ltd., East Sussex, UK). Appearance o f a 
single peak on the graph suggest pure sample while an additional peak suggests residual chemical 
contamination from  extraction procedures.
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11. Reverse Transcriptase (RT) reaction
RNA extracted from  samples can be quantified as a marker fo r specific gene expression. This was 
carried out by converting RNA into cDNA and subjected them  to  quantitative analysis by PCR. The RT 
reaction was done using ImProm-ll™ Reverse Transcription System. For the initial dénaturation and 
primer combination step, RNA (up to  Ipg), random prim er (O.Spg/reaction) and nuclease-free water 
to  add up to  SpL were pipetted inside l.SmL microfuge tube and heated at 70°C fo r 5 minutes. The 
tube was then immediately placed on ice fo r at least 5 minutes. Each microfuge was shortly 
centrifuged and put on ice. Reaction m ixture comprised o f ImProm-ll™ 5X Reaction Buffer (used at 
IX), dNTP mix (final concentration O.SmM o f each dNTP), magnesium chloride (final concentration 
3mM), recombinant ribonuclease inh ibitor RNasin® (20U) and nuclease-free water to  top up to  14pL 
were added into the microfuge tube containing experimental RNA-random primer mix. If there were 
several samples, a master mix containing all components mentioned previously should be prepared 
and dispensed to  the separate samples accordingly. Finally, ImProm-ll™ Reverse Transcriptase 
(lU /20pL reaction) was added into each tube followed by mixing and short spin. Annealing was done 
at 25°C fo r 5 minutes followed by extension step (42°C, 1 hour) and enzyme inactivation (70°C, 15 
minutes). The end product was cDNA which were then labelled and stored at -20°C. The cDNA 
concentration (ng/pL) and its quality was verified using Nanodrop NP-lOO spectrophotometer. 
cDNAs generated were used in quantitative real-time PCR to  look at the level o f gene expression.
12. Quantitative real-time PCR (qPCR) assay
QuantiTect® SYBR® Green PCR kit was utilised fo r qPCR assay fo llow ing recommended procedures by 
the manufacturer o f primers. The reaction was prepared in a 96-well plate w ith  duplicate reaction 
fo r each sample. Each sample has to  be prepared in tw o sets, a set is fo r the gene o f interest (GOI) 
and another is fo r the housekeeping gene (HKG), either GAPDH or 3-Actin. Master mix fo r each 
reaction was 2X QuantiTect® SYBR® Green PCR master mix (use at IX), gene-specific RT  ^qPCR
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Primers (lOpM stock fo r each primer, variable amount) and nuclease-free water to  top up to  24pL 
reaction. Master mix was dispensed into an optical plate (MicroAmp™ Optical 96-well reaction plate) 
(Applied Biosystem, Life Technologies Ltd.) followed by an addition o f template cDNAs. Template 
concentration was determined based on optim ization and then diluted so that the final volume of 
template cDNA fo r the reaction was IpL. The plate was then overlayed w ith  an adhesive film  
(MicroAmp™ Optical Adhesive Film Kit) (Applied Biosystem, Life Technologies Ltd.). The plate was 
centrifuged at 3,000rpm fo r 3 minutes to  remove bubbles before being placed into the thermal 
cycler ABI 5700 Real Time PCR System (Applied Biosystem, Life Technologies Ltd.). Two-step cycling 
program was employed as recommended by the primer's manufacturer. The first step is an initial 
activation fo r the HotStart DNA polymerase at 95°C fo r 15 minutes. This is followed by a repetitive 
cycle o f template dénaturation (95°C, 15 seconds) and primer annealing (55 to  60°C based on the 
primer selected, 1 minute) fo r 40 cycles. This system produced a quantitative analysis o f target 
genes GOI and housekeeping gene HKG expression level in a form  o f a Cj value fo r each sample. Cj 
values o f samples were employed in the data analysis using AACt method. In this analysis, expression 
levels o f GOI were normalised to  the HKG by calculating the differences between the GOI and the 
HKG Ct values (ACj). Then the differences o f ACj values fo r each pair-wise set o f control and 
experimental samples were calculated (AACj). Finally, the fold-change value was calculated using the 
formula 2^'^^^'. Positive value indicates an increase in gene expression while negative value 
represents gene downregulation in experimental samples compared to control.
13. Short interference RNA (siRNA) transfection
The siRNA transfection method was employed to  transfect a gene-specific siRNA into the selected 
cell lines o f interest in order to  assess the effects o f (artificial) gene knockdown. The cells were 
seeded into a 6-well plate w ith a density o f 1.0 to  5x10^ cells/well depending on the cell line selected 
and left overnight. Transfection procedures were carried out based on the manufacturer's
52
[CHAPTER 2]
recommendation w ith slight modification. Two separate tubes were prepared in a similar volume. 
Tube 1 is a diluted SiRNA consists o f a calculated concentration o f siRNA, 5X SiRNA Buffer (used at 
IX) and serum-free medium (SFM). Tube 2 is a diluted transfection buffer DharmaFECT® reagent in 
SFM. The solutions were left in room temperature fo r 5 minutes before being gently mixed together 
and left fo r a fu rther 20 minutes. A fter overnight incubation, cells in plate were washed w ith  sterile 
PBS tw ice before being treated w ith  siRNA mixture fo r 4 hours. Complete medium w ith  fetal calf 
serum (FCS) final concentration o f 10% was added to  the well after 4 hours and cells were incubated 
overnight. Medium in the well was then replaced w ith  a new complete medium on the second day. 
Cells were harvested 72 hours post-transfection fo r subsequent analysis. Silenced cells can be 
harvested fo r protein and/or mRNA either directly from  the 6-well plate, or by harvesting and 
seeding the cells into a T25 flask and incubated until it reached approximately 90% confluence. To 
do a drug-response analysis on the silenced cells, cells were seeded in a T25 flask and left overnight. 
Drug treatments were carried out using a predetermined concentration fo r 48 hours before being 
subjected to  Annexin V-FITC and/or fixed fo r DNA analysis.
SiRNAs utilised were Human CDKNIC (p57'^'''^). Human W ee l, Human SFN, Human GAPDH and Non­
targeting siRNA Pool #1 (as negative control). Human W e e l and Human SFN siRNAs were ON- 
TARGET plus SMARTpool® consists o f a mixture o f four d ifferent siRNAs targeting one specific gene. 
Human CDKNIC and GAPDH siRNAs were ON-TARGET plus siRNA consists o f single siRNA targeting 
specific gene. siRNA sequences are as follows (Table 2-3):
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Human CDKNIC G AGCCAAU U U AG AGCCCAA
CUGAGAAGUCGUCGGGCGA
Human W e e l CGACAGACUCCUCAAGUGA
GAUCAUAUGCUUAUACAGA
AAUAUGAAGUCCCGGUAUA
AAUAGAACAUCUCGACUUA
Human SFN AGACUGAGCUCCAGGGCGU
CGAGACAACCUGACACUGU
CGACAAGAAG CGCAUCAUU
CAAGACCACUUUCGACGAG
Human GAPDH GACCUGACCUGCCGUCUAG
Table 2-3: Target sequence for sIRNAs used in the study.
2.16 Annexin V-FITC assay
The Annexin V-FITC assay was employed in flow  cytometry analysis to  aid in analysis o f cell death. 
Annexin V is an anticoagulant that binds phosphatidyl serine (PS) in presence o f calcium w ith  a rapid 
high a ffin ity binding. It acts as an early marker o f apoptosis. PS in viable cells is situated on the 
cytoplasmic surface o f the cell membrane. Early apoptosis induction brings rapid changes to  the cell 
membrane causing PS to  be exposed on the cell surface. Translocation o f PS w ill be followed by 
nuclear breakdown, DNA fragmentation and other molecules o f apoptosis-related. The function of 
Fluorescein isothiocyanate (FITC) in this assay is to  enable analysis using flow  cytometry or 
fluorescence microscopy. FITC acts as a conjugate to  Annexin V. To distinguish between viable cells, 
early apoptosis and late apoptosis and late apoptosis or necrosis stages, PI is incorporated in the 
assay. As stated previously, PI is able to  intercalate w ith  DNA. DNA staining in samples indicates the 
disintegration o f the cell membrane. Based on the properties o f both Annexin V and PI, 
determ ination o f cell death can be made. Viable cells w ill not bind any o f the dye whereas early 
apoptotic cells binds to  Annexin V-FITC but not PI. Necrotic cells were both PI- and FITC-positive.. 
Cell staining using Annexin V-FITC Apoptotic Detection kit can be performed follow ing three
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methods; Rapid and Conventional Annexin V binding (with or w ithout binding buffer) and Annexin V 
binding to adherent cells. Conventional Annexin V binding was the method o f choice in this study. 
Cells were grown in a T25 or a 6-well plate according to  the experimental settings. At the end of the 
experiment, cells were harvested w ith trypsin. Floating cells in the medium were also collected. Cell 
suspension was then washed w ith PBS before resuspension w ith ice-cold IX  binding buffer prepared 
earlier. To prepare IX  binding buffer, 5X Binding buffer stock was diluted w ith deionised water and 
left on ice. Care has to be taken in washing and resuspension step in order not to  introduce artefact. 
Staining process was carried out by an addition o f Annexin V-FITC (0.5p,g/mL) followed by 30 
minutes incubation at room temperature in the dark. Following incubation, tubes were centrifuged 
at lOGOg fo r 5 minutes at room temperature to collect cells. Binding buffer was removed and cells 
were gently resuspended in a new cold IX  Binding Buffer followed by an addition o f PI (0.6pg/mL). 
Samples were kept on ice away from light. Samples were analysed by flow  cytometry immediately 
using Beckman Coulter Epics XL flow  cytometer analyser. The follow ing figure (:) is an example o f 
flow  cytometer's cytogram o f a sample treated w ith drug and analysed w ith Annexin V-FITC:
El (upper left quadrant)
Primary/secondary
necrosis/debri
(5.9%)
E3 (lower left quadrant)
Viable
(66.9%)
1
' f i i :
n nm— i r i i i i ni— r - r
E2 (upper right quadrant)
Late apoptosis/secondary
necrosis
(12.4%)
E4 (lower right quadrant)
Early/mid-phase apoptosis 
(14.7%)
Log FITC
Figure 2-3: Typical cytogram readout of flow cytometer.
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14. DNA extraction from cell lines
DNA extraction and purification was carried out to  harvest the DNA from parental and drug-resistant 
cell lines fo r subsequent analysis o f DNA méthylation. The method was modified from  GenElute 
Blood Genomic DNA kit. Cells were grown in a T25 flask until it reached approximately 90% 
confluence. Cells were then harvested using trypsin or PBS and collected in a 2mL microfuge tube. 
Cells were resuspended in 500p.L PBS. RNase A (2 iig/|iL  sample) was added directly and sample 
incubated fo r 2 minutes at room temperature. Proteinase K was then added to  the sample (2|ig/|j.L 
sample). To lyse the sample. Lysis solution C was added and sample vortexed fo r approximately 15 
seconds until homogenous before fu rthe r incubation at 55°C fo r 10 minutes. Binding column was 
prepared by an addition o f column preparation solution into the column followed by centrifugation 
at 12,000g fo r 1 minute. Flow-through was discarded into waste. A fter incubation, 95-100% ethanol 
was added into the lysate and vortexed until homogenous (5 to  10 seconds) and loaded into the 
column. The column was then centrifuged at a minimum o f 6,500g fo r 1 minutes and flow-through 
discarded. The step was repeated fo r the rest o f the lysate. The column was placed into a new 2mL 
collection tube and washed w ith centrifugation (>6,500g fo r 3 minutes) tw ice using Wash solution. 
DNA was then eluted using Elution Solution that was pipetted directly into the centre of the column 
followed by 5 minutes incubation at room temperature fo r better elution efficiency before being 
centrifuged. The eluate containing DNA was labelled and stored at 2-8°C (short-term) or -20°C (long­
term). DNA in the eluate was quantified w ith the Nanodrop NP-lOO spectrophotometer. Purified 
genomic DNA was used in méthylation PCR analysis.
15. Agarose gel electrophoresis
Agarose gel electrophoresis is principally similar to  SDS-PAGE. In this study, agarose gel 
electrophoresis was utilised as a validation method fo r DNA bisulphite conversion and fo r detecting 
mycoplasma contamination on the cell cultures. 2% (w/v) agarose was used and the gel was
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prepared by dissolving the agarose in IXTAE. IXTAE was also utilised as a running buffer. Agarose 
gel powder were weighed and mixed w ith  IXTAE before being dissolved in the microwave. The gel 
mixture was left to  cool down slightly; Ethidium Bromide (EtBr) was added and thoroughly mixed 
before being poured into a gel casting apparatus tha t was assembled earlier. A fter the gel has 
solidified, running buffer was poured over the gel. Samples were mixed w ith  a loading dye and 
loaded into the well. Samples were run alongside a marker at lOOV fo r approximately 40 minutes or 
until the dye was at the edge o f the gel. To analyze the gel, GeneGenius gel documentation and 
analysis system (Syngene UK, Cambridge, UK) was employed. The picture o f the gel was captured 
and printed out. The gel was discarded accordingly.
16. Mycoplasma PCR
In some cases, mycoplasma infection can affect cultured cell growth. Cells become slower in growth 
or die w ithout showing any symptoms o f bacterial infection or other contamination. Some cell lines 
were particularly easily affected by mycoplasma. PCR was utilised to  determine mycoplasma 
infection using a specific primers available in Mycoplasma Plus PCR Primer Set. In preparation fo r 
mycoplasma detection, cells need to be cultured w ithou t antib iotic fo r several days. W ith this kit, 
cell culture supernatant or cells itself can act as a template fo r mycoplasma detection. Cell extract 
was the choice o f template fo r this study because it offers higher sensitivity o f detection compared 
to  cell culture supernatant. To prepare cell extract, cells were grown in a T25 flask until 
approximately 90% confluence. Cells were trypsinized and collected in l.SmL microfuge tube. Cells 
were then centrifuged to collect cell pellet and washed tw ice w ith  PBS carefully to  prevent loss o f 
cells. The cell pellet was resuspended w ith  sterile water and boiled at 95°C fo r 10 minutes followed 
by brief centrifugation. StrataClean resin from  the kit was thawed and resuspended by vortexing 
until its pellet disappears. Resin was then added into the sample and tube was flicked gently before 
being centrifugated fo r approximately 5 to  10 seconds to  pellet the resin. The supernatant was
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carefully transferred into a new tube by avoiding the resin pellet. Supernatant was used directly as a 
template in PCR and stable fo r several days at 4°C. 2X Thermo-Start™ PCR Master Mix (used at IX), 
samples, primers supplied and nuclease-free water w ith  or w ithout internal control topped up to 
50p.L reaction was prepared and dispensed into the PCR tube. Thermal cycler was programmed as 
per recommendation o f the kit manufacturer. Details o f the optimized program are as stated (Table 
2-4):
1 94 2
50 2
>- 1
72 2
2 94 1
50 1
 ^ 40
72 2
Table 2-4: PCR setting the thermal cycler to detect mycoplasma sequence amplification
Following PCR reaction, samples were analyzed w ith  agarose gel electrophoresis as explained 
previously. The gel was photographed and discarded accordingly. The presence of amplicon w ith  a 
size o f 874bp is consistent w ith  mycoplasma infection regardless o f species. Internal control sample 
yields IKbp band. Further enzymatic digestion o f the amplicons w ith  Sau3A I can be done to  
determine the species o f mycoplasma if needed.
Mycoplasma PCR detection was done routinely and as part o f troubleshooting process alongside 
experiments.
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17. Déméthylation treatment
Downregulation o f gene expression is a regular event in carcinogenesis. One factor contributing to 
this event comes from  epigenetic modification including hypermethylation o f gene's promoter 
region. In laboratory setting, the effect o f hypermethylation towards gene expression can be 
investigated through déméthylation treatm ent to  cell lines. In this study, déméthylation treatm ent 
was carried out on A2780TaxR taxane-resistant cell line based on method employed by Sato et al. 
(2005). Déméthylation treatm ent was done to  assess the level o f W e e l and Stratifin expression pre- 
and post-treatment. Cells were seeded in T25 flasks and treatm ent was carried out using 
demethylating agent 5-aza-2'-deoxycytidine ( I j iM )  and/or the HDAC inhibitor Trichostatin A (Ip-M). 
The difference in toxicity leads to  a varying incubation tim e fo r each agent. Cells treated w ith  5-aza- 
2'-deoxycytidine was incubated fo r 4 days while cells treated w ith  Trichostatin A was incubated fo r 
24 hours and the medium was changed the next day. For cells tha t received a combination 
treatm ent, cells were treated alternately fo r every passage. Cells were treated fo r several passages 
before being harvested fo r protein and mRNA samples. These samples were subjected to  analysis 
using western blotting or qPCR accordingly.
18. Statistical analysis
Statistical analysis values were expressed as mean ± standard deviation, calculated w ith  GraphPad 
PRISM® (GraphPad Software, Inc., USA) and M icrosoft Excel software. Student's Paired T-Test was 
performed where applicable and results were expressed as p values. Additionally, one-way AN OVA 
w ith Tu key's test fo r multiple comparisons was also performed where applicable.
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Introduction
1. Cancer of the ovary
structurally, the ovarian surface is lined w ith  epithelial cells, which are contiguous w ith  the 
peritoneal mésothélium. Ovarian cancer that originates from  malignant transformation o f this 
epithelium lining is called epithelial cancer o f the ovary (Cannistra 2004). Epithelial ovarian cancer 
(EOC) can be subtyped based on d ifferent histologic features; serous, mucinous, endometroid, clear 
cell, and undifferentiated carcinoma (Cannistra 2004; Nam and Kim 2008) (Table 3-). The average 
risk fo r women to  get EOC in the ir lifetime is approximately 1 in 70 and the median age fo r patients 
w ith EOC is 60 years. Several risk factors o f this malignancy include a genetic predisposition o f 
ovarian cancer, breast cancer or both and nulliparity. Oral contraceptive usage, pregnancy and 
lactation are associated w ith  reduced risk. There is a suggestion o f acquiring EOC during nulliparity 
state as a result o f uninterrupted ovulation which leads to  repeated stimulation of the epithelial 
lining o f the ovaries and consequences in malignant transformation. However, women who have 
undergone tubal ligation seem to be at a lower risk fo r developing EOC, however the exact 
mechanism remains unclear (Cannistra 2004).
EOC has the highest fatality-to-case ratio o f all gynaecological malignancies. It is also a relatively 
common malignancy in women, rated as the 5*  ^in the US (Jemal et al. 2004; Nam and Kim 2008).
The 5 year survival expectancy fo r these patients is only 20-40% (Nam and Kim 2008). Most patients 
w ith  an early-stage EOC do not exhibit specific symptoms or are asymptomatic, while almost 80% o f 
EOC cases are diagnosed during the ir advanced stage. Several markers such as the serum CA-125 
level apart from  physical examinations have been used in detecting EOC. However, lack o f symptoms 
and insufficient sensitivity and specificity o f serum CA-125 measurement makes EOC diagnosis 
difficult. The m ajority o f patients in advanced stage o f the disease often relapse after treatm ent w ith  
only 10-30% o f them having long-term survival. This relapse is caused by development o f resistance
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towards platinum-based therapy which is the firs t line o f treatm ent fo r EOC follow ing cytoreductive 
surgery (Cannistra 2004; Joo et al. 2009; Nam and Kim 2008; Rosenberg et al. 2001). Apart from  an 
advanced tum our stage, some subtypes o f EOC such as high-grade or clear-cell histologic findings 
have been associated w ith  inferior survival o f EOC patients (Cannistra 2004).
The International Federation o f Gynaecology and Obstetrics (FIGO) have established guidelines fo r 
staging o f EOC. The stages are divided into I, II, III and IV w ith  higher rates o f long-term survival fo r 
patients at the early stage o f the disease (stage I and II is as high as 80-95%). W ith advancement of 
the disease, the long-term survival rates decrease to  only 10-30% (Cannistra 2004).
Papillary serous The most common type o f EOC; may contain psammoma bodies 
and often associated w ith  elevated CA-125 level; histologic features 
identical to  those o f primary peritoneal serous cancer
Endometrioid Sometimes associated w ith endometriosis, a separate primary 
uterine cancer w ith in similar histologic features, or both; may occur 
w ith in  early-stage disease in younger patients, although advanced 
disease is also possible
Mucinous May be associated w ith  pseudomyxomaperitonei (rarely); CA-125 
level may not be markedly elevated; like clear-cell ovarian cancer, 
relatively resistant to  chemotherapy; not typically associated w ith  
BRCAl or BRCA2 germ-line mutations; differential diagnosis 
includes metastasic disease from  primary cancer o f the appendix, 
especially if ovarian involvement is bilateral
Clear-cell The most chemoresistant type o f ovarian cancer; characterized by 
hobnail-shaped tum our cells w ith  cleared out cytoplasm; 
sometimes associated w ith  endometriosis, humorally mediated 
hypercalcemia, or both
Table 3-1: Common histologic types of EOC (Cannistra 2004).
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1.1 Current treatment of EOC
After initial examination and confirmation o f staging, cytoreductive surgery is a method chosen as a 
primary treatm ent o f EOC followed by platinum-based chemotherapy to  eradicate residual disease. 
Drugs o f choice are a combination o f paclitaxel and carboplatin in high-risk patients. Platinum 
analogs such as carboplatin and cisplatin exert the ir effect by form ing a cross-link w ith  DNA 
interstrand and intrastrand, termed drug-DNA adducts. Platinum analogs also introduce DNA strand 
breaks. Formation o f adducts and strand breaks interfere w ith  protein binding which is essential fo r 
intracellular process such as transcription and DNA replication. As an addition, form ation o f DNA 
lesions can be recognized by high m obility group and mismatch repair protein which subsequently 
leads to  apoptosis initiated by p53 (Cannistra 2004; Li et al. 2009; Shah and Schwartz 2001). The 
taxanes are a group o f chemotherapeutic agents tha t act as a m icrotubule polymerizes. They exert 
the ir effect by promoting m icrotubule assembly, binding and stabilizing microtubules and promoting 
tubulin polymerization. Because o f the ir action, there is a shift in equilibrium, which results in the 
failure o f assembly because o f inadequate concentration o f tubulin. Taxanes also interfere w ith  
m itotic spindle assembly thus compromising segregation o f chromosomes resulting in G2M arrest 
and apoptosis. Additionally, paclitaxel has been associated w ith  downregulation o f CDK4 which 
brings about GiS arrest (Cannistra 2004; Shah and Schwartz 2001).
Some patients diagnosed w ith  EOC receiving treatm ent may face disease relapse, particularly if the 
malignancy is diagnosed during its late stage. Generally not curable, recurrent EOC is treated w ith  
approaches which aim at palliation o f symptoms and prevention o f complications, such as intestinal 
obstruction. There are patients w ith a short remission in which the cancer Is recurrent in less than six 
months after 1^ * line chemotherapy. Usually this group o f patients has a cancer tha t is resistant to  
platinum treatm ent. W ith this group, treatments are based on alternative agents such as liposomal 
doxorubicin, topotecan, gemcitabine, paclitaxel, oral etoposide and vinorelbine (Cannistra 2004).
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1.2 Cell cycle changes in EOC subtypes
D'Andrilli et al. (2008) have summarized features o f cell cycle changes in each o f the EOC subtypes. 
The change is not restricted to  only one component o f the cell cycle and this implies the effect o f 
cancer is as a result o f cumulative defects. CyclinE upregulation is found in serous, clear cell and 
undifferentiated carcinomas while increased p l6  expression can be seen in serous, mucinous and 
endometrioid EOC subtypes. P53 overexpression is a feature o f serous carcinoma while its 
downregulation is consistent w ith  endometrioid and clear cell carcinomas. Other cell cycle changes 
in serous EOC include CyclinDl overexpression and downregulation o f p27’^ '‘^  ^and In
endometrioid carcinoma, alterations in the p l5  and p l6  level and increased c-myc expression can be 
seen. Clear cell carcinoma, which is associated w ith  poor survival o f EOC patients also features 
CyclinA downregulation and upregulation o f p21^'’^ ^(D'Andrilli et al. 2008).
1.3 Acquired drug-resistance phenotype in EOC
As stated earlier, many EOC patients have recurrent disease a fter chemotherapy and surgical 
management. The cancer does not respond well fo llow ing treatm ent w ith  platinum-based agents. 
This is due to  the development o f a drug-resistant phenotype w ith in  the malignancy. These patients 
have short median survival (2-3 years) w ith  a lower survival percentage (Baird and Kaye 2003; 
Gifford et al. 2004).
Several mechanisms have been proposed to explain the development o f drug-resistant EOC. Some 
broad mechanisms include drug inactivation, decreased accumulation o f DNA adducts, defective 
DNA damage recognition, enhanced nucleotide-excision repair, and impaired apoptotic responses 
(Gottesman 2002; Li et al. 2009) which become parts o f alterations gained by the cancer cell itself 
(Baird and Kaye 2003). These alterations enable the cancer cell to  increase drug efflux, evade
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apoptosis, activate detoxification systems and in some cases, alteration o f drug targets inside the 
cells reduced the ability o f the drug to  bind and cause effect. Generally, some o f the mechanisms 
result in increased drug efflux from  cancer cells while others result in reduced drug uptake by the 
cells. Inadequate drug exposure caused by insufficient dose, poor drug distribution or impaired 
diffusion to  cancer cells may also give rise to  drug-resistant phenotype (Baird and Kaye 2003). Other 
mechanisms include compartmentalization o f drug inside the cells, alteration in membrane lipids 
and altered cell cycle checkpoints (Gottesman 2002).
Several epigenetic changes w ith in  the cell may play a role in the rise o f EOC drug resistant 
phenotype (Lopez et al. 2009). Hypermethylation o f CpG islands at the prom oter o f several genes 
renders them inactive. Alternatively, treatm ent w ith drug may induce promoter m éthylation by 
means o f DNA adduct form ation. Distortion o f DNA strands w ith  adducts increases accessibility o f 
DNA to DNA-methyltransferase (DNMT) enzymes and/or other auxilliary méthylation machinery 
components thus promoting DNA méthylation (Li et al. 2009). Some o f the genes whose expression 
is affected by promoter hypermethylation in EOC includes hMLHl; a DNA mismatch repair gene 
(Baird and Kaye 2003; Gifford et al. 2004), TGF61; involved in various cell adhesion process and 
maintains the extracellular matrix structure (Kang e t al. 2010), SFRP5; an extracellular signalling 
molecules that acts as an antagonist to  W nt signalling pathway (Su et al. 2010), Stratifin (14-3-3o); 
which induces Gz arrest as a response to  a DNA damaging agents (Kang et al. 2010), and p57" '^^  ^
(Coley et al. 2012; Sui et al. 2002).
1.4 Strategies to overcome drug-resistance in EOC
As EOC accounts fo r the highest m orta lity o f all gynaecological malignancies and its tendency to  
develop resistance after treatm ent, a strategy to  overcome the drug-resistant phenotype is crucial.
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Changing several aspects such as the treatm ent schedule, route o f drug administration, drug dose, 
duration o f drug administration and using combinations o f agents give some scope in managing the 
EOC using current chemotherapy agents. Research to  develop novel targeted therapeutic agents fo r 
the treatm ent o f EOC is ongoing w ith  three main objectives; reduction in toxicity, ease o f drug 
administration and overcoming drug resistance. There are a number o f areas tha t can be 
manipulated to  tackle drug resistance in EOC. Currently, research in this area includes hormonal 
therapy, growth factor inhibitor, apoptosis induction, anti-angiogenic therapy, gene therapy and 
immunotherapy (reviewed in Agarwal et al. 2006).
Targeting the cell cycle has recently emerged as one o f the new approaches in drug development for 
cancer treatm ent. Cell cycle components are often deregulated in cancer cells. Overexpression o f 
cyclins and/or downregulation o f CKIs often results in cancer progression (Dickson and Schwartz 
2009). In ovarian cancer, CyclinE levels are often deregulated and expression o f the low molecular 
weight form  o f CyclinE (less than SOKDa) is associated w ith  oncogenesis. This along w ith  histological 
findings may assist in clinical diagnosis o f EOC and opens the possibility fo r CyclinE to  become a 
target fo r cancer therapy because o f its dual role in cell proliferation and apoptosis (Mazumder et al. 
2004). Additionally, inhibition o f cell cycle can induce apoptosis. This feature can be manipulated to  
cause apoptotic cell death to  the cancer cell. Inhibition o f RNA polymerase II, a key enzyme in 
transcription mechanism decreased the level o f anti-apoptotic protein M c l- l thus promoting 
apoptosis. RNA polymerase II is regulated by several CDKs via phosphorylation. Inhibition o f CDKs by 
a CDK inh ib itor agents such as flavopiridol and seliciclib downregulates activation o f RNA polymerase 
II and subsequently leads to  apoptotic events in cancer cells (Aldoss et al. 2009; Dickson and 
Schwartz 2009). Since cell cycle alterations is significant in tumorigenesis and cancer progression, the 
study o f cell cycle components is paramount in order to  establish molecular features o f cancer and 
provide fu rther insight into its mechanism, in the hope tha t it assists w ith  fighting cancers.
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2. p5?K ip2
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Figure 3-1: protein structure.
2.1 The gene
Human p57' '^'"  ^ protein is encoded by the CDKNIC gene situated at the telomeric end o f chromosome 
11, at the locus l lp l5 .5 .  Several binding sites can be found in the promoter region of this gene, 
including Sp-1 (strimulatory protein-1), ETS (erythroblastosis virus E26 oncogene), e g rl (early growth 
response 1), a TATA box, OCTl (octamer-binding transcription factor 1), NFl (neurofibrom in 1), CAT 
element, a GRE (glucocorticoid-response element), a binding site fo r p63 isoform and binding sites 
fo r Hesl and Herp2 notch effectors (Pateras et al. 2009). p63 has been shown to regulate 
transcriptional activation and repression of Beretta et al. 2005) while treatm ent o f HeLa cells
w ith dexamethasone, a glucocorticoid, upregulates p57^''’  ^expression (Kamura et al. 2003). Human 
p57^'^^ protein consists o f 3 distinct domains. Domain I (N-terminal region) consists o f KID (CDK 
inhibitory domain) that is conserved among family members. KID contains 3 regions: a cyclin binding 
sequence, a CDK-binding site and an additional binding m otif 3io helix. Thus, KID is essential in 
p5 7 Kip2 inhibitory mechanism. Domain I also contains sequence important in interaction w ith 
certain transcription factor, fo r example MyoD. Domain II contains a distinct proline-alanine rich 
repeat region termed PAPA region, which is not available in mouse p57’^ ''"^ . Domain III is a C-terminal 
region comprises o f a conserved m otif QT domain. QT domain interacts w ith PCNA (proliferating 
nuclear antigen) and block DNA synthesis. This domain is also im portant in nuclear localization of 
p57 '^'^ .^ The amino- and carboxy-terminal domains are conserved between human and mouse. 
Features o f this protein are lack o f stable helical and 3-sheet structure which make it a highly
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unfolded molecules, degraded faster and have a higher rate o f evolution in comparison w ith  folded 
protein (Borriello et al. 2011; Pateras et al. 2009). Additionally, p57' '^'"  ^only adopts tertia ry protein 
structure after binding to  target proteins, thus might explain its interaction w ith  a broad range o f 
proteins and its involvement in regulating numerous cellular activities (Borriello et al. 2011).
2.2 p5 ?Kip2 mode of action
p57' '^'^ i^s a member o f Cip/Kip fam ily if  CKIs, other members include p21 '^"^  ^and p27’^ '’’\  p57' '^'’  ^exerts 
its inhibitory action on the follow ing CDK-cyclin complexes; CDK2-CyclinE, CDK2-cyclinA, CDK3- 
CyclinE, CDK4-cyclinDl, CDK4-cyclinD2 and to  a lesser extent CDKl(CDK2)-cyclinB and CDK6- 
cyclinD2; in a cyclin-dependent manner. Higher concentrations o f p57'^''’  ^w ill inhibit kinase activity o f 
CDK-cyclin complexes while at lower concentrations it forms an active complex w ith  CDK2-cyclinA. 
Inhibition o f CDK-cyclin kinase activity comes from  the amino-term inal region o f the protein, which 
enables it to  bind inside the catalytic cleft in amino-term inal region o f CDK2 mimicking adenosine 
triphosphate (ATP) action (Pateras et al. 2009). The central area o f p57'^''’  ^may function in o ther non- 
CDK inhibitory roles (Pateras et al. 2009), and the PAPA region has been proposed to be involved in 
interaction between p57'^''’^and the p220'^'’^VHiNF-P complex which is a CDK2 substrates associated 
w ith  nucleosome packaging during Gi-S phase transition (M itra et al. 2009) (Figure 3-).
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Figure 3-2: Inh ib itory action o f on Rbp/E2F and p220^''*^/HiNF-P pathways. CDK2-CyclinE phosphorylates p220'^
and Rbp. binds and inhibit CDK2-CyclinE activity and able to  bind to p220''"’" ‘/HiNF-P complex and inactivate it.
2.3 Genomic imprinting of pST '^pz
CDKNIC, the gene encoding p57 '^'"^ is situated at l lp l5 .5 ,  a locus well known fo r containing several 
imprinted genes that shows preferential parent-of-origin gene expression (Borriello et al. 2011). 
Gene expression at this locus is controlled via tw o imprinting centre/im printed control region (ICR): 
ICRl (H19) and ICR2 (KNCQl). ICRl controls expression o f H19 and insulin-like growth factor 2 
(IGFR2), while ICR2 controls among several genes, CDKNIC expression. Both ICR sits near to each 
other which pose different méthylation status based on allele inheritance. As a result, p57' '^'"  ^ is 
expressed from maternally inherited allele but fa in t expression is also present from paternally 
inherited alleles. However, the exact mechanism o f ICR2 in regulating gene expression is unclear. 
Translocation can disrupt physical distance between ICR2 and CDKNIC, which leads to 
downregulation of expression via loss o f imprinting (LOI). LOI leads to overexpression o f one
gene w ith silencing of the other gene controlled by the same ICR (Borriello et al. 2011; Feinberg and 
Tycko 2004; Schulz 2007).
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2.4 p57Kip2 roles in normal tissues
As stated previously, CDK inhibitory function o f p57'^'’’  ^is essential in cell cycle regulation. p57' "^^  ^
reaches its peak expression during Go and Gi cell cycle phase, and declines subsequently, p57'^"'^ also 
plays a role in endoreduplication, which is replication o f the nuclear genome in the absence o f cell 
division ultim ately resulted in increased genome content and polyploidy (Borriello et al. 2011; Ullah 
et al. 2009). p57'^'’'^ controls organogenesis, embryogenesis and cell differentiation in a temporal, 
spatial and cellular specific manner. Its expression is most apparent during organogenesis. During 
this stage, the protein is widely localized in tissue and reaches peak at key stages o f differentiation 
fo r each specific organ. It is present in all major organs during embryonic development. Precise 
regulation o f p57'^'’’^is im portant in embryonic growth. The p57'^'‘^  ^protein starts to  decline 
afterwards and only organs that mature after birth, such as testis, exhibit strong p57' '^^^ staining in 
certain tissue compartments (Borriello et al. 2011; Pateras et al. 2009). D ifferentiation o f several 
types o f tissues such as lens-fiber, podocytes, placental cells, kératinocytes, pancreatic cells, 
hepatocytes, T-lymphocytes, spermatozoa. Ley dig cells, chondrocytes, adrenal cortex cells and the 
nervous system is regulated by pST'^"’ .^ It also takes part in myogenesis via interaction w ith  MyoD, a 
specific transcription factor needed in myogenic d ifferentia tion (Borriello et al. 2011). In adult 
tissues, p57' '^^^ expression is lim ited to  chondrocytes and some differentiated epithelial cells such as 
gastrointestinal villi, smooth muscle cells o f intestinal wall, and basal and parabasal cells o f normal 
oesophageal epithelium (Rosenberg et al. 2001). Significant amounts o f p57" '^^  ^mRNA can be 
detected in human adult tissue mainly in skeletal muscle, brain, heart, lung, kidney, pancreas, testis 
and placenta (Borriello et al. 2011; Pateras et al. 2009). This restricted pattern o f expression is due to  
CpG méthylation dependent imprinting o f the gene (M itra et al. 2009).Other roles o f p57' '^'^  ^includes 
promoting erythrocyte differentiation, regulating cytoskeletal dynamics and cell m otility, inducing 
senescence phenotype in certain cell types, promoting apoptosis in cancer cells and it also plays a 
role in transcriptional regulation. Apoptosis-inducing role o f p57" '^^  ^is through CDK-independent 
mechanism by translocation into mitochondria and activating the intrinsic apoptotic pathway. P57"^ "^ ^
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is able to  inh ibit transcription indirectly by CDK inhibition which prevents Rbp phosphorylation and 
directly via binding o f p57'^'’’  ^to  E2F1 and reducing serine residue phosphorylation o f RNA 
polymerase II (Borriello et al. 2011).
2.5 p5 ?Kip2 expression in cancerous tissues
Because o f its role in cell cycle, deregulation o f p57' '^^^ is one o f the features o f many human cancers 
(Pateras et al. 2009; Roeb et al. 2007). Its downregulation can be found, fo r example, in breast 
cancer, W ilms' tumour, ovarian carcinoma and Beckwith-Wiedemann Syndrome (BWS). p57" '^^  ^
downregulation is associated w ith  the level o f tum our aggressiveness in some malignancies and 
inversely correlated w ith cell proliferation (Borriello et al. 2011; Lee and Yang 2001; Pateras et al. 
2009; Vue et al. 2003). Reduced p57'^''’  ^expression predicts poor prognosis in cancers such as oral 
squamous cell carcinoma, hepatocellular carcinoma, breast cancer and in malignant ovarian tumours 
(Pateras et al. 2009). Reduced expression o f p57'^'‘^  ^can be observed in patients w ith  malignant 
trophoblastic neoplasm (Kim et al. 2005). In some o f other malignancies, increased level o f p57'^ '"^  ^
together w ith  the level o f cyclinE can be observed which may suggest an activation o f feedback 
mechanism to  contain uncontrolled cell proliferation. To summarize, the level o f p57' '^'^  ^in early 
stages o f cancer is elevated before steadily decreasing along w ith  progression o f the malignancy 
(Pateras et al. 2009). Decreased p57' '^'^  ^gene expression is associated w ith  the immortalization 
process and exogenous overexpression of p57' '^^^ reverts malignant phenotypes (Borriello et al. 
2011).
Downregulation o f p57' '^'"  ^can take place transcriptionally and translationally. However, mutation of 
the gene itself is not found in cancer samples analyzed, thus, the most probable mechanism o f 
p57'^''’^downregulation in cancers comes from epigenetic silencing. This alteration leads to  genome
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instability w ith  subsequent loss o f heterozygosity (LOH), histone deacetylation, méthylation at CpG 
islands in the promoter region and 5' regulatory sequences, and nucleosome remodelling. Epigenetic 
alterations in cancer cells lead to  activation o f oncogenes, silencing o f tum our suppressor genes like 
and inactivation o f the DNA repair system (Taylor 2006). Increase in prom oter méthylation 
and LOH accounts fo r a decrease in mRNA levels (Borriello et al. 2011; Pateras et al. 2009; Shin et al. 
2000; Vue et al. 2003). Deacetylation o f histones leads to  the transcriptionally inactive state as it 
permits form ation o f normal nucleosome structure (Shin e t al. 2000). Reactivation o f genes by 
treatm ent w ith  demethylating agents such 5'aza-cytidine or w ith  histone deacetylase inhibitors 
offers an alternative potential strategy fo r the treatm ent o f some cancers, as stated previously in 
Chapter 1 (Seidel et al. 2012).
In lung cancer, downregulation o f pS?"^ '"^  ^may be as a result o f several mechanisms such as 
decreased pS?’^ ''^  ^expression coupled w ith  increased Skp2 level and decreased at the 
transcriptional level. Some subsets o f cases investigated by Pateras et al. (2009) shows upregulation 
o f mRNA together w ith  a decreased protein level which might be an effect o f increased Skp2 
level. Since some miRNAs have been shown to regulate p57' '^^^ level (discussed in the next 
paragraph), increases in miRNA levels associated w ith  decreased p57'^'’^  ^ is seen in several cancers 
including gastric, ovarian, colorectal and hepatic carcinomas (Table 3-2). Finally, deregulation o f 
some transcription factors such as p73 also affect p57'^ ''^  ^activity (Borriello et al. 2011).
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Liver tum ours Hepatocellular
carcinoma
Downregulation o f p57'^'’^  ^serves as an independent 
prognostic factors associated w ith  poor outcome 
Comparison w ith  nm23 (metastasis suppressor) 
expression - abnormal coexpression o f nm23/p57'^''^^ 
maybe a useful molecular marker fo r metastasis and 
unfavourable prognosis
Urothelial
carcinomas
Protein was decreased in approximately 50% o f 
cases, correlated w ith  the more aggressive forms o f 
cancer
Colorectal
cancers
Significant correlation between low expression o f 
p57'^"’  ^and large size o f tum our 
Significant decrease during the transition from 
adenoma to  carcinoma
Adrenocortical
cancers
Absence o f expression in malignant samples 
Downregulation was associated w ith  increased CDK2 
activity
Thyroid
cancers
Overexpressed in follicular adenomas and minimally 
invasive follicular adenomas 
Upregulation diminished in invasive follicular 
carcinomas
Reduced in poorly differentiated and 
undifferentiated carcinomas 
Significant reduction o f protein in > 50% o f thyroid 
lymphoma cases
Ovarian
cancers
- Frequent decrease o f protein w ithou t any 
correlation w ith  poor survival
Gastric cancers - Lower level o f protein compared to  normal tissues, 
good correlation w ith  lymph node involvement
Oral and 
laryngeal 
cancers
Low protein expression.
Absence o f p57'^ ''^  ^is correlated w ith  worst 5-year 
survival rate (squamous cell carcinoma &leukoplakia) 
Increased miR221 and miR222 expression in oral 
carcinoma cells
Lung cancers Non-small cell 
lung carcinomas
p57"^'^^expression is selectively downregulated 
Reduction was due to  epigenetic modification 
(méthylation, allelic imprinting and increased 
degradation)
Breast cancers - Hypermethylation & reduction o f mRNA level
Haematological
tumours
CIVIL (chronic 
myelogenous 
leukaemia)
Decreased protein expression
ALL (acute
lymphoblastic
leukaemia)
Increased promoter méthylation
Epigenetic changes o f the gene as an independent
marker o f ALL
Diffuse large B-cell 
lymphoma
M éthylation o f the gene in more than 50% cases 
M éthylation status as detection o f minimal residual 
disease
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2.6 regulation
levels are regulated transcriptionally and post-translationally. Transcriptional regulation o f 
pS?' '^’'^ comes from  an epigenetic control mechanism, as mutational inactivation o f this gene and its 
fam ily members is uncommon (Pateras et al. 2009; Shin et al. 2000). Epigenetic is defined as 
modified DNA other than in the DNA sequence itself. Genomic imprinting is an epigenetic event that 
leads to  the silencing o f gene's expression. DNA méthylation and histone modification are closely 
related w ith  the mechanism o f genomic imprinting (Feinberg and Tycko 2004). Imprinting 
comes from CpG méthylation and histone deacetylase activités. The pS?' '^^  ^gene is rich in CpG 
islands both upstream and downstream o f its transcriptional start site and binding o f stimulatory 
proteins to  the gene promoter is enhanced by histone hyperacetylation (Borriello et al. 2011;
Pateras et al. 2009). In normal status, the p57'^'^^ gene is expressed by the maternal allele while 
paternal allele is imprinted. However in most human tissues, low levels o f expression leakage 
from  the paternal allele can be detected (Pateras et al. 2009; Yue et al. 2003).Imprinting control o f
is also tissue-specific, as the gene is hypomethylated in normal human kidneys and 
methylated in normal human bronchial tissues. Treatment w ith  a demethylating agent or a histone 
deacetylase inh ib itor activates expression by increasing accessibility o f DNA to  transcription 
factors (Pateras et al. 2009; Shin et al. 2000). Silencing o f pS?' '^^  ^expression can also come from 
various types o f non-coding RNA transcripts, as recent findings show tha t a series o f micro-RNAs 
(miR) miR221, miR-222 and miR-25 (to name a few) are able to  downregulate pS?' '^'^^  expression in 
various human cell lines and in vivo human hepatocellular and gastric carcinomas (Borriello et al. 
2011; Pateras et al. 2009). The possibility o f a post-transcriptional regulation mechanism is shown by 
a different expression pattern o f pS?' '^'^^  mRNA and protein in mouse placenta (Kim et al. 2005).
Various other pathways also contribute to  controlling p5?' '^^^ expression by activation o f epigenetic 
mechanisms, either in inducing or in downregulating its expression. Transforming growth factor p i
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(TGFpi) and E47 transcription factor participating in human development, upregulates p57" '^^  ^
expression (Ma and Cress 2006; Pateras et al. 2009). However in osteoblasts, TGPP causes 
p57'^''’^degradation (Lee and Yang 2001). Treatment w ith  several agents such as histone deacetylase 
inhibitor, demethylating agent and several drugs such as glucocorticoids, vitamin D3 analog EB1089 
and BMS-38703 also induces p57' '^^^ expression (Ma and Cress 2006; Pateras et al. 2009). Other 
examples that induce upregulation o f p57'^ ''^  ^are atrial natriuretic peptide and p73p. Several 
molecules have been described as downregulators o f p57' '^'^  ^expression such as IGF2, Notch 
effectors Hesl and Herp2, inh ib itor o f differentiation 2 (Id2) and Pax3-F0X01. PAX3-F0X01 is a 
fusion protein found in rhabdomyosarcoma which downregulates p57'^'‘^  ^through degradation of 
transcription factor e g rl, thus interfering w ith p57' '^'^  ^activation (Pateras et al. 2009; Roeb et al.
2007).
2.7 p5 7 Kip2 relationship with Skp2
Regulation o f p57' '^'^  ^protein level post-translationally is provided by the ubiquitin-proteosome ligase 
system, specifically by interaction w ith  Skp2. Skp2 is a subunit o f SCF-type E3 ligase, which belongs 
to  the F-box protein family. The SCF m ultisubunit complex consists o f three constant subunits and 
one variable subunit. The constant subunits are Skpl, C u ll and R bxl/R ocl, while the variable 
subunit is an F-Box protein which performs as a receptor fo r target proteins. F-box protein thus 
determines substrate specificity fo r SCF ligase. Skp2 and another protein - Fbw7 - are among the F- 
Box proteins that are well characterized and have been shown to  control protein levels in cancer 
cells. Identification o f the target protein is in a phosphorylation-dependent manner, as E3 ligase 
often needs target modification to enable the recognition (Borriello et al. 2011; Kamura et al. 2003; 
Kitagawa et al. 2009; Pateras et al. 2009; Rodier et al. 2008). Target modification also serves as a way 
o f controlling the activity o f SCF E3 ligase (Rodier et al. 2008). Modification o f Skp2 target, p57'^'‘^  ^
comes from phosphorylation o f p57'^ ''^  ^by CDK-cyclin complexes. CDK2-CyclinE phosphorylated
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at ThrSlO residue which serves as a negative feedback loop (Kamura et al. 2003). 
Identification o f the target protein is then followed by polyubiquitination and subsequent 
degradation by proteosome. Skp2 in turn is targeted by another E3 ligase APC“ '^  ^fo r degradation 
and serves as another way to regulate the ligase activity (Rodier et al. 2008). Besides p57'^'''^ Skp2 
also targets p27'^''^\ p 2 l‘'''^\ hyperphosphorylated Rbp, p l30 , E2F1, free CyclinE and c-Myc amongst 
others, fo r ubiquitination (Kamura et al. 2003; Kitagawa et al. 2009; Rodier et al. 2008; Sun et al.
2007). During the cell cycle, the Skp2 protein level is low in Go/early Gi before gradually increasing 
during S phase and continues until the cell reaches mitosis (Kamura et al. 2003; Rodier et al. 2008). 
As Skp2 promotes degradation of negative regulators of the cell cycle, it is considered as an 
oncogene. Furthermore, there is Skp2 amplification in human gastric cancers and elevated 
expression of Skp2 can be found in various other human cancers (Kitagawa et al. 2009; Rodier et al.
2008).
C onstant
s ubunit
s ubunit
*S ubstrate  recognition m odu le  Tum our-associated substrates
F b w l (P-TrCP) B-catenin, IkB, CDC25, W e e l,  Period
Skp2 P130, T o b l, c-M yc, p27, p57
Fbw7 c-M yc, c -M yb, CyclinE, c-Jun, Notch,
-  r  F - b o i p r o t e i r ^  *
T t  I  "  ■■ FBX4-aBcrystallln CyclinD l
Figure 3-3: SCF E3 ligase structure. Different F-box proteins have different tumour-associated substrates (adapted from 
Kitagawa et al. 2009).
3. CyclinE as a partner of
CyclinE is the activator of CDK2. CDK2-CyclinE complex is essential in cell cycle progression from  Gi 
to  S phase of the cell cycle and this complex is regulated by p57^'^^ among others. CyclinE protein is 
both synthesized and degraded in the cytoplasm. It is translocated into the nucleus and forms a 
complex w ith its partner CDK2. The CDK2-CyclinE complex is essential in cell cycle progression from 
Gi to  S phase of the cell cycle (Malumbres and Barbacid 2005; Mazumder et al. 2004). CDK2-CyclinE 
phosphorylates an array of substrates that promotes cell cycle progression. CyclinE also contributes
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in the regulation o f DNA replication and apoptosis. The cyclinE gene encodes fo r an approximately 
50kDa protein. CyclinE has an isoform CyclinE2, approximately 47kDa molecular weight w ith  47% 
overall homology and sharing 75% homology to  CyclinE's cyclin box. CDK2-CyclinE downstream 
targets include Rbp, Cdc6, NPAT and nucleophosmin (Mazumder et al. 2004).
3.1 CyclinE activation and functions
In addition to  Gi-S cell cycle progression, CDK2-CyclinE complex interacts w ith  Cdc6, a pre-replication 
protein that enables its binding to  chromatin. Loading o f Cdc6 onto chromatin initiates DNA 
replication. Continual CyclinE binding to  chromatin during DNA replication progression might serve 
as a means o f preventing DNA re-replication. Phosphorylation o f CyclinE during mitosis prompted 
CyclinE dissociation from chromatin. This interaction is re-established again via CyclinE 
dephosphorylation after mitosis exit, thus promoting another round o f DNA replication. CDK2- 
CyclinE promotes centriole disorientation w ith  subsequent splitting by phosphorylating 
nucleophosmin, which is a part o f the centrosome. Nucleophosmin phosphorylation promotes its 
dissociation from  the centrosome thus allowing centriole disorientation. Apart from  that, interaction 
o f CDK2-CyclinE w ith  p220’^ '^^  ^during the beginning o f S phase induces histone gene transcription 
(Malumbres and Barbacid 2005; Mazumder et al. 2004). As stated earlier, p220'^'’'^VHiNF-P complex 
is a CDK2 substrate associated w ith nucleosome packaging and is regulated by p57'^’'’  ^ (Figure 3-) 
(M itra et al. 2009).
Apart from  its role in DNA replication and cell cycle progression, CyclinE also plays a part in 
apoptosis. Following radiation treatm ent on m ultiple myeloma and lymphoma cells, CyclinE mRNA 
and protein level increased substantially followed by increased CDK2-CyclinE kinase activity. 
Activation o f CDK2 is important in apoptosis induction, thus increase in CDK2-CyclinE in these cases
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might point to  the activation o f apoptosis mechanism. In haematopoietic cells, CyclinE 
overexpression sensitizes cells to  radiation-induced apoptosis, while its downregulation protect cells 
from  death. During the progression o f apoptosis after radiation and chemotherapeutic agent 
treatm ent, a smaller fragment o f CyclinE called plSCyclinE is generated possibly by caspase- 
mediated cleavage o f full-length CyclinE protein. PlSCyclinE binds to  Ku70, a component o f non- 
homologous end-joining (NHEJ) DNA repair mechanism which is activated follow ing DNA damage. 
Binding o f plSCyclinE to  Ku70 is proposed to  act as regulatory mechanism, preventing DNA damage 
repair during the course o f apoptosis. CyclinE is known to  phosphorylates p27"^ '^  ^thus promoting 
p2 7 kipi degradation via the ubiquitin-proteasome pathway (Maddika et al. 2007; Mazumder et al. 
2004).
3.2 CyclinE regulation and deregulation in cancers
CyclinE is regulated transcriptionally and post-transcriptionally. CyclinE falls under the control o f the 
E2F transcription factor regulation since the CyclinE promoter contains several binding sites fo r E2F. 
The E2F binding site is also found in CyclinE repressor module tha t acts to  repress CyclinE expression 
until late G I phase. W ithin this site, E2F is bound w ith  Rbp and pocket protein DPI. Rbp interacts 
w ith  histone deacetylase (HDAC) and several other proteins to  form  a repressor complex. 
Phosphorylation o f Rbp by CDK4-CyclinD releases Rbp from  the repressor complex, enabling gene 
transcription (including CyciinE) by E2F. Post-translational regulation o f CyclinE comes from  its 
interaction w ith several proteins and its ability to  autophosphorylate. CDC25A, an upstream 
regulator o f CyclinE removes inhibitory phosphorylation on CDK2 thus indirectly influence CyclinE 
activation. Apart from  activating CyclinE, CDK2 binding protects CyclinE from  degradation since 
unbound CyclinE is degraded via ubiquitin-proteosome system. Skp2, an F-box protein involved in 
regulating p57' "^^  ^has been found to  play a role in CyclinE degradation. Skp2 silencing leads to  
accumulation o f CKIs w ith  a subsequent negative effect on CDK2 activation and CyclinE
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autophosphorylation, ultimately promoting CyclinE degradation. Another F-box protein, Fbw7 shows 
specific binding to  CyclinE. Fbw7 phosphorylates Thr380 and Thr62, promoting CyclinE degradation 
via ubiquitin-proteasome pathway. M utation o f Fbw7 is found in cancers w ith  high CyclinE, 
suggesting its role in regulating CyclinE levels (Mazumder et al. 2004).
Deregulation o f CyclinE had been reported in breast, colon, lung, ovary and prostate carcinomas 
(Maddika et al. 2007; Mazumder et al. 2004). In some tumours, CyclinE upregulation is an early 
event during the transformation however in others it is a late event. Several mechanisms 
contributing to  high CyclinE level in tumours are increased protein synthesis, decreased degradation 
and impaired translocation into the nucleus. In ovarian cancer, loss o f p27"^ '^  ^expression and CyclinE 
or CDK2 overexpression significantly correlates w ith  malignancy. High CyclinE expression correlates 
w ith  lower life expectancy and poor prognosis (Mazumder et al. 2004; Rosenberg et al. 2001).
CyclinE deregulation might be associated w ith  certain ovarian cancer sub-types, particularly clear 
cell, serous and poorly differentiated carcinomas o f the ovary (Rosenberg et al. 2001; Stamatakos et 
al. 2010). Low p27' '^'’  ^expression coupled w ith  high CyclinE level is also significantly correlated w ith  
poor prognosis in lymphoma. Malignant transformation o f breast ductal carcinoma in situ to  invasive 
carcinoma is associated w ith increased CyclinE expression. Another form  o f biochemically active low 
molecular weight CyclinE is found to  be commonly expressed in majority o f breast cancer cell lines 
and breast cancer patients. Its level is associated w ith  increased CDK2 kinase activity, higher rate o f 
cell proliferation and poor outcome (Mazumder et al. 2004). In ovarian cancer, CyclinE is associated 
w ith  higher tum our grade, late stage disease, suboptimal cytoreduction and patients aged more 
than 60 years at the tim e o f diagnosis (Stamatakos et al. 2010).
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4. Exogenous modulation of the cell cycle by use of synthetic CDK inhibitors
4.1 Selidclib: Mode of Action
hn^ n - ^ n  
OH
Figure 3-4: Selidclib (CYC202, R-roscovitine) chemical structure (Golsteyn 2005).
Seliciclib (CYC202, R-roscovitine) is the r-enantiomer o f the cell cycle inh ib ito r agent roscovitine. It is 
a second generation o f CDK inhibitory agent, w ith  a higher selectivity fo r its CDK target compared to  
the firs t generation small molecule CDK inhibitors such as flavopiridol. In contrast to  seliciclib, 
flavopiridol is a pan-CDK inh ib itor w ith  a global inhibition effects. Seliciclib on the other hand has a 
high specificity fo r CDK2-cyclinE, CDK9-cyclinT, CDK7-cyclinH and CDKl-cyclinB and it is a potent 
inh ibitor o f CDK2-cyclinE relatively (Aldoss et al. 2009; Coley et al. 2007; W hittaker et al. 2007). 
Seliciclib is able to  block cell proliferation in almost all stages o f the cell cycle by a number o f 
mechanisms. The main mechanism involved in cell cycle blockage by seliciclib is through the ATP 
pocket o f the kinase catalytic subunit. Seliciclib reversibly binds to  and competes fo r the ATP-binding 
site which inhibits CDK-cyclin activities (Aldoss et al. 2009; Galimberti et al. 2010). Other 
mechanisms include cell cycle arrest as a consequence o f CDK inhibition at GiS and G2 M, and 
apoptosis promotion. Seliciclib promotes apoptosis by means o f several ways. It inhibits CDK7 and 
CDK9 thus downregulating phosphorylation o f RNA polymerase II carboxy term inal domain, which 
has a role in transcription machinery. This event leads to  downregulation o f anti-apoptotic proteins 
such as M c l- l and other proteins involved in transcription and translation, fo r example CyclinDl. 
Seliciclib also inhibits Rbp phosphorylation and downregulates expression o f XIAP and survivin. All 
these events lead to  cell cycle arrest at GiS and G2M, and initiation o f caspase-dependent apoptosis 
(Aldoss et al. 2009; MacCallum et al. 2005; W hittaker et al. 2007). Inhibition o f CDK9 by seliciclib also
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affects the level o f MDM2, a negative regulator o f the tum our suppressor protein p53. Reduced level 
of MDM2 results in stabilization and accumulation o f transcriptionally active p53 in nuclei which will 
lead to  apoptosis. Cells w ith functional p53 are more susceptible to  seliciclib effects (Paprskâfovâ et 
al. 2009). However, seliciclib is also able to  induce killing in cells w ith m utation of either ATM or 
TP53 genes as in B-cell chronic lymphocytic leukaemia (B-CLL) through downregulation of 
transcription and cell survival w ithout noticeable effect on normal lymphocytes (AIvi et al. 2005).
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Figure 3-5: Summary of seliciclib mode of actions.
4.2 Seliciclib as single agent and in combination with other drugs
Seliciclib has shown its antitum our effect against a spectrum o f human cancer cell lines, both 
haematological and solid tumours. Treatment of B-CLL cell lines w ith  seliciclib promotes apoptosis 
irrespective of ATM/TP53 mutations while in combination w ith  alemtuzumab (a monoclonal 
antibody drug) seliciclib promotes apoptosis of alemtuzumab-resistant cells (Aldoss et al. 2009; AIvi 
et al. 2005). Seliciclib also induces apoptosis in diffuse large B cell lymphoma (DLBCL) and mantle cel
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lymphoma (MCL) by accumulation o f lymphoma cells in G; or G2 M phases. A synergistic effect can 
also be seen in combination w ith  doxorubicin or bortezomib (a proteasome inhibitor) against 
multiple myeloma (MM) cells. In lung cancer studies, seliciclib has shown induction o f apoptotic 
activity either as a single agent or in combination w ith  EGFR and HER-2 pathway inhibitors through 
form ation o f anaphase catastrophe during cell division (Aldoss et al. 2009; Galimberti et al. 2010). 
Treatment o f breast cancer cell lines w ith  seliciclib promotes apoptosis by sensitizing cells to  tum our 
necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) followed by cell cycle arrest. 
Combination w ith  doxorubicin ortrastuzum ab also produces a synergistic effect (Aldoss et al. 2009). 
In uterine sarcoma cell lines, seliciclib treatm ent shows synergism in combination w ith  cisplatin. 
However, as a single agent seliciclib does not elicit a profound cell cycle effect as compared to  other 
cytotoxic agents such as paclitaxel but a consistent G2M accumulation has been reported. Again p53 
status did not have an influence on seliciclib-cisplatin synergism (Aldoss et al. 2009; Coley et al. 
2007b). Combination o f seliciclib w ith  paclitaxel also shows synergism, preferably by follow ing the 
sequence o f adding seliciclib firs t before paclitaxel treatm ent on SK-LMS-1 cell line (Coley e t al., 
2007b). Apoptotic activity caused by seliciclib treatm ent can also be observed in cervical cancer, 
malignant gliomas and undifferentiated nasopharyngeal carcinoma cell lines (Aldoss et al. 2009).
5. Platinum compounds (cisplatin and carboplatin)
=) c , ^  y w ,  "I
Pt
/  \
Cl NH3 H3N
Figure 3-6: Chemical structures of platinum-based compounds used in this study: a) Cisplatin (c/s- 
diamminedichioropiatinum(li)) b) Carboplatin (c/s-diammine-l,l-cyclobutane-dicarboxviatoplatinum(ll)).
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Cisplatin was introduced in the late 1970s fo r treatm ent o f ovarian and testicular cancers, and since 
has become the most commonly used anticancer drug in the United States. Its less toxic analog, 
carboplatin was approved as chemotherapeutic agent used to  trea t ovarian cancer during the late 
1980s. Both o f these drugs together w ith  another platinum compound oxaliplatin are widely used to 
trea t solid tumours such as lung, colorectal, ovarian, breast, head and neck, bladder and testicular 
cancers. Both compounds d iffer in terms o f chemical reactivity, pharmacokinetics and toxicity, 
among others. Carboplatin, apart from  its lower toxicity compared to  cisplatin is also more stable 
w ith  comparable activity in some tumours (Burger et al. 2011; McWhinney et al. 2009).
5.1 Mode of action
Platinum compounds were classified under alkylating agents as they give rise to  similar DNA 
damaging effects. They exert the ir effect by binding to  DNA basepairs and creating DNA adducts, 
intra- and inter-strand crosslink and strand breaks. Cisplatin reacts w ith  purine bases in DNA, causing 
DNA-protein and DNA-DNA inter-strand and intra-strand crosslinks. As a result, nuclear metabolism 
and chromatin organization is disrupted and DNA replication is inhibited (McWhinney et al. 2009; 
Siddik 2003). These events lead to  activation o f DNA damage response (DDR) mechanism via 
Gadd45a (growth arrest and DNA damage inducible) gene and nucleotide excision repair (NER).
Apart from  DDR, cisplatin-induced DNA damage also triggers several pathways including cell cycle 
checkpoints and apoptosis. To remove DNA adducts caused by cisplatin, NER complex is activated 
and cell cycle progression is halted to  enable adducts removal. However, upon incomplete DNA 
repair caused by overwhelming damage, the apoptosis mechanism is activated. These three 
pathways (DDR, cell cycle arrest and apoptosis) are closely related w ith  p53 and its downstream 
effector's activation. Experiments conducted on human colocarcinoma cell line HCT-116 showed 
that cisplatin induced p53 activation via ATR (ATM and Rad3-related) (Damia et al. 2001; Siddik 
2003). ATR phosphorylates SerlS o f p53 as well as C hkl to  facilitate additional p53 phosphorylation
83
[CHAPTER 3]
and activation. Chkl in turn phosphorylates p53 additionally at Ser20. Apart from  Chkl, cisplatin is 
also found to  activate Chk2, a downstream effector o f ATM in an ATM-independent way (Damia et 
al. 2001; Siddik 2003). The CKI p 2 l‘''’’  ^ is also activated (transactivation) via p53 after cisplatin 
treatm ent in experiments done on human ovarian cancer cell line 2008 (Delmastro et al. 1997; Siddik 
2003). Observable cisplatin effects on cell cycle include transient S phase cell cycle blockage followed 
by Gz or M cell cycle arrest via inhibition o f CDKl-CyclinA/B. another CKI has been shown to
facilitate inhibition o f Gi phase kinases (CDK4/CDK6) fo llow ing cisplatin-induced DNA damage. 
However, accumulation o f cells in Gi is infrequent as cells mainly trap in GzM phase (Shah and 
Schwartz 2001; Siddik 2003). Cisplatin increases S phase duration and cell cycle blockage in a dose- 
dependent manner. This event u ltim ately leads to  aberrant mitosis (Shah and Schwartz 2001). Bax, a 
pro-apoptotic gene is also activated by cisplatin via p53. However, in cancer cells w ith  defective 
apoptosis mechanism, p53 downregulation may not make cells resistant towards platinum. Instead, 
p53 disruption can sensitize cells to  platinum drug treatm ent possibly through downregulation o f 
p2l^'P^ which results in premature mitosis and cell death (Shah and Schwartz 2001; Siddik 2003).
5.2 Platinum toxicity
The general toxicity profile fo r platinum compounds differs from  each other. Cisplatin causes mild 
hematologic toxicity and cumulative ototoxicity. The most common toxicity profile caused by 
cisplatin is peripheral neurotoxicity, starting w ith painful paraesthesia (sensation o f tingling or 
numbness o f skin) followed by loss o f vibration sense and ataxia (lack o f voluntary coordination o f 
muscle movement) in parallel w ith  increasing treatm ent cycles. Cisplatin also induces severe nausea 
and vomiting. Severe renal tubular damage and decrease glomerular filtra tion  are also side effects o f 
cisplatin and manageable w ith saline hydration and mannitol diuresis to  minimize kidney damage. 
Carboplatin on the other hand causes dose-dependent thrombocytopenia and higher rates o f 
anaemia in comparison w ith  cisplatin. However, neurotoxicity caused by carboplatin is less frequent
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and less severe whilst no ototoxicity is observed in patients receiving carboplatin treatm ent. Patients 
also experience less nausea and/or vom iting and renal toxicity (McWhinney et al. 2009). Platinum- 
induced nephrotoxicity is thought to  relate to  transporter activity in renal tubular cells. Interaction 
between transporter SLC22A2 (solute carrier 22 fam ily member A2/OCT2-organic cation transporter 
2) and CTRl (copper transporter 1) w ith  cisplatin may induce its uptake and cause renal toxicity. Oral 
administration o f imatinib together w ith  platinum compounds is shown to reduce renal 
accumulation o f that platinum compound; however the exact mechanism is unknown. SLC22A2 is 
also postulated as the primary mediator o f ototoxicity by regulating cisplatin uptake in the cochlea 
hair cells (Burger et al. 2011).
5.3 Acquired resistance to platinum compounds
Tumours tha t are resistant to  cisplatin are also resistant towards carboplatin treatm ent, suggesting 
these platinum compounds evoke similar cellular responses. Specific mechanisms fo r acquired 
resistance to  cisplatin have been described. These include reduced intracellular drug accumulation 
by means o f inhibition in drug uptake, increase in drug efflux or both (Burger et al. 2011; Siddik 
2003). Binding o f cisplatin to  thiol-containing molecules such as glutathione (GSH) and cysteine-rich 
metallothionein inactivates cisplatin thus reducing its cytotoxic effect. Upregulation o f GSH and 
metallothionein have been recorded in several cisplatin-resistant tum our models. Since cisplatin 
induces the DDR mechanism, alteration in components o f DDR affect the cisplatin response in cells. 
Testicular tumours that are sensitive towards cisplatin treatm ent had been shown to  express a very 
low level o f XPA and ERCCl/XPF, proteins that are part o f NER complex. Overexpression ofXPA 
promotes cell repair and contributes towards cisplatin resistance. Loss of hMLHl or hMSH2, part o f 
mismatch repair (MMR) complex is constantly seen in cisplatin resistance and are associated w ith  
microsatellite instability and resistance to  cell death. Dysfunctional p53 has a close association w ith  
deficiency in MMR. Mutation in p53 gene is observed in variety o f cancers w ith  correlation between
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cisplatin sensitivity and p53 level. Lower response rate was seen in cancers w ith  high p53 mutation 
level such as ovarian, head and neck and metastatic bladder cancers while seminomatous germ cell 
tumours w ith  wild-type p53 showed greater cisplatin sensitivity. However, p53 status m ight not be 
the definitive characteristic o f cisplatin resistance since resistance do occurs irrespective o f p53 
status in some cases. Another mechanism by which cells acquire cisplatin resistance is inhibiting 
apoptosis pathway. Inhibitor o f apoptosis, such as survivin and XIAP overexpression promotes 
cisplatin resistance. These proteins directly or indirectly affect caspases activities which are essential 
in apoptosis mechanism (Shah and Schwartz 2001; Siddik 2003). Other mechanisms o f acquired 
cisplatin resistance include overexpression o f HER2, increased activity o f PI3K/Akt pathway and 
deregulation in ras/MAPK pathway, are not discussed here.
Limiting platinum-DNA adduct form ation Impaired transport leading to  reduced 
platinum accumulation: decreased drug uptake 
and increased drug efflux
Inactivation o f platinum compounds: 
glutathione and metallothionein
Preventing cell death upon treatm ent Increased repair o f DNA adducts 
Increased tolerance to  DNA adducts 
Failure to  provoke apoptotic pathways
Table 3-3: Major cellular mechanisms involved in piatinum resistance (Burger et al. 2011).
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Aim
This study focuses on and its association w ith  platinum resistant ovarian cancer. From here 
we have gone on to  look at the effects o f the CDK inh ib itor seliciclib in cells w ith  p57' '^'^  ^deficient 
cells.
Hypotheses
•  Downregulation o f p57'^'’’  ^plays a functional role in mediating anticancer drug resistance
•  In the absence o f adequate p57'^'‘^  ^function (due to  low expression levels) the use o f a 
synthetic CKI, such as seliciclib can compensate fo r this deficiency and possibly re-sensitise 
drug resistant cells to  platinum
Methods
Cell lines used in this work are ovarian cancer cell lines PEOl and its drug-resistant variant 
PEOlCarbR (carboplatin-resistant) and PEOlCisR (cisplatin-resistant); and SK-OV-3. Cells were 
cultured in a suitable media accordingly. Techniques used are viability assay using MTT, whole cell 
lysate preparation, SDS-PAGE, Western blotting, alcohol fixation and DNA analysis using flow  
cytometry, mRNA isolation, RT and qPCR analysis, siRNA transfection, AnnexinV-FITC assay and 
isobologram analysis. All techniques have been explained previously in Chapter 2. Graphs were 
constructed using M icrosoft Excel and GraphPAD PRISM softwares. Student's paired T-Test and one­
way AN OVA w ith  Tukey's test fo r multiple comparisons were done where applicable, and the results 
were expressed as p values.
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Results
1. Cross-resistance between platinum compounds in ovarian cancer
a) Dose-response curve of PEOl panel treated with
carboplatin
■o- PE01 
o  PEOlCarbR 
’éi' PEdCisR
120
110
lOOi
Q.
50:
40-
30-
20 -
10-
1.0 1.5 2.0 2.5 3.0
Log dose ( i^M)
b)Dose response curve of PEOl panel treated with
cisplatin
o 130-1
¥ 120-
O 110-
o 100-
X I 90-
S 80-
§. 70-
E 60-
8 50-
40-
30-
.2 20-> 10-
0-1
-0.5
^  PE01 
PEOlCisR 
-A- PEOlCarbR
  ..
0.0 0.5 1.0 1.5
Log dose (ixM)
2.0 2.5
Figure 3-7: Dose-response curve of PEOl, PEOlCisR and PEOlCarbR treated with carboplatin (a) and cisplatin (b). Both 
PEOlCisR and PEOlCarbR showed cross-resistance to cisplatin and carboplatin treatment, while PEOl parental cell line 
remained relatively sensitive to both platinum compounds. This cross-resistance phenotype was widely documented in 
clinical cases (Siddik 2003). (n >3)
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Platinum treatm ent followed by viability test using MTT was performed on the PEOl panel (drug- 
sensitive and drug-resistant). The dose-response curves were drawn to  acquire IC50 values of 
carboplatin and cisplatin fo r each cell lines in the respective panel. All cell lines used in this 
experiment and other subsequent experiments were tested negative fo r mycoplasma.
Table below was derived from  the data obtained via viability assay results (Figure 3-):
PEOl 20.1 (±9.2) - 1.02 (±0.5) -
PEOlCarbR 68.1 (±22.9) 3.39 5.17 (±1.8) 5.01
PEOlCisR 67.7 (±21.3) 3.37 5.64 (±1.0) 5.53
Table 3-4: Carboplatin and cisplatin IC5 0 values In PEOl, PEOlCarbR and PEOlCisR. RF refers to resistance factor. To
achieve similar effect as cisplatin, carboplatin needs to be used at higher concentration. Based on the IC5 0 values, 
PEOlCarbR and PEOlCisR showed cross-resistance by having a very close IC5 0 values to each other for both drugs. IC50 
values were derived from dose-response curve analysis (n >3).
Figure 3-7 and Table 3-4 shows the difference o f drug dose needed to  achieve similar effect between 
drug-sensitive and drug-resistant cancer cells. Both PEOlCarbR and PEOlCisR showed cross­
resistance towards cisplatin and carboplatin w ith  IC50 values near to  each other.
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2. p57 '^P^ and Skp2 mRNA level in PEOl panel
QPCR was performed in order to  quantify p57' '^'"  ^and Skp2 mRNA level in PEOl panel.
a)
n- 2
qPCR analysis o f p57"('P  ^expression in PEOl and 
platinum-resistant PEOlCisR and PEOlCarbR
I PEOl 
I PEOlCisR 
I PEOlCarbR
b) 4.5 
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Figure 3-8: QPCR analysis of pST '^'’^  and Skp2 level In PEOl parental and platinum-resistant PEOlCarbR and PEOlCisR. 
Skp2 Is the negative regulator of pS?'^  ''^ . a) Result shown that pB?' '^’’  ^mRNA level in PEOlCisR was higher compared to 
PEOl. In PEOlCarbR, mRNA level was significantly low. Thus the level o f expression was in the order of
PEOlCisR > PEOl > PEOlCarbR. b) Skp2 mRNA expression was shown to be increased in cisplatin-resistant PEOl in a higher 
magnitude compared to PEOlCarbR. The level o f Skp2 expression in this panel was PEOlCisR > PEOlCarbR > PEOl. Using 
One-way ANOVA w ith Tukey's test, the significant differences between expression levels o f proteins in each line were 
calculated. The difference in pS?' '^'’  ^expression between PEOl, PEOlCisR and PEOlCarbR was significant. Similar results 
were also achieved fo r Skp2 expression in ail three ceil lines.All results were normalized against GAPDH. (*p < 0.05, **p  < 
0.005) (n=7).
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p57'^ ''^  ^and Skp2 gene expression in the PEOl panel were quantified using qPCR analysis and results 
were presented as bar charts. Results obtained showed p57' '^^^ and Skp2 upregulation in PEOlCisR 
compared to parental cell line PEOl. However, significant downregulation o f p57' '^'^  ^was seen in 
PEOlCarbR w ith higher Skp2 level in the same cell line compared to  parental.
3. Level of target proteins in cell lines
Western blotting using several antibodies was performed to look at the protein levels in each cell 
lines. Antibodies used were against CKIs p57'^'’^  ^and p27'^''^\ and GiS cell cycle regulators CyclinE, 
E2F1 and Survivin. Results were scanned and labelled accordingly.
3.1 p5?Kip2
Approx.
57KDa  ^ p57X'P2
Approx. ia g m m  P-actin
Figure 3-9: level in PEOl, PEOlCisR and PEOlCarbR as assessed by western blotting. pS?' '^'^  ^protein band
appeared in PEOl and PEOlCisR. However, there was no p5?' '^'’  ^band in PEOlCarbR. Based on the results, expression o f 
pS?' '^'’  ^in PEOl and PEOlCisR were higher than in PEOlCarbR, which was almost undetected. This pattern reflected mRNA
expression analysis of p57^'^^ using qPCR.
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Figure 3-10: Protein level of CyclinE (a), E2F1 (b), Survivin (c) and p2?' '^’’  ^(d) in PEOl, PEOlCarbR and PEOlCisR assessed 
by western blotting. Platinum-resistant ceil lines have a higher expression o f these proteins compared to  the parental ceil 
line (showed by higher density of the bands) except fo r p2?' '^'^ .^ p27"^ ''^  ^expression was diminished (as shown by the 
reduced band intensity) in PEOlCarbR compared to PEOl and PEOlCisR, which also holds true fo r p57' '^'’  ^expression. This 
might be caused by epigenetic modification presents in PEOlCarbR. Downregulation of these proteins m ight contribute to 
the higher sensitivity of PEOlCarbR towards seliciclib treatm ent compared to PEOl and PEOlCisR. Expression of E2F1, a 
transcription factor is elevated in drug-resistant phenotype compared to PEOl cell line, showed by the increased band 
intensity. This is an evidence of drug-resistant cell lines are transcriptionally more active than the parental cell line.
Based on the western blotting results, drug-resistant cell lines acquire changes in comparison w ith  
parental (drug-sensitive) cell line. These changes might play a role in the drug resistance 
development.
4. ICso values of cell lines treated with seliciclib
Seliciclib treatm ent followed by viability test using MTT was performed on PEOl panel (drug- 
sensitive and drug-resistant). The dose-response curves were drawn to acquire Seliciclib IC50 values 
fo r each cell lines in the panel.
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Dose-response curve of PE01 panel treated with 
seliciclib
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Figure 3-11: Comparison of IC5 0  values of PEOl, PEOlCarbR and PEOlCisR treated with seliciclib. PEOlCisR shows highest 
IC50  values and PEOlCarbR have the lowest IC50  of seliciclib. Paired T-Test was done to determine the significance of IC5 0  
differences between PEOlCarbR and PEOlCisR. p value of less than 0.005 proved that the differences was statistically 
significant (n > 3).
Based on the results, PEOlCarbR w ith  the lowest expression o f p57'^'‘^  ^showed the highest response 
towards seliciclib treatm ent compared to PEOl and PEOlCisR.
5. Level of target proteins in seliciclib-treated cell lines
Based on the IC50 values obtained from  the viability assay, PEOl panel was treated w ith  seliciclib to  
assess protein level o f p57'^''’  ^and several GiS cell cycle regulators (CyclinE, E2F1 and Survivin) before 
and after treatm ent. Control and treated cells were then harvested and used fo r western blotting.
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5.1 p57K:p2 western blotting
Several attempts to do western blotting using p57' '^^^ antibodies yield unsatisfactory results. This 
problem arises from the fact tha t the antibodies were not specific enough to give a strong signal in 
some of our cell lines. Most o f the antibodies used produced non-specific bands despite several 
optimizations done to  the procedures, such as changing the concentration, modification to  the 
washing reagents and blocking reagents used and changing exposure times.
5.2 CyclinE
a) PEOl
Oh 24h
15pM  Seliciclib ^ . a*» Approx. SOKDa
GAPDH Approx. 37KDa
b) PEOlCisR
15[iM  Seliciclib
GAPDH
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Approx. SOKDa
Approx. 37KDa
c) PEOlCarbR
IS p M  Seliciclib 
GAPDH
Oh 24h
Approx. SOKDa
Approx. 37KDa
Figure 3-12: Western blotting results showing CyclinE level in PEOl (a), PEOlCisR (b) and PEOlCarbR (c) cell lines treated 
with ISnlVI seliciclib and harvested on 0 and 24 hours post-treatment. Each cell line behaves differently in terms o f cyclinE 
expression after seliciclib treatment. Seliciclib treatm ent in PEOlCisR results in an elevated CyclinE level showed by the size 
and the intensity of the protein band. In PEOlCarbR, cyclinE protein level is unchanged after 24 hour treatm ent w ith 
seliciclib, but overall expression o f this cyclin is much higher in this cell line compared w ith the other two cell lines. (n=3)
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Figure 3-13: Western blotting results of Survivin level in PEOl (a), PEOlCisR (b) and PEOlCarbR (c) cell lines treated with 
IS iiM  seliciclib and harvested on 0 and 24 hours post-treatment.Based on the results,the level o f survivin expression in 
PEOl is unchanged after the treatm ent w ith 15pM seliciclib for 24 hours. Result o f the same seliciclib treatm ent to 
PEOlCisR yields higher level o f survivin expression after 24 hours treatm ent compared w ith 0 hour control, indicated by 
the size and the intensity o f the band. Survivin expression decreases in PEOlCarbR after seliciclib treatment. PEOlCarbR 
has the highest survivin expression compared w ith the other two cell lines while PEOlCisR has the lowest survivin 
expression among these three cell lines. (n=3)
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Figure 3-14: Western blotting results of E2F1 level in PEOl (a), PEOlCisR (b) and PEOlCarbR (c) cell lines treated with 
15|iM seliciclib and harvested on 0 and 24 hours post-treatment. Based on the results, ISpM  seliciclib treatm ent o f PEOl 
cells resulted in a slight decrease o f E2F1 protein level on 24 hour post-treatment. Same seliciclib treatm ent on PEOlCisR 
yields higher protein expression after 24 hours, indicated by the increase of protein band size. PEOlCarbR shows the 
lowest E2F1 expression compared to the other tw o cell lines at 0 hour. Seliciclib treatm ent further reduces E2F1 protein 
level in PEOlCarbR. This downregulation was shown by the protein band that has almost disappeared 24 hours post­
treatment. (n=3)
Based on the western blotting results of several GiS cell cycle regulators, seliciclib treatm ent evokes 
different response in each cell line after 24 hours treatm ent.
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6. Comparison of apoptotic response in seliciclib-treated cells
PEOl panel was treated w ith seliciclib and subjected to Annexin V-FITC analysis to assess the ir 
apoptotic response towards seliciclib. Dose chosen was based on the IC50 values obtained previously.
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Figure 3-15: Annexin V-FITC analysis of PEOl, PEOlCarbR and PEOlCisR treated with seliciclib for 48 hours. Data shown 
are typical of repeat experiments (n = 3). Each quadrant in a cytogram represents d ifferent state o f apoptosis and
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percentage of cells. Lower left quadrant represents live cells, lower right represent cells in early apoptosis (Annexin V-FITC 
positive, PI negative), upper right represents cells in late apoptosis/necrotic (Annexin V-FITC and PI positive) and upper left 
represents debris. Control cells fo r all 3 cell lines were in a good condition (live cells > 90% of total cell percentage). 
Seliciclib treatm ent caused apoptosis in all 3 cell lines, w ith the highest rate in PEOlCarbR. PEOl parental and PEOlCisR 
have approximately similar response towards seliciclib treatment.
7. Alteration in DNA content in cells treated with seliciclib
PEOl panel was treated w ith seliciclib and subjected to flow  cytometry analysis to assess DNA 
changes obtained after treatm ent. Seliciclib affects cell cycle components. Thus, treatm ent w ith 
seliciclib w ill influence DNA content o f the cell as well. Dose chosen was based on the IC50 values 
obtained previously.
Comparison between PEOl, PEOlCisR and PEOlCarbR DNA content 
before and after seliciclib treatment
Sub-Gl G I S
Cell cycle phases
G2M
H  P E O l control
■  P E O l 2 5 u M  seliciclib  
Q PEOlCisR control
B  PEOlCisR 2 5 u M  seliciclib  
0  PEO lCarbR control
■  PEO lCarbR 2 5 u M  seliciclib
Figure 3-16: Cell cycle phases percentage according to the DNA analysis of cell lines untreated and treated with 25pM  
seliciclib for 48 hours. Treatment induced apoptosis to  all cell lines, represented by increased sub-GI proportion after 
treatment. *p < 0.05 (n = 3)
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Based on the DNA histogram analysis, treatm ent w ith  25nM seliciclib fo r 48 hours induced apoptosis 
in all cell lines treated. This was represented by increased sub-Gi population in cells treated w ith 
seliciclib. Seliciclib produced more profound effects on PEOlCarbR compared to  PEOl and PEOlCisR. 
In treated PEOlCarbR cells, the higher cell cycle arrest level can be seen w ith an increase in S phase 
and decrease Gi phase populations compared to  untreated PEOlCarbR.
8. p57Kip2 gene silencing and its effect on seliciclib and cisplatin cellular 
response
PEOl parental and cisplatin-resistant cell lines were transfected w ith  siRNA to look at the 
effect o f p57' '^^^ downregulation in these cell lines. Transfection was followed by treatm ents w ith  
seliciclib and cisplatin fo r 24 hours before being subjected to  Annexin V-FITC and flow  cytometry 
analysis. GAPDH siRNA was used as a control to  assess transfection efficiency. mRNA from control 
and transfected cells were harvested and subjected to  qPCR analysis. Based on the analysis, 
transfection o f GAPDH siRNA reduced the expression o f GAPDH mRNA in samples to  approximately 
32% (mean fold change 0.32 ± 0.09). Two variation o f siRNA (13 and 14) were used in this 
experiment. Transfection using siRNA p57' '^'^  ^(13) failed to work as there is no downregulation o f 
p57'^'^^ mRNA after qPCR analysis. siRNA (14) produced p57^ '^^  ^silencing o f only approximately 
22% (mean fold change 0.78 ± 0.26). Several optim isation have been carried out such as changing o f 
Dharmafect reagent concentration (from 4pL per 400pL reaction to  2 \il per 400pL reaction) and 
changing seeding count o f the cell (seeding count tha t have been used were 1x10^ cel Is/m L, 2.5x10^ 
cells/mL, 3x10^ cells/mLand 4x10^ cells/mL) but the silencing effect did not d iffer significantly from  
the previous values.
Because o f difficulties working w ith  PEOl cell lines in terms o f silencing efficiency, we have tried  
p57^'^^ silencing method on other cell line, SK-OV-3. SK-OV-3 is another type o f human ovarian 
carcinoma cell line. siRNA p57" '^^  ^(13) produced approximately 50% silencing o f p57 '^ ’^  ^based on
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qPCR analysis. Treatment of p57^'^^-silenced samples w ith seliciclib and cisplatin resulted in 
increased sensitivity to  seliciclib and increased resistance to  cisplatin (Figure 3-).
SK-OV-3
Control
Untreated
-rTiTTj 1 .  1 T . - i iT
10’ 1 0 ' II
SK-OV-3
K ip 2
p57 siRNA
Untreated
» ’ l I i l i n i  "i "iV .ii'| 1" „ i ------ i—n -
10'  10’  10'  10*
SK-OV-3
Control
20pM  cisplatin
SK-OV-3 
Control
SOuM seliciclib ‘'°’l
77.8% A
125.2%
SK-OV-3
K ip 2
p57 SiRNA
2 0 pM  cisplatin
SK-OV-3
K ip 2
p57 SiRNA
SOpM seliciclib
Log FITC
Figure 3-17: Annexin V-FITC results of SK-OV-3 control and p57^''’^ -silenced samples. Control and silenced samples were 
treated w ith BOpM seliciclib and 20pM cisplatin fo r 48 hours before being subjected to  the analysis using flow  cytometry. 
Fligher apoptotic response was seen in control cells treated w ith cisplatin compared to the silenced cells. However, the 
apoptotic pattern was reversed w ith seliciclib treatment. This represents the relationship between downregulation
w ith platinum resistance and collateral sensitivity to seliciclib.
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9. Isobologram analysis to assess drug synergism on PEOl and PEOlCarbR
Isobologram analysis was performed in order to  assess drug synergism fo r carboplatin and seliciclib
combination treatm ent on PEOl and PEOlCarbR. Cells were treated w ith  several predetermined 
drug doses followed by viability assay. Values obtained were then used to  calculate combination 
index (Cl) values using CalcuSyn software.
9.1 Carboplatin-seliciclib combination treatment on PEOl
a) Median-effect plot
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Figure 3-18: Median-effect plot (a) and combination Index (Cl) (b) of PEOl treated with combination of seliciclib and 
carboplatin after data analysis In CalcuSyn software. Dotted line represents Cl value of 1 (n = 7). This figure is a 
representative. The effects are additive but there is some antagonism at higher doses. Combination treatment of seliciclib 
and carboplatin on lower dose results in Cl < 1 in PEOl parental cell line. Subsequent higher doses produces Cl = 1 and later 
Cl > 1 at the highest dose used (40pM seliciclib and 320pM carboplatin).
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9.2 Carboplatin-seliciclib combination treatment on PEOlCarbR
a) Median-effect plot
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Figure 3-19: Median-effect plot (a) and combination index (Cl) (b) of PEOlCarbR treated with combination of seliciclib 
and carboplatin after data analysis in CalcuSyn software. Dotted line represents Cl value of 1 (n = 7). This figure is a 
representative. Seliciclib and carboplatin combination in PEOlCarbR results in Cl > 1 at lower dosage before the index value 
decreasing to nearly Cl=l following increasing doses. The effects were mainly antagonism but with higher dosage the effect 
was nearly additive.
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Discussion
In this firs t part o f the PhD study, three cell lines were used. Two o f them being drug-resistant - 
PEOlCarbR and PEOlCisR derived from the parental cell line PEOl. PEOlCarbR shows the highest 
sensitivity towards seliciclib treatm ent compared to  the parental PEOl and PEOlCisR cell lines based 
on the seliciclib IC50 values. The analysis o f apoptosis indicated an apoptotic level- tha t was 
appropriate and in line w ith the drug sensitivity results. Accumulation o f cells at S phase, which is a 
feature o f cell cycle blockade by seliciclib can be seen particularly in PEOlCarbR.
p57' '^^^ is a cell regulatory proteins and its downregulation is a feature o f several cancers including 
EOC. Downregulation o f p57' '^^  ^ in PEOlCarbR has been demonstrated before and treatm ent w ith  
demethylating agent reactivates the gene (Coley et al. 2012). The level o f mRNA and protein 
expression o f in parental and drug-resistant cell lines used in this study was assessed. 
Another member o f Cl P/KIP family, p27"^ '"^  ^ is also found to  be downregulated in drug-resistant cell 
lines w ith  PEOlCarbR has the lowest protein expression level. Other cell cycle regulatory proteins 
such as E2F1, CyclinE and survivin have also been found to  be upregulated in drug-resistant cell lines 
compared to PEOl. The upregulation o f CyclinE is associated w ith  malignancy status o f ovarian 
cancer together w ith  the downregulation o f p27'^''’  ^as reviewed by Mazumder et al. (2004) and 
D'Andrilli et al. (2008). Accumulation o f CyclinE reflects either the increase in synthesis or decrease 
in degradation. Upregulation o f CyclinE in these drug-resistant cell lines might be the end result o f 
E2F1 upregulation and downregulation o f p57'^ ''^ ,^ as the Skp2 level which is a regulator o f CyclinE 
does not change significantly w ith  drug treatm ent although its level was significantly higher in both 
carboplatin- and cisplatin-resistant PEOl compared to  the parental cell line. Survivin is associated 
w ith  cancer cell survival and has been shown to be upregulated in drug-resistant variant cell lines 
(Coley et al., 2007).
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This study also looked at the effect o f seliciclib treatm ent to  the expression level o f Skp2, CyclinE and 
Survivin in the cell lines. Based on the results, seliciclib treatm ent did not affect Skp2 protein levels 
in all experimented cell lines. The Survivin level after seliciclib treatm ent however presents quite 
complicated results. Taken into consideration, downregulation o f Survivin after 24 hour seliciclib 
treatm ent is in agreement w ith  work by Aldoss et al. (2009). Higher seliciclib dose usage is able to 
induce more downregulation o f Survivin compared to  the lower dose (30pM dose data not shown). 
However the increase in Survivin level after 48 hours treatm ent points to  the e ffo rt o f cells to  evade 
apoptosis caused by seliciclib.
Collectively, seliciclib treatm ent caused steady upregulation o f CyclinE in PEOlCisR towards 48 hours 
after treatm ent. W ith no noticeable changes in Skp2 level, upregulation o f CyclinE in seliciclib- 
treated cells maybe a mechanism o f compensation fo r lack o f CDK2-CyclinE activity in these cells.
The lack o f activity comes from  seliciclib binding to  the CDK ATP pocket site thus renders them 
inactive. This event w ill lead to  cell cycle blockade. More CyclinE is expressed in order to  overcome 
the cell cycle blockade due to  seliciclib which reflects in increased protein level. This result is in 
accordance w ith  Mazumder et al. (2004) who reported tha t treatm ent w ith chemotherapeutic 
agents such as topoisomerase I inh ib itor leads to  increased CyclinE level in hematopoietic cells. On 
the other hand, CyclinE level in PEOlCarbR do not d iffer much 24 hour after seliciclib treatm ent.
E2F1 is an im portant transcription factor that promotes expression o f various genes needed in Gi to  
S phase transition. A fter seliciclib treatm ent E2F1 level become inconsistent in PEOl cell line up until 
48 hours post-treatment. Increasing levels o f E2F1 can be taken as a sign o f a transcriptionally active 
state. Thus, the increased CyclinE level in PEOlCisR and PEOlCarbR after seliciclib treatm ent is a 
result o f increased E2F1 expression. This can be considered as an effect o f the drug to  the cells.
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Upregulation o f E2F1 after CKI treatm ent has been reported by Ma and Cress (2007). In the ir report, 
treatm ent o f breast cancer cell lines w ith  CKI BMS-387032 upregulated the E2F1 protein. 
Additionally, BMS-387032 treatm ent caused more cell death in cells tha t lacked p57' '^'’^  which is in 
line w ith  our findings fo r seliciclib in PEOlCarbR. is a direct target and inducible by E2F1 
action thus upregulation o f E2F1 induce expression o f p57' '^'^  ^which leads to  apoptotic events.
Seliciclib has been shown to  have a synergistic effect when combined w ith  cisplatin and paclitaxel in 
uterine sarcoma cell lines (Coley et al., 2007). We investigated w hether seliciclib could produce a 
similar effect in combination w ith  carboplatin on PEOl and PEOlCarbR. Based on the results, 
combinations o f seliciclib and carboplatin produced an additive effect at lower dose and an 
antagonistic effect on higher dose on both cell lines. There was also no evidence o f drug sequence 
dependence as changing the sequence o f the drug produced similar results (data not shown).
To explain the reason behind PEOlCarbR sensitivity towards seliciclib treatm ent compared to  PEOl 
and PEOlCisR, the seliciclib mechanism o f action and PEOlCarbR molecular biology have to  be taken 
into consideration. In PEOlCarbR several genes have been found to  be downregulated including 
p57' '^'^^ a CDK inhibitor. Seliciclib which is also a CDK inh ib ito r drug works well in this cell line 
because it replaces p57'^'’’  ^ role as a cell cycle inh ib itor through binding to  the ATP site o f the CDKs. 
Seliciclib also can inhibit o ther CDK-cyclin complexes but the most profound effect is on CDK2- 
CyclinE which is also a target o f p57" '^^ .^ Inhibition o f CDK-cyclin complexes results in cell cycle 
blockade and eventually apoptosis. The data presented herein are in agreement w ith  the findings 
reported by Ma and Cress (2007) who showed tha t overexpression o f p57'^''’  ^ restrains E2Fl-driven 
transcription thus reducing S phase. Seliciclib promotes expression o f E2F1, which subsequently
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leads to  increased S phase fraction. However as seliciclib is able to  inh ibit phosphorylation o f RNA 
polymerase II via inhibition o f CDK7/CDK9, apoptosis is triggered.
Based on the present work, the cell lines presented a d ifferent level o f sensitivity towards a cell cycle 
inhibitor seliciclib treatm ent. It is tem pting to  look more closely at the differences between platinum 
resistant cells at the level o f gene méthylation. Methylation-specific PGR and pyro-sequencing w ill be 
the methods used to address this and some o f this work has already been carried out prior to  this 
project. The hypotheses presented were partially correct, since re-sensitization is d ifficu lt to  achieve 
based on isobologram analysis.
Conclusion
In conclusion, downregulation o f p57' '^^  ^in cancer cell is a marker o f seliciclib sensitivity and 
measurement o f this could be considered as a biomarker in clinical trials o f this agent. Seliciclib is 
also a potential drug to  be used in advanced malignancies w ith  drug-resistance phenotype.
Since the drug-resistant ovarian cancer cell lines have been shown to  have multiple gene changes, 
the next step is to  assess several regulatory protein such as Stratifin and Weel in terms o f the ir 
contribution to  the drug-resistant phenotype. These regulatory genes have been shown to  be 
downregulated in taxane-resistant cell lines, based on analysis using microarray screening.
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Introduction
1. GzM DNA damage checkpoint
DNA damage response (DDR) is im portant in recognizing and repairing damaged DNA before mitosis. 
Unrepaired DNA might lead to  cell senescence or tumorigenesis. DDR comprises of proteins w ithin 
networks that act immediately upon exogenous and endogenous causes o f DNA damage. W ithin the 
signal transduction pathway, proteins involved in DDR can be divided into sensors, mediators, 
transducers and effectors. Ultimately, DDR will result in e ither DNA repair, cell cycle arrest or if the 
damage is overwhelming, apoptosis. DNA damage is detected by sensors which w ill recruit 
mediators, often proteins w ith  BRCAl C-terminus repeat (BRCT)-containing domain acting as 
protein-phosphoprotein interaction modules. Mediators w ill then recruit PIKK (Phosphoinositide-3- 
kinase-related protein kinase) family members, which are large proteins w ith the ability to 
phosphorylate a wide range of substrates that sometimes have overlapping functions w ith other 
family members, showing crosstalk between them. PIKK fam ily members act as transducers of the 
signal and the ir activation depends on the type o f DNA damage acquired. Subsequently the signal is 
passes over to the effectors by means o f substrate phosphorylation. Activated effectors will 
phosphorylate downstream substrates and eventually cause cell cycle arrest and DNA repair or 
activation of apoptotic pathways if the damage is overwhelming (Giunta and Jackson 2011; Niida and 
Nakanishi 2006).
• DSB
• SSB
• BRCT- 
containing 
proteins
• MRN complex
• p53
• CDC25
• CDKs
• RFCl-like • ATM/ATR
• Chkl/Chk2
• Cell cycle arrest
• DNA repair
• Apoptosis• PCNA-like
DNA damage
Sensors
mediators
Transducers
Effectors
Cell cycle 
effect
Figure 4-1: Flow of cell response following DNA damage. DNA damage can be either double strand break (DSB) or single 
strand break (SSB). Damage sustained is recognized by sensors, which recruit mediators that w ill pass the signal to 
transducers, which in turn will phosphorylate effectors. Further substrate phosphorylation by effectors will result in cell 
cycle arrest, DNA repair or apoptosis.
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Sensors Replication factor C (RFCl)-like RAD17
RFC2-5
Proliferating cell nuclear antigen (PCNA)-like RAD9
RADI
HUSl
M ediators BRCT-containing BRCAl
53BP1
TopBPl
MDCl
DSB recognition/repair (MRN complex) M re ll
RAD50
NBSl
Transducers PI3 kinase-like protein ATM
ATR
PIKK binding protein ATRIP
Protein kinase CHKl
CHK2
Effectors Transcription factor p53
Phosphatase CDC25A,B,C
Protein kinase CDKs
CDC7
Table 4-l:Classification of genes involved in DDR (Adapted from Niida and Nakanishi 2006).
2. ATM
ATM (Ataxia-telangiectasia mutated) is a member o f the PIKK family. ATM is a large serine/threonine 
protein kinase w ith  the gene situated at chromosome llq 2 2 -2 3 . M utation o f ATM causes ataxia- 
telangiectasia, a rare autosomal recessive disorder characterized by cerebellar ataxia, neuro­
degeneration, radiosensitivity, cell cycle checkpoint defects, genome instability and predisposition to  
cancer.
2.1 ATM activation and function
Activation and function o f ATM is achieved via association w ith various proteins or protein 
complexes, a feature shared among PIKK family members. Inactive ATM exists as a 
m ultim er/hom odim er. When activated, the ATM homodimer dissociates and binds to  several
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proteins, mainly those involved in cell cycle control. ATM plays a major role in maintaining DNA 
integrity through cell cycle control and DNA repair mechanisms. In cell cycle, ionizing radiation that 
produces DNA double strand break (DSB) induces ATM activation. The joined e ffo rt o f mediator 
complex MRN (M re l l ,  RadSO and Nbsl) and phosphorylation o f a variant H2A histone, H2AX near 
the breakage recruits ATM to  the site o f the DSB. MRN recruitm ent to  the damaged DNA was 
thought to  be the earliest event fo llow ing DSB occurrence since at least one o f the protein (Nbsl) is 
recruited to  the site independently o f H2AX phosphorylation. Additionally, N bsl immobilizes ATM at 
the site o f DSB. ATM then undergoes rapid phosphorylation at Serl981 to  dissociate into active 
monomers. However, acétylation o f ATM by acetyl transferase Tip60 is thought to  be the critical 
activating event in comparison to  ATM phosphorylation. Apart from  form ing a complex w ith  ATM, 
Tip60 also interacts w ith  MRN complex via its cofactor Trrap. Downregulation o f Tip60 leads to  failed 
ATM activation and reduced cell survival follow ing DNA damage. Active ATM then phosphorylates 
H2AX, producing y-H2AX that is recognized by M DCl, another mediator protein. ATM also 
subsequently phosphorylates MDCl, which enables recruitm ent o f E3 ubiquitin ligase RNF8. RNF8 
promotes H2AX ubiquitination and recruitment o f the DNA repair complex BRCAl (BreastCancerl) 
and 53BP1 (p53 binding protein 1). BRCAl mediates DNA repair via homologous recombination (HR) 
and 53BP1 via non-homologous end joining (NHEJ). Phosphorylation o f RNF8 by CK2 promotes its 
binding to  MRN resulting in the complex stabilization and enhancement o f ATM auto-amplification 
loop (Derheimer and Kastan 2010; Niida and Nakanishi 2006; Reinhardt and Yaffe 2009) (Figure 4-2).
Following ATM activation, it phosphorylates p53 and proteins tha t interact w ith  p53 including 
MDM2 and Chk2. Activation o f p53 by ATM enables p53 to  fu rthe r activate downstream genes and 
triggers S phase and G2M checkpoints. Activation o f S phase arrest is achieved via phosphorylation o f 
FANCD2 (Fanconi anaemia group D2) and SMCl by ATM while G2 M checkpoint arrest via Chk2 
phosphorylation and activation (Derheimer and Kastan 2010).
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Double strand break 
(DSB)
/ ■ Ionizing radiation
RadSO
VH2AX
(D
Figure 4-2: ATM activation sequence following DSB generated by ionizing radiation. (1) The MRN complex is recruited to 
the DSB site. DSB also promotes H2AX phosphorylation. ATM is recruited to the site following these events. Activated ATM 
then further phosphorylates the H2AX and the MDCl (2). M DCl mediates recruitment of the BRCAl and the 53BP1 
proteins which initiates the DNA repair mechanisms (HR or NHEJ, respectively) (3). ATM also phosphorylates p53 and Chk2,
which activates the G2M cell cycle arrest (4).
Apart from its critical role in cell cycle checkpoint, ATM is also involved in DNA repair via interaction 
w ith the DNA repair enzyme, Artemis in the G2 phase. Optimal DNA damage repair m ight involve 
ATM activity. KAPl (KRAB-associated protein 1) is a component o f heterochromatin that is a direct 
target o f ATM. ATM binding to  KAPl is believed to promote heterochromatin relaxation thus 
facilitating DNA repair. TRF2 protein, which is a part o f shelterin is another protein that interacts 
w ith ATM. Shelterin is a complex o f telomere cap functioning to  prevent recognition of the free end 
o f chromosome as the free end o f a double strand break. By binding to ATM, TRF2 inhibits ATM 
activity locally at the telomeres (Derheimer and Kastan 2010).
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3. ATR
AIR, a serine/threonine protein kinase is another family member o f PIKK fam ily sharing some 
similarities w ith  ATM and Rad3, hence the name (ATM and Rad3-related). Other fam ily members 
include DNA-PKcs (DNA dependent protein kinase catalytic subunits), mTOR (mammalian target o f 
rapamycin) and hSMGl (suppressor w ith  morphological effect on genitalia). Generally, the PIKK 
family members share common structural features: N-terminal HEAT repeats, a FAT domain, a 
protein kinase domain and a C-Terminal FAT-C domain (Derheimer and Kastan 2010). ATR plays a 
role in DDR via recognition o f single strand DNA (ssDNA) generated as a product o f processed DSBs, 
replication stress caused by stalled replication forks or nucleotide excision repair. Treatment w ith 
drugs such as Aphidicolin, a DNA polymerase inh ib itor or hydroxyurea, inh ib ito r o f ribonucleotide 
reductase also results in ATR activation.
3.1 ATR activation and function
Activation o f ATR in ATM-dependent manner takes place during late S or Gg phase by the form ation 
o f RPA-coated ssDNA follow ing endo- and/or exonuclease activity o f M re l/C tIP  complexes. During S 
phase, ssDNA forms when MCM helicase continues unwinding the DNA template despite a stalled 
replication fork. ATR forms a complex w ith  its regulator ATRIP (ATR-lnteracting protein). ATR binds 
to  ssDNA through ATRIP interaction w ith  RPA (replication protein A). RPA is a ssDNA-binding protein 
that recognizes exposed ssDNA and can rapidly coat it. Following its recruitm ent to  the site o f 
exposed ssDNA, ATR is activated through binding o f ATR-ATRIP to  9-1-1 (Rad9-Radl-Husl), a DNA- 
associated protein complex. 9-1-1 recruits BRCT domain-containing protein TopBPl (Topoisomerase 
II binding protein 1) in a phospho-dependent manner which in turn activates ATR. ATR is also 
activated by Claspin and together w ith  TopBl, these proteins are co-mediators fo r ATR to activate 
downstream protein Chkl (Chen et al. 2012; Lopez-Contreras and Fernandez-Capetillo 2010; 
Reinhardt and Yaffe 2009; Shechter et al. 2004). Claspin is thought to  serve as an adaptor protein.
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bringing the substrates together, as it has been shown that Claspin binds both Rad9 (part o f 9-1-1 
complex) and Chkl (Shechter et al. 2004). Apart from  Chkl as the primary target and proteins that 
activate ATR/Chkl pathway, ATR also phosphorylates several other proteins such as H2AX, WRN 
(Werner syndrome helicase), BLM (Blooms syndrome helicase), BRCAl and FANCD2 showing 
crosstalk between ATR/Chkl and ATM/Chk2 pathways (Chen et al. 2012) (Figure 4-3).
R es e c ted  DSB
O th e r  e v e n ts  t h a t  c re a te s  s sD N A  
a re  s ta lle d  re p lic a tio n  fo rk  a n d  
n u c le o t id e  exc is ion  re p a ir  (N E R )
4
ChkTop
B P l
Rad 17 ssDNA
RPA RPA RPA
9-1-1 complex
Figure 4-3: ATR activation sequence following generation of ssDNA. (1) The ssDNA generated is coated w ith the RPA. (2) 
The ATR-ATRIP complex is recruited by the RPA-coated ssDNA. (3) The RPA-ssDNA also recruited the Radl7. This followed 
by recruitment of 9-1-1 complex by rad l7  to  the damage site. (4) The 9-1-1 complex brings TopBPl, an ATR-ATRIP activator 
near to  the complex, thus activating it. (5) Following the ATR activation, Chkl is activated via phosphorylation. 
Subsequently this event leads to  the cell cycle arrest.
Besides the role in DDR, ATR is also indispensable in normal cells. At lower expression levels , ATR 
regulates the progression of DNA replications thus moderating the rate of S phase and prevents the 
accumulation of abnormal DNA structures (Shechter et al. 2004). In cells w ith low ATM protein, 
many o f its substrates were eventually phosphorylated after IR exposure showing the possibility o f 
ATR compensating for lack o f ATM activity (Kastan and Bartek 2004).
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4. Chkl
 1-------------
Kinase domain 
(N-terminal domain)
SCO PIPI
C-terminal
domain
Figure 4- 4: Chkl protein structure.
The Chkl protein consists of a kinase domain in its N-terminal followed by the SQ/TQ cluster domain 
(SCD), a nuclear localization signal and a PCNA interacting protein (PIP) motif. The C-terminal domain 
of Chkl is thought to  function as its auto-regulator (Stracker et al. 2009). Chkl serine/threonine 
checkpoint kinase is a downstream effector o f ATR and is associated w ith chromatin. In proliferating 
cells, Chkl expression peaks at S and G2 phases while in quiescent and differentiated cells its 
expression is almost undetectable. Chkl activation follows DNA damage signalling from  ATR. ATR 
phosphorylates Chkl at Ser345 and Ser317 and thus activates it. In turn, Chkl phosphorylates CDC25 
to initiate cell cycle arrest at S and G2 phases (de Career et al. 2007; Niida and Nakanishi 2006). 
Activation of Chkl by ATR phosphorylation requires Claspin as a mediator protein. Recruitment of 
Claspin to  ssDNA is facilitated by ATR-mediated phosphorylation of Radl7, a ssDNA binding protein 
(Reinhardt and Yaffe 2009). Phosphorylation of Chkl at Ser345 is essential fo r its activation while 
Ser317 serves as additional support. Phosphorylated Chkl undergoes autophosphorylation at 
another Ser residue (Ser296) prompting its dissociation from the chromatin and then localizes to  the 
cytoplasm and interphase centrosomes. Subsequently, activated Chkl binds to  and phosphorylates 
CDC25A to promote S phase cell cycle arrest and CDC25C to promote G2 checkpoint via inhibitory 
phosphorylation mechanism. Apart from CDC25, Chkl also binds and phosphorylates W ee l. W ee l 
phosphorylation serves as a recognition site for SFN that in turn binds to and promotes W ee l 
stability and kinase activity. Other Chkl targets include RadSl, FANCD2 and FANCE (Fanconi anaemia 
group E), proliferating cell nuclear antigen (PCNA) and the TIMELESS complex of replication fork- 
associated proteins. By interacting w ith these proteins, Chkl plays a role in regulation o f DNA repair
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and stability o f stalled replication forks. Chkl was shown to promote p53 activity by targeting and 
phosphorylating the ubiquitin ligase Mdm4/X together w ith  Chk2 (Chen et al. 2012; Reinhardt and 
Yaffe 2009; Stracker et al. 2009). Inhibitory phosphorylation o f TLKl (Tousled like kinase 1) by Chkl 
after DNA damage inhibits TLKl activity at S phase. TLKl targets A s fl, a protein required in 
maintaining chromatin dynamics and progression o f replication fork during S phase (Stracker et al. 
2009).
Chkl and Claspin expression are under the control o f the transcription factor E2F1 (Verlinden et al. 
2007). Regulation of Chkl comes from modulation o f Claspin levels via proteosomal degradation. At 
the onset of mitosis, PIkl (Polo like kinase 1) is activated and phosphorylates Claspin to  promote its 
degradation via recognition by SCFfiTrcp ubiquitin ligase. W ithout Claspin, Chkl activation is halted 
thus promoting mitosis. Following DNA damage signal, both Claspin and PIkl are ubiquitinated by 
APC/C*"'^^ .^ While PIkl is degraded, Claspin is protected from degradation by ubiquitin protease 
USP28 thus enabling activation o f Chkl. Chkl is also regulated via phosphatase action by stimulating 
PP2A (Protein phosphatase 2A) activity on itself. However, the exact mechanism still needs to  be 
elucidated. p53-inducible type-2C phosphatase W ip l also binds and regulates Chkl activity (Stracker 
e ta l. 2009).
5. Chk2
SCD FHA
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Figure 4-5: Chk2 protein structure.
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Albeit sharing conserved kinase domains w ith  Chkl and thus sharing some similar substrates, Chk2 is 
structurally and functionally d ifferent from  Chkl. The Chk2 protein consists o f an N-terminal SCD, a 
Forkhead associated (FHA) domain and kinase domain near the C-terminus. FHA is involved in 
phosphorylation-dependent protein-protein interactions. Atm carries out Chk2 activation follow ing 
DSB form ation via phosphorylation at Thr68 and several additional sites, creating a binding site 
recognized by FHA domain o f the second Chk2 monomer. M ultimerization o f Chk2 is im portant fo r 
fu rther autophosphorylation and activation o f Chk2. Apart from  direct phosphorylation o f Chk2 by 
ATM, other PIKK family members (ATR, DNAPK) have been shown to  phosphorylate Chk2 in vitro 
suggesting ATM-independent Chk2 activation is also possible. Following its activation, Chk2 
phosphorylates CDC25A to  promote Gi and S phase cell cycle arrest in a similar manner as Chkl. It is 
thought tha t Chk2 plays accessory roles to  Chkl activity (de Career et al. 2007; Reinhardt and Yaffe 
2009; Stracker et al. 2009). Additionally, C hkl has been shown to  compensate fo r lack o f Chk2 
activity (Bartek and Lukas 2003). Besides CDC25A, Chk2 also phosphorylates the transcription factor 
E2F1 tha t results in its stabilisation. Phosphorylation o f Rbp by Chk2 also enhances its interaction 
w ith  E2F1 follow ing DNA damage. E2F1 requires ATM and Chk2 activity to  in itiate the transcription 
o f proapoptotic genes (Apafl and p73) thus promoting apoptosis. Chk2 promotes IR-induced 
apoptosis partially through phosphorylation o f the PML (promyelocytic leukaemia) protein in a p53- 
independent manner. FOXOl, a transcription factor responsible fo r apoptosis activation, is also 
regulated by Chk2. Phosphorylation o f FOXOl by Chk2 inhibits its activity. DNA damage results in 
checkpoint activation and inhibition o f CDK2 activity, thus promoting FOXOl translocation into the 
nucleus to  initiate apoptosis. Another very im portant protein downstream o f ATM is p53, which is a 
direct target o f Chk2. Besides direct phosphorylation o f p53, Chk2 regulates p53 degradation by 
inhibition o f ubiquitin ligase MDM4/X. Phosphorylation o f MDM4/X by Chk2 and Chkl promotes its 
nuclear retention and degradation, and promotes dissociation o f HAUSP ubiquitin protease. 
Phosphorylation o f the Chel/AATF kinase by Chk2 and ATM fu rthe r influences p53-dependent 
transcriptional responses by increasing Chel stability and recruitm ent to  the promoters o f p53-
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responsive genes after DNA damage (Castedo et al. 2004; Stracker et al. 2009). Other proteins that 
are phosphorylated by Chk2 include CDC25C and BRCAl (Niida and Nakanishi 2006). Additionally, 
Chk2 is also an endogenous repressor o f m itotic catastrophe. Inhibition o f Chk2 or Chk2-activating 
partners sensitizes cells to  m itotic catastrophe via prolonged activation o f CDKl-CyclinB (Castedo et 
al. 2004).
Regulation o f Chk2 by PIkl is part o f mechanism in checkpoint deactivation during mitosis and 
checkpoint recovery. This regulation comes via phosphorylation o f the Chk2 FHA domain (van Vugt 
et al. 2010). W ip l and PP2A which binds and regulate Chkl, also exert similar regulatory 
mechanisms to  Chk2 (Stracker et al. 2009).
6. p53, guardian of the genome
p53 is a transcription factor central in regulating cell cycle processes. The central domain o f the p53 
protein acts as a DNA binding domain while N-terminal domain functions in transactivation. The C- 
term inal domain o f p53 is required fo r oligomerization and regulates DNA binding. Upon activation, 
p53 binds directly to  promoter or enhancer o f a gene. The binding results in transcription rate 
alteration o f the target genes (Liang et al. 2011; Schulz 2007). As a transcription factor, p53 is able to  
promote transcription o f target genes and interacts w ith a wide range o f genes. However, p53 
interaction w ith the basal transcription factor TBP or w ith  transcriptional repressors such as SIN3A 
results in transcriptional repression of several o ther genes as well (Schulz 2007). In the normal state, 
p53 activity is kept low due to  its inactivity and short half-life o f approximately 10-20 minutes which 
is insufficient fo r activity (Liang et al. 2011; Niida and Nakanishi 2006). The short half-life o f p53 
comes from its post-translational modification and degradation by MDM2/HDM2. MDM2 is 
responsible fo r p53 regulation by binding to  the p53 N-terminal region, blocking its transcriptional
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activity and initiating p53 nuclear export. MDM2 is also a specific E3 ubiquitin ligase fo r p53, 
promoting its ubiquitination and subsequent proteosomal degradation (Coschi and Dick 2012; Schulz 
2007). Apart from phosphorylation, regulation o f p53 activity occurs through other means o f 
posttranslational modification such as acétylation, neddation and sumoylation (Niida and Nakanishi 
2006; Schulz 2007).
6.1 p53 activation and functions
p53 is activated through phosphorylation by several proteins. Upon activation, p53 forms a te tram er 
and binds to  target DNA sequences (Liang et al. 2011; Schulz 2007). As stated before, ATM, ATR, 
C hkl and Chk2 are shown to  interact w ith  and phosphorylates Ser residues o f p53, promoting p53 
stabilization and subsequently eliciting several pathway interactions after the cell has sustained 
genotoxic stress (Coschi and Dick 2012; Damia et al. 2001; Schulz 2007; Siddik 2003). Ser residue 
phosphorylation also increases p53 stability and half-life by preventing interaction w ith  MDM2 
(Coschi and Dick 2012). Downregulation o f MDM2 also promotes p53 activity and MDM2 
phosphorylation by ATM impairs its ability to  promote nucleo-cytoplasmic shuttling o f p53 (Niida 
and Nakanishi 2006). p53 phosphorylation at the N-terminal domain promotes p53 transcriptional 
activity while acétylation at Lys (Lysine) residues can modulate p53 DNA-binding activity, 
transcriptional activation and localization. Stabilization o f p53 follow ing DNA damage promotes 
transcriptional activation o f target genes and determines the fate o f the cell (Coschi and Dick 2012). 
Thus, p53 influences various cellular functions, including cell cycle arrest, apoptosis and DNA repair 
(Nam and Kim 2008; Schulz 2007). Activation o f p 2 l‘"''’  ^and SFN by p53 can lead to  induced cell cycle 
arrest via inhibition o f CDKl-CyclinB and CDK2-CyclinE. p53 also activates GADD45, another CDKl- 
CyclinB inh ib itor involved in DNA repair (Niida and Nakanishi 2006; Schulz 2007). p53 together w ith  
Rbp serves as Gi checkpoint moderators by supervising Ras, Myc and E2F oncogenic activity. E2F 
promotes transcription o f genes responsible fo r cell cycle progression, including CKIs plO'^'^'’  ^and
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is responsible fo r inhibition of MDM2 thus promoting p53 stability and activity. 
Hyperactivation of Ras or Myc promotes pl4^'^'' transcription and indirectly activates p53 (Massague 
2004; Schulz 2007). Apoptosis mediated by p53 is through transcription o f several pro-apoptotic 
genes and release o f cytochrome C from the mitochondria. Cytochrome C subsequently binds to 
A pa fl (apoptotic protease activating factor 1) which leads to  activation of caspases (Coschi and Dick 
2012; Maddika et al. 2007). Apart from  activation, phosphorylation of Ser residues at d ifferent sites 
on p53 by Protein kinase C (PKC) and Chk2 modulates its activity. p53 also promotes MDM2 
induction as a feedback mechanism controlling its activity (Schulz 2007). Other than roles stated 
previously, p53 also plays an additional role in maintaining genomic stability. p53 can recognize DNA 
damage-related structures and bind to  ssDNA and dsDNA to promote strand exchange and repair. 
Additionally, p53 regulates DNA repair mechanisms such as homologous recombination and NHEJ 
(Coschi and Dick 2012). Due to its central role in controlling cell fate after DNA damage, p53 has 
acquired the title  'guardian o f the genome' (Coschi and Dick 2012; Debernardis et al. 1997; Lane 
1992).
DNA
damage
Nuclear
exclusion
ATM/ATR
l y
CyclinB
Figure 4-6: ATM, ATR, Chkl, Chk2 and p53 in GjM DDR control.
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7. Deregulation in cancers
7.1 ATM/Chk2 deregulation
The m ajority o f deleterious mutations in the ATM gene lead to  the generation o f the truncated 
version o f the protein, while other mutations are missense substitutions and in-frame deletions 
(Derheimer and Kastan 2010; Kastan and Bartek 2004). This condition leads to  radioresistant DNA 
synthesis and increased sensitivity towards radiotherapy (radiosensitivity). Radioresistant DNA 
synthesis is a term  used to  describe the condition o f defect in DNA synthesis during S phase after 
exposure to  ionizing radiation. These tw o characteristics are fundamental in identification o f ataxia- 
telangiectasia, a disease caused by m utation of ATM. As described before, ataxia-telangiectasia is a 
rare, autosomal recessive disorder. Patients w ith  this disorder showed progressive cerebral ataxia, 
neuro-degeneration, genome instability, predisposition to develop leukaemia and lymphoma 
together w ith radioresistant DNA synthesis and radiosensitivity. Ataxia-telangiectasia patients also 
exhibit resistance to  insulin as ATM produces adverse effects on insulin-dependent signalling. 
Germline mutations o f ATM-interacting proteins such as M re ll  and Nbsl lead to  disorders 
presented in a similar way to  ataxia-telangiectasia phenotypes. Hypomorphic mutations in M re ll  
lead to  an AT-like disorder (ATLD) while m utation in Nbsl leads to  Nijmegen breakage syndrome 
(NBS) (reviewed by Curtin 2012; Derheimer and Kastan 2010; Kastan and Bartek 2004).
Mutations in Chk2 have been reported in carcinomas o f the breast, lung, vulva, urinary bladder, 
colon and ovary, osteosarcomas and lymphomas. These mutations are clustered in three domains o f 
Chk2: N-terminal w ith  the SCD regulatory domain, FHA protein-protein interaction domains and the 
catalytic C-terminal domain. In human prostate and breast cancer, Chk2 mutations were considered 
as low penetrance alleles while in mice, mutations can promote genome instability. Mutations 
comprise o f either missense or results in truncated protein sequences. Experiments in mice showed 
that Chk2 deletion is insufficient to  cause spontaneous cancers but causes increases in susceptibility
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towards skin tumours induced by carcinogens. Additional m utation e ither in BRCAl or in M re ll  in 
these cases promotes development o f various other tumours. Conversely, in some human cancer 
cell lines particularly p53-deficient primary breast and colon carcinomas, upregulation o f Chk2 
activity via phosphorylation at Thr68 was found in the absence o f chemotherapy or radiotherapy 
treatm ent. This shows the importance o f Chk2 deregulation in carcinogenesis (Bartek and Lukas 
2003; Stracker et al. 2009). Chk2 is dispensable fo r prenatal development, thus supporting the role 
o f Chk2 as an 'am plifier' fo r Chkl (Niida and Nakanishi 2006). A subset o f patients w ith  Li-Fraumeni 
syndrome was found to  have heterozygous germline mutations in Chk2 w ithout any p53 mutations. 
Li-Fraumeni patients are also predisposed to  develop sarcomas, leukaemias, brain tumours, adrenal 
tumours and other cancers (reviewed by Kastan and Bartek 2004).
7.2 ATR/Chkl deregulation
As stated previously, ATR plays a significant role in normal cell development. Lack o f ATR expression 
leads to  a condition called Seckel syndrome. The syndrome's characteristics include dwarfism and 
craniofacial abnormalities and are associated w ith  severe hypomorphism o f ATR. Downregulation o f 
ATR in the mouse results in increased DNA damage during embryogenesis and replication. Loss of 
one allele o f ATR or Chkl was shown to  modestly increase carcinogenesis and ATR activation leads 
to  senescence. In adult mice, constitutive ATR hypomorphism or deletion leads to  accelerated ageing 
(Lopez-Contreras and Fernandez-Capetillo 2010; Stracker et al. 2009).
M utation o f Chkl is a rare event in cancer (Carrassa et al. 2012). Aberration o f the gene is reported 
in endometrial, gastric and colorectal carcinomas. In colon and endometrial carcinomas presenting 
w ith  microsatellite instability, frameshift mutations as a result o f e ither insertion or deletion o f 
single adenine in Chkl gene were found. Expression o f a shorter isoform o f Chkl mRNA can be seen
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in a subset o f small cell lung carcinoma. This isoform translates into a Chkl protein tha t is missing a 
part o f its conserved catalytic domain. Since a to ta l lack o f Chkl promotes early embryonic lethality 
in mice, it is understandable tha t Chkl is essential in both normal and cancerous cells (reviewed by 
Bartek and Lukas 2003). Microcephalin (MCPHl/BRITl), a gene mutated in hereditary microcephaly, 
was found to  interact w ith  Chkl. Microcephalin gene m utation shows impaired interaction w ith  
Chkl, thus influencing its transcriptional regulation and checkpoint induction. In mice, 
haploinsufficiency o f Chkl is associated w ith tumorigenesis phenotypes such as impaired cellular 
proliferation, genetic instability and elevated CDC25A fo llow ing DNA damage. Additionally, C hkl is 
indispensable fo r prenatal development (Niida and Nakanishi 2006; Stracker et al. 2009). 
Upregulation o f Chkl mRNA was found in M/CAZ-amplified neuroblastoma (Sorensen and Syljuasen 
2012). C hkl was found to  be highly expressed in grade 3 breast carcinomas w ith  trip le  negative 
phenotype (oestrogen receptor (ER)-/progesterone receptor (PR)-/HER2-) in comparison w ith  other 
grade 3 tumours (Verlinden et al. 2007).
7.3 p53 deregulation
The p53 tum our suppressor protein is the most commonly deregulated gene in human cancers 
(Baird and Kaye 2003; Coschi and Dick 2012; Siddik 2003). Defects in TP53 perm it accumulation o f 
genetic changes tha t favour malignant transform ation over many cell generations. The effect o f p53 
m utation is evident in the Li-Fraumeni syndrome, firs t described by Li and Fraumeni (1969). Li- 
Fraumeni syndrome is based on observations o f childhood rhabdomyosarcoma patients and 
identification o f four families in which its children and young adults had an autosomal dom inant 
pattern o f soft tissue sarcoma, breast cancer and other neoplasms (Li et al. 1988; Malkin et al. 1990). 
Patients w ith  Li-Fraumeni syndrome develop numerous cancers ranging from  those o f blood, 
lymphoid organs, soft tissues, the nervous system and epithelia. Malkin et al. first describes germline 
mutations o f p53 via analysis o f five families w ith  Li-Fraumeni syndrome (Malkin et al. 1990).One
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mutant copy o f p53 gene is inherited in these patients, in combination w ith  mutational inactivation 
o f the other gene copy or loss o f heterozygosity (LOH) at chromosome 17p (Coschi and Dick 2012; 
Schulz 2007). LOH is a term  used to  describe a process in which heterozygous sequences become 
homozygous through several mechanisms, such as loss o f chromosomes w ith  intact alleles leaving 
only the defective allele. Deletion o f the intact allele - or recombination that results in tw o  defective 
alleles - is also correlates w ith  LOH. There are also other mechanisms o f p53 inactivation in human 
cancers. Missense mutations o f p53 in one allele combined w ith  LOH o f another allele is the most 
common mechanism o f p53 inactivation in human cancers. Nonsense and splice mutations are also 
observed albeit less frequently (Schulz 2007). These alterations result in aneuploidy and aberration 
o f chromosome structure. There is a significant correlation between TP53 mutations and tum our 
aneuploidy. It is shown that cells w ith  p53 mutations are to lerant o f both te trap lo idy and 
aneuploidy. Missense p53 mutation correlates w ith  poor prognosis in comparison w ith  p53-null 
patients. Loss o f p53 altogether only results in the absence o f p53 tum our suppressor action while 
dom inant mutated p53 can also acquire gain-of-function o f genes tha t are selected fo r malignancy 
apart from  losing its' tum our suppressor action. This phenomenon is caused by the ability o f 
mutated p53 to  bind and transactivate genes encoding growth stimulators, such as Myc tha t provide 
survival and proliferative advantages (Coschi and Dick 2012). Overexpression o f MDM2, which 
promotes accelerated p53 degradation, is another mechanism o f p53 deregulation seen in cancers 
such as sarcomas and gliomas. Loss o f the MDM2 negative regulator pl4^'^''via gene deletion, 
mutation or promoter hypermethylation also affects the p53 level. Other mechanisms involved in 
p53 inactivation include downregulation o f upstream activators such as ATM or C hkl and 
inactivation by viral oncoproteins e.g. HPV E6 involved in cervical cancer (Kessis et al. 1993; Schulz 
2007; Siddik 2003). Mutation o f p53 can correlate w ith  cisplatin response in certain types o f cancers. 
W ild-type p53 cancers show a higher response rate towards cisplatin treatm ent compared to  
cancers w ith  high frequency o f p53 mutation such as ovarian, head and neck, and metastatic bladder
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cancers (reviewed in Siddik 2003). This is due to increased cell ability to  amplify drug resistance gene 
loci (Coschi and Dick 2012).
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Aim
To screen fo r any deregulation o f DNA damage response proteins and those relating to  G2 M cell 
cycle regulation in several panels o f ovarian, breast, head and neck and melanoma paired parental 
and drug-resistant cell lines.
Hypothesis
Changes in expression levels o f DNA damage sensors and cell cycle checkpoint controllers underlie 
cell cycle changes in drug resistant cell lines -  particularly at the G2M phases -  and these changes 
may be duplicated across many drug resistant cell line panels.
Method
Cell lines used were PEOl parental and carboplatin-, cisplatin- and Taxol-resistant variants, SK-OV-3 
parental and cisplatin- and Taxol-resistant variants, MCF7 parental and Taxol-resistant variant, T47D 
parental and Taxol-resistant variant, and HN5 parental and cisplatin-resistant variant. Cells were 
grown in suitable medium accordingly. Protein samples were harvested and Western blotting was 
carried out as described in Chapter 2. At least three repetitions o f western blotting experiments 
were carried out.
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Results
Western blotting using several antibodies against d ifferent G2 M cell cycle regulators was performed 
on selected panels o f drug-sensitive and drug-resistant cancer cell lines: ovarian cancer (PEOl and 
SK-OV-3), breast cancer (MCF7 and T47D) and head and neck cancer (HNS). The selected G2 M cell 
cycle regulators are ATM, ATR, Chkl, Chk2 and p53. The experiments were conducted on whole cell 
lysate o f cells harvested at approximately 90% confluence to assess differences in protein levels 
between drug sensitive and drug resistant cancer cells.
1. Ovarian cancer: Western blotting results of PEOl panel
Approx. BSOKDa
PEOl PEOl 
Parental CarbR
PEOl
CisR
PEOl
TaxR
ATM
Approx. 250KDa 
Approx. 56KDa aAmamgmgk
ATR 
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Approx. 85KDa
Approx. 30KDa 
Approx. 53KDa
Approx. 42KDa
Chk2
W ee l
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Figure 4-7: Cell cycle regulators protein level in ovarian cancer cell line PEOl and drug-resistant variants PEOlCarbR 
(carboplatin-resistant), PEOlCisR (cisplatin-resistant) and PEOlTaxR (Taxol-resistant) assessed by western blotting. ATM
and Chk2 expression were unaltered in all cell lines. SFN, which is a downstream effector of ATM-Chk2 showed little  
differences between parental and drug-resistant variants. W ee l, a downstream effector o f ATR-Chkl pathway was 
expressed in parental cell line but the expression was less or diminished in drug-resistant cell lines. Expression level o f p53 
is unaltered in drug-resistant cell lines in comparison w ith parental cell line apart from  PEOlCarbR, which shows p53 
downregulation. For PEOl the p53 status was reported as mutant (according to  various literatures).
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2. Ovarian cancer: Western blotting results of SK-OV-3 panel
Approx. BSOKDa
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Figure 4-8: Cell cycle regulators protein level in ovarian cancer cell line SK-OV-3 and its drug resistant variants SK0V3CR 
(carboplatin-resistant) and SK0V3TaxR (Taxol-resistant) assessed by western blotting. Across cell lines, ATM, Chk2 and 
SFN protein levels were unchanged. There was low ATR level in parental but higher level in drug-resistant. Chkl level in 
cisplatin-resistant SK-OV-3 was higher compared to parental and Taxol-resistant SK-OV-3 and this was also true fo r W ee l 
level, although the W ee l band was hardly detected. The p53 expression for all cell lines was not detected using the p53 
antibody as a consequence of the previously reported mutation.
Act in
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3. Breast cancer: Western blotting results of MCF7 panel
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Figure 4-9: Cell cycle regulators protein level in breast cancer cell line MCF7 and its Taxol-resistant variant MCF7TaxR 
assessed by western blotting. Apart from ATM and ATR level, other proteins were shown to be expressed differently in 
these tw o cell lines. There was higher Chkl and W ee l level in MCF7TaxR in comparison w ith  parental cell line MCF7. SFN, 
while expressed in MCF7 was not expressed in MCF7TaxR. Chk2 appeared to be expressed in a similar level in both cell 
lines but in MCF7TaxR, the band was slightly lower than MCF7. In MCF7, p53 is expressed (in line w ith its wild-type status) 
but diminished in MCF7TaxR (shown to be deleted, Coley unpublished data).
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4. Breast cancer: Western blotting results of T47D panel
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Figure 4-10: Cell cycle regulators protein level in breast cancer cell line T47D and Taxol-resistant T47DTaxR assessed by 
western blotting. Apart from  SFN, other proteins were expressed differently in both cell lines. There was higher expression 
of ATM, ATR and Chk2 in Taxol-resistant T47DTaxR however W ee l level was slightly lower than parental cell lines. This was 
also the case fo r Chkl expression. There was no significant difference of p53 expression between parental and Taxol- 
resistant T47D (reported as mutant).
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5. Head and neck cancer: Western blotting results of HN5 panel
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Figure 4-11: Cell cycle regulators protein level in head and neck cancer cell line HN5 and its cisplatin-resistant HNSCisR 
assessed by western blotting. Apart from slightly higher expression o f Chkl and SFN, other proteins o f interest were 
expressed in a similar level in both cell lines. The p53 status has been reported to be mutated.
Based on the western blotting results, drug-resistant cancers showed differences in expression of 
almost all proteins screened compared to  their parental cell lines, apart from cisplatin-resistant HN5 
(head and neck cancer). It appears that the changes seen was cell type-specific and might be 
influenced by p53 status.
Western blotting results were scored accordingly and the results were presented in the follow ing 
tables.
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[CHAPTER 4]
Discussion
To describe cancers tha t may have arisen from  multiple sites o f origin is a challenge, since each type 
o f cancer tends to  have specific features, particularly in terms o f genetic background. However, 
various tum our types do share some similarities in DDR component deregulation, and hence analysis 
o f this can be done using a variety o f d ifferent cancer cell line models. Cell lines used in this study 
were o f epithelial origin. Drug-resistant cell lines were developed using agents commonly used to 
trea t cancers; cisplatin, carboplatin and paclitaxel (Taxol™). Several key cell cycle regulators were 
found to  have similar expression patterns across the panels o f cell lines examined. Based on the data 
obtained, cell cycle regulators Chkl, Chk2, and ATM were present in the m ajority o f cancer cell lines 
looked at, despite here being d ifferent expression patterns between parental and drug-resistant 
variants, and also between cell lines o f d ifferent origin (refer Table 4.2). As previously stated, C hkl is 
essential in DDR as well as in the normal cell cycle progression to  ensure successful cell division. 
Downregulation o f Chkl leads to  cell cycle arrest and loss o f cell viability (refer 7.1 ATM/Chk2 
deregulation in cancers). Thus, cancer cells are thought to  maintain at least a m inimum level o f Chkl 
expression to  prevent cell death. Cancer cells m ight gain alterations tha t result in Chkl 
downregulation and therefore this may result in changes in the Chk2 levels to  compensate the lack 
o f Chkl activity. Acquired resistance towards anticancer drugs might alter expression levels as a part 
o f the resistance mechanism but in doing so, ATR and Chk2 levels are maintained. Chk2, which is 
downstream o f ATM, was found to  be expressed at low levels in the m ajority o f cell lines, w ith  the 
exception o f the T47D Taxol resistant line. ATM mutations which result in the absence o f the 
functional protein is a feature o f AT patients, showing tha t ATM does not drastically influence 
viability. The ATM protein was detected in all cell lines used in this study w ith  d ifferent expression 
level between parental and drug-resistant variant in certain pair o f cell lines. Interestingly, in the 
ovarian cancer cell line A2780TaxR, the ATR level was undetectable despite the fact tha t ATR 
downregulation might affect cell viability via induction o f cell cycle arrest (refer to  Introduction).
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There is a possible explanation fo r the adaptations seen fo r this cell line, discussed fu rthe r in Chapter 
5.
Platinum compounds and Taxol are tw o chemotherapy agents used commonly in treating cancers. 
Various reports have been published about the ability o f cancer cells to  adapt and subsequently 
acquire resistance to  these agents. Both agents have different mechanism o f action. Platinum 
compounds (cisplatin and carboplatin) bind to  DNA, causing DNA adducts and cross-links, which 
subsequently cause DNA strand breaks and inhibit DNA replication. Taxanes however do not directly 
bind to  DNA strands but cause cell cycle arrest via interaction w ith  m icrotubule dynamics and 
interfering w ith  mitosis (Shah and Schwartz 2001). In the context o f cell cycle, platinum compounds 
cause cell cycle arrest at Gi and G2 whilst taxanes induce G2M cell cycle arrest. Thus it is more 
appropriate to  discuss cell cycle deregulation in drug resistance according to  the class o f 
chemotherapy drug.
Based on western blotting data o f PEOl, SK-OV-3 and HNS parental and platinum-resistant cell lines, 
C hkl was shown to  be the most deregulated protein compared w ith  other cell cycle regulators 
examined. Chkl downregulation was seen in carboplatin-resistance while upregulation was seen in 
cisplatin-resistant cell lines, in comparison w ith  parental cells (refer Table 4.3). Chkl expression 
seems to  fo llow  the ATR expression pattern in the m ajority o f platinum-resistant cancer cells. 
However, W ee l is downregulated in both types o f platinum resistance. Thus, in the context o f this 
study, W ee l downregulation is part o f the survival mechanism adaptation by drug resistant cancer 
cells after platinum treatm ent (Figure 4-6). Apart from  these deregulations seen in ATR-Chkl-W eel 
pathway, there were relatively little  changes seen in the expression o f the ATM-Chk2-SFN pathway 
seen in platinum-resistant cell lines compared w ith  the ir parental cell lines respectively. Acquired 
resistance towards platinum compound had been associated w ith  increased DNA repair and higher
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tolerance towards DNA adducts form ation. In these cases, alteration in ATR-Chkl-W eel pathway 
might serve as an adaptive response towards platinum treatm ent since platinum compounds induce 
cell cycle arrest at Gi and G2 in platinum-sensitive cells.
a) Carboplatin resistance b) Cisplatin resistance
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Figure 4-6: Alteration of G2M cell cycle regulators in platinum resistance, a) Carboplatin resistance, b) Cisplatin 
resistance. p53 status is according to parental cell line. ATR, Chkl and W ee l are components mostly deregulated in 
platinum resistance. Downregulation of p53 can be seen in carboplatin-resistant cell line (PEOlCarbR) compared to 
parental but not in cisplatin-resistant cell lines. *ATR upregulation was seen in SK0V3CR.
Taxanes conversely, bind to microtubules and stabilized them, thus interfering w ith m itotic 
progression and ultimately causing G2 M cell cycle blockade and cell death. In Taxol-resistant cell 
lines, the ATR-Chkl-W eel pathway was again found to be mostly deregulated in comparison w ith 
ATM-Chk2-SFN pathway. The majority o f Taxol-resistant cell lines showed upregulation o f ATR 
compared to the ir respective parental cell lines. In Taxol-resistant breast cancer cell lines, Chkl and 
W ee l expression seemed matched in the ir relative expression (refer Table 4.4). This situation is 
conceivable since W ee l has been shown to be downstream target o f Chkl. Upregulation o f W ee l 
seen in the Taxol-resistant MCF-7 cell line might be due to the role o f W ee l in preventing m itotic 
catastrophe (discussed further in Chapter 5). Additionally, W ee l expression does not reflects p53 
status (wild-type or mutant) o f cell lines, showing that p53 might not play a role in W ee l regulation
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but appears to influence SFN expression (being a downstream target), as seen fo r the MCF-7TaxR 
line. SFN is discussed further in Chapter 6.
Taxol resistance:
a) MCF7 ->MCf7TaxR 
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Figure 4-7: Alteration of G^ IVI cell cycle regulators in Taxol-resistant breast cancer cell lines. p53 status is according to 
parental cell lines, a) Wild-type p53. b) Mutated p53.
In Taxol-resistant ovarian cancers, Chkl, W ee l and SFN were found to be downregulated in the 
m ajority of cell lines. ATR deregulation was cell line-specific while Chk2 was shown to  be highly 
expressed in A2780TaxR (refer Table 4.4) and all Taxol resistant lines possessed mutated or deleted 
p53. To summarize, the ATR-Chkl-Weel pathway is frequently deregulated in Taxol resistance of 
both breast and ovarian cancers (Figure 4-8).
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Taxol resistance: 
Ovarian cancers [ A TM J
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Figure 4-8: Alteration of C jM  cell cycle regulators in Taxol-resistant ovarian cancers. Downregulation o f Chkl, W ee l and 
SFN were observed in majority of Taxol-resistant cell lines screened. *p53 status and its deregulation observed were 
different according to cell lines. **Massive upregulation was observed in A2780TaxR in comparison w ith parental cell line.
Analyses o f deregulation of cell cycle components on the basis of agent specific resistance possess 
some exceptions which made a unifying explanatory model d ifficult to  develop. This may have been 
influenced by the variety of p53 status seen in all cell lines studied but is also evidence o f the 
m ultip licity and complexity of cancers. Additionally, the ATM-Chk2-SFN pathway is known to carry 
out crosstalk activity w ith the ATR-Chkl-W eel pathway. The crosstalk is carried out by means of the 
pathway interactions via phosphorylation events either directly or indirectly, thus adding more 
complexity to the study o f their deregulation in cancers. PEOl has a mutated p53 while MCF7 has 
w ild-type p53. Other cell lines (SK-OV-3, T47D and HN5) have either null or mutated p53 status. 
Apart from MCF7TaxR where the p53-deleted (confirmed via sequencing, unpublished data), p53 
status o f the other drug-resistant cell line variants are unknown. p53 known as the guardian o f the 
genome, plays an important part in determining cell response towards various stress and the most 
frequently altered gene in cancers. Moreover, Taxol and platinum compounds have been shown to 
promote different patterns of p53 phosphorylation that affect its action on other cell cycle 
component. Taxol can induce Ser20 phosphorylation possibly via Chk2 which promotes its
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stabilization. This also leads to  induction o f activity. Cisplatin is also able to  evoke such 
reaction w ith  greater p21^'’’  ^ induction, possibly via additional p53 phosphorylation at SerlS. P53 
SerlS phosphorylation event is known to  promote p53-DNA binding stabilization (Damia et al. 2001). 
However, the p53 status o f ovarian cancer cell line SK-OV-3 does not influence its sensitivity towards 
Taxol or cisplatin treatm ent (De Feudis et al. 1997; Debernardis et al. 1997).
Overall, the ATR-Chkl-W eel pathway seems to  be the most deregulated in drug-resistant cancer cell 
lines based on comparisons o f protein expression levels between parental and drug-resistant cell 
lines. Although Chkl is frequently deregulated, its wide range o f downstream targets may provide a 
challenge fo r drug development specifically aims at targeting Chkl. However, considering each cell 
line's genetic background, W e e l emerges as a possible candidate fo r determ ination o f drug- 
resistance and represents a viable druggable target, since it specifically targets CDKl-CyclinB.
The results presented f it  the hypothesis. Expression levels o f key components o f G2 M cell cycle 
checkpoints were altered in drug-resistant cell lines and some duplication were seen in o ther cell 
lines w ith  some similarities in term  o f genetic background and a specific causal agent.
Conclusion
Differential expression levels o f key cell cycle regulation and DNA damage recognition factors such 
as Chkl and ATR appear im portant in mediating anticancer drug resistance. Based on the data 
accrued from  the cell lines studied, W ee l and lesser so SFN emerge as interesting targets that 
appear to  mediate cellular response towards taxanes and platinum compounds. Their dysregulation 
would appear to  be important in the consideration o f anticancer drug resistance mechanisms and it 
m ight depend on the individual cellular context.
139
[CHAPTER 4]
The complexity o f the cell cycle machinery and the biology o f the cell itself make it d ifficu lt to  
determine precisely the mechanism(s) behind dysregulation o f cell cycle and checkpoint control in 
Taxol- and platinum-resistance. However, this study that focuses on the cell cycle deregulation at the 
G2 M cell cycle checkpoint has attempted to  delineate such mechanisms and work continues to  
define fu rthe r the mechanism between W ee l expression and drug resistance.
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Weel as a Candidate 
Biomarker in 
Taxol Resistance
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Introduction and Background
1. Weel
1.1 Weel gene structure
RxLl
Wee
Box
I
N-terminal regulatory domain
 1---------
Kinase domain C-terminal
domain
Figure 5-1: Primary structure o f somatic W ee l protein.
W ee l tyrosine kinase derived its name from an after effect on the size o f the cells resulting from 
Weel silencing in 5. pombe. W ee l originally cloned in S. pombe and characterized by Russell and 
Nurse (1989) plays an important role in mitosis by allowing cells to  attain an appropriate size before 
being allowed to go into mitosis. Silencing o f Weel promotes cell cycle progression into M phase 
prematurely and as a result, produced small or 'wee' cells (reviewed by Suryadinata and Sarcevic 
2008). W ee l is a part o f the W ee l kinases family, M y tl being the only other family members (Perry 
and Kornbluth 2007). However in 2000, Nakanishi et al. characterized and proposed a new member 
of W ee l family, naming it W eelB. W eelB  possess a close sequence sim ilarity w ith W e e l by having a 
putative nuclear localization signal in its N-terminal domain and was shown to regulate mitosis 
(Nakanishi et al. 2000). Therefore, based on studies in mammalian and Xenopus systems, currently 
there are two isoforms of W ee l, maternal or embryonic isoform (W eelA in Xenopus, W eelB  in 
human) and somatic isoform (W eelB/W ee2 in Xenopus and W ee lA  in human) (Perry and Kornbluth 
2007).
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1.2 Expression
Intracellularly, W ee l is mainly found as a nuclear protein while M y t l is membrane-bound (Lee and 
Yang 2001; Nakanishi et al. 2000). Analysis o f W e e l isoforms has revealed that W ee lA  (somatic) 
isoform and W eelB  (embryonic) isoform plays a role in d ifferent stages o f early embryogenesis. 
Using northern blot analysis, W eelB  was shown to  be highly expressed in testis while W ee lA  
showed a broader spectrum o f expression sites including brain, pancreas, uterus and lung apart from  
testis (Nakanishi et al. 2000).
Expression pattern Expressed in oocytes and early 
embryos
Expressed later in development stage 
into adulthood
Function Control meiotic cell cycle and early 
m itotic cell cycle
Control somatic cell cycle which 
commences after zygotic transcription 
begun
Table 5-1: Two isoforms o f W ee l in Xenopus and mammalian systems (Perry and Kornbluth 2007).
1.3 Mechanism of action of W eel
W e e l phosphorylates the tyrosine 15 (Tyr-15) residue on CDKl. Inhibitory phosphorylation by W ee l 
ensures CDKl inactivation until the completion o f DNA replication - or until cells have reached a 
suitable size before progressing into mitosis (M phase). In comparison w ith  W ee l, M y t l can 
phosphorylate Thr-14 and Tyr-15 residues o f cyclin-associated CDKl. Both residues lie w ith in  the ATP 
binding pocket o f CDKl (de Career et al. 2007). However, M y t l has a restricted substrate since W e e l 
can bind to  other CDKs as well, including CDK2 via Thr residue phosphorylation (Lee and Yang 2001; 
Nakanishi et al. 2000; Reinhardt and Yaffe 2009; Sorensen and Syljuasen 2012; Suryadinata and 
Sarcevic 2008). As a predominantly nuclear protein, W e e l acts by reducing the active CDKl-CyclinB 
level in the nucleus during interphase while M y t l additionally binds to  CDKl-CyclinB complex, thus 
sequestering it at the membrane. W ee l and M y t l are inactivated in the 6% to  M phase transition to  
allow m itotic progression (Perry and Kornbluth 2007). Inhibition o f CDKl phosphorylation activity is
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also maintained in G2 cell cycle arrest a fter DNA damage as a result o f the G2 M checkpoint control 
(Lee and Yang 2001). This checkpoint is essential in order to  avoid cell cycle progression w ith  
damaged DNA and results e ither in cell death or if  faulty w ill result in carcinogenesis. DNA damage 
signals transm itted via Chkl/Chk2 (checkpoint kinases) subsequently activates W e e l and 
concomitantly inactivates CDC25C (Cell Division Cycle 25-C). The function o f CDC25C phosphatase is 
to  activate CDKl by removing its inhibitory phosphorylation; hence its inactivation halts CDKl 
activation. Active CDKl-CyclinB has been shown to  be phosphorylated by W ee l and M y t l or 
sequestered outside the nucleus by the action o f another protein called Stratifin or 14-3-3o 
(described in detail in Chapter 6) and consequently, cell cycle progression w ill be halted (Indovina 
and Giordano 2010). W ee l also m ight play other ancillary roles in mitosis via phosphorylation o f 
Serine (Ser) 549 residue of CDKl (Perry and Kornbluth 2007).
W e e l interaction w ith CDK2-CyclinA is less well understood. CDK2 plays a role in promoting mitosis 
by reducing the phosphorylation o f the CDKl-CyclinB complex, which normally gives rise to  a delay 
in m itotic entry. Inhibition o f CyclinA activity via siRNA or by using CDKl-CyclinA inhibitors leads to  
m itotic blockade and decreased CDC25 activity. Targeted deletion o f CyclinA proved to  be lethal in 
mouse embryo as well as in adult animals w ith evidence o f G2 cell accumulation (Enders 2010; 
Kalaszczynska et al. 2009). However, the exact mechanism behind CyclinA inhibition and cell cycle 
effects remains elusive. Based on works in Xenopus, CDK2 has been shown to  interact w ith  W e e l 
through its RxLl binding m otif. CDK2 binds and phosphorylates the Wee box and makes it inactive. 
Additionally, CDK2 might play a role in the cytoplasmic distribution o f W e e l by phosphorylating 
another residue that promotes W ee l nuclear export via interaction w ith  C rm l (Enders 2010). This 
mechanism remains to  be fu rther clarified. As such, CDK2 is negative regulator o f W e e l (Figure 5-).
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( In a c t iv e )
Cydm A
N u c le a r
e xc lus ion Cyclin B
Figure 5-2: Relationship between CDKl-CyclinB, CDK2-CyclinA and W eel. W eel negatively regulates CDKl-CyclinB by 
inhibitory phosphorylation (**). CDK2-CyclinA promotes m itotic entry by reducing inhibitory phosphorylation o f CDKl- 
CyclinB through negative regulation of W eel.
1.4 Regulation
W ee l is expressed in S and Gz phases and its activity corresponds w ith W ee l protein concentration. 
W ee l activation comes from interaction w ith Chkl and stimulation from CABLES (CDK5 and Abl 
enzyme substrate), a CDK-interacting protein (Sorensen and Syljuasen 2012). CABLES was first 
isolated by Zukerberg et al. (2000) via screening o f a mouse cDNA library. CABLES links CDK5 to c-AbI 
tyrosine kinase, thereby promoting CDKS Tyr residue phosphorylation by c-AbI (Zukerberg et al. 
2000). Low levels of CDK activity in the G2 phase can also contribute towards W ee l activation in 
budding yeast (Sorensen and Syljuasen 2012). W ee l is able to undergo autophosphorylation at Tyr 
residues, a process which acts as a positive regulator. Regulation o f W ee l also comes from 
interaction via phosphorylation and binding w ith  14-3-3 proteins during interphase. Human W ee l 
interacts w ith 14-3-3 proteins by C-terminal consensus m otif that enhances the stability and ability 
o f W ee l to maintain interphase. It has been shown that this binding occurs in interphase but not in 
mitosis. It requires phosphorylation o f Ser residue in C-terminus o f W ee l to create a binding site for 
14-3-3 proteins (Perry and Kornbluth 2007; Reinhardt and Yaffe 2009) (Figure 5-13). However, 
interaction between W ee l and 14-3-3 proteins might also negatively regulate its activity. Akt 
promotes cell cycle progression by phosphorylating the Ser642 residue of W ee l, promoting its
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cytoplasmic localization during late S and G2 phases. Phosphorylation of W ee l Ser642 creates 
binding site fo r 14-3-30, an isoform of 14-3-3 proteins. Allegedly, binding w ith d ifferent isoforms o f 
14-3-3 determines W ee l activity. Binding w ith  3, y and  ^isoforms w ill promote its activity while 14- 
3-30 promotes its nuclear sequestration (Perry and Kornbluth 2007).
Low G2 CDK 
activity (Inactive)
Cyclin B
Cyclin B y
(Active)
M
Figure 5-13: Positive regulation of W eel. W eel phosphorylates CDKl thus making it inactive and results in G2M cell cycle 
arrest. Low CDK activity and interaction w ith CABLES enhances W ee l activity (1). W ee l is also able to  undergo auto­
phosphorylation (2). Chkl promotes W ee l activity via phosphorylation that creates binding site fo r 14-3-3 protein which 
further promotes its activity and stability (3).
Inactivation o f W ee l is poorly understood. It is thought that inhibition of W ee l activity at the 
beginning o f mitosis is promoted by its phosphorylation and degradation. W ee l phosphorylation is 
part o f a negative feedback loop initiated by CDKl-CyclinB. CDKl-CyclinB phosphorylates the Serl23 
residue of W ee l. Following phosphorylation, W ee l becomes a target fo r ubiquitination by SCF 
ubiquitin ligase 3-TrCP via interaction w ith  its WD40 domain and later subjected to proteosomal 
degradation. Serl23 phosphorylation also acts as a docking site fo r polo-like kinase PIkl. Apart from  
W ee l, PIkl is also able to inhibit M y tl. Another SCF-type ubiquitin ligase Tome-1 (Trigger o f M itotic 
Entry) might also play a role in enhancing 3-TrCP activity. Tome-1, originally described by Ay ad et al.
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(2003), promotes W ee l degradation and m itotic entry through Ser38 phosphorylation o f Xenopus 
W ee l as a recognition label (Perry and Kornbluth 2007; Sorensen and Syljuasen 2012). Thus, the 
level o f active CDK increases thereby promoting cell cycle progression.
Nuclear W ee l stability is controlled by DNA-responsive checkpoints. A study in Xenopus showed that 
upon inhibition of DNA replication or DNA damage, W e e l protein was stabilized and degraded 
intranuclearly during m itotic entry. W eel-interacting protein Hsl7 might play a role in intra-nuclear 
degradation o f Xenopus W ee l at G^ IVI transition. This was shown through overexpression and 
depletion experiments involving Hsl7. Hsl7 overexpression overrides checkpoint into mitosis by 
excess W ee l degradation, whilst depletion o f Hsl7 stabilized W ee l could promote cell cycle arrest 
(Perry and Kornbluth 2007) (Figure 5-14).
Cyclin B
Degradation
B-TrCP
Nuclear exclusion
Figure 5-14: Negative regulation o f W ee l. CDKl-CyclinB phosphorylates W ee l as a negative feedback loop. W ee l 
phosphorylation creates binding site for PIkl and p-TrCP ubiquitin ligase thus promoting its degradation. 14-3-3 isoform 
binds to phosphorylated W ee l and promotes its nuclear export. Binding o f W ee l w ith Hsl7 directly w ithout CDK 
phosphorylation also promotes W ee l degradation internuclearly.
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1.5 Expression of W eel in cancer
Deregulation o f W e e l has been reported in several cancers (Backert et al. 1999; Kiviharju-af 
Hallstrom et al. 2007; Magnussen et al. 2012; Masaki et al. 2003). Using cDNA array, Backert et al. 
(1999) reported significant downregulation o f Weel in colon carcinoma cells o f both non-mucinous 
and mucinous phenotypes. These findings also correlated w ith  Weel expression levels in patients' 
tissue samples (Backert et al. 1999; Lee and Yang 2001). There is evidence fo r various microRNAs 
(miRs) that target W ee l and, therefore, play a role in W e e l transcriptional control, as described fo r 
some cancers. MiR-155, fo r example, has been shown to  be overexpressed during the innate 
immune response, autoimmune disorders and various malignancies. Tili et al. examined the ability o f 
microRNA-155 (miR-155) to  induce m utation and found evidence fo r targeting W ee l, causing its 
downregulation (Sorensen and Syljuasen 2012; Tili et al. 2011). Additionally, low W e e l expression 
could increase susceptibility to  carcinogenesis. Gamma-irradiation on human primary prostate 
epithelial cells and human prostate tissues revealed tha t prostate epithelium retained CDK2- 
associated kinase activity as a result o f low inhibitory phosphorylation o f CDK2. Ectopic W e e l 
expression however rescues the checkpoints. Thus it showed tha t prostate epithelium expressed 
very low levels o f W ee l thus increasing its susceptibility to  acquire DNA lesions and development 
into prostate cancer (Kiviharju-af Hallstrom et al. 2007; Sorensen and Syljuasen 2012). 
Downregulation o f W ee l was also reported in non-small-cell lung cancer (Magnussen e t al. 2012).
However, overexpression o f W ee l has been reported in several cancers including in osteosarcoma, 
hepatocellular carcinoma (HCC), glioblastoma and breast cancer. A comparative study o f HCC versus 
cirrhosis revealed that protein level and kinase activity o f W e e l is higher in HCC compared w ith  
surrounding cirrhotic tissues (Masaki et al. 2003). There is higher W ee l expression in glioblastoma 
cell nuclei in comparison w ith  normal brain regions and its expression was well correlated w ith  
patient survival (M ir et al. 2010). A high level o f W e e l was associated w ith  poor disease-free survival
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in malignant melanoma and markers o f increased tum our cell proliferation (thicker primary tumours 
and ulceration) based on analysis performed on paraffin-embedded patient derived tissues and 
cultured melanocytes (Magnussen et al. 2012).
1.6 W eel and DNA damage recognition (DDR)
DNA damage occurs naturally and also as a result o f exposure to  certain type o f chemicals used in 
cancer treatm ent. DNA damaging agents as chemotherapeutic agents are classified according to  
the ir mode o f action. There are radiomimetics, topoisomerase inhibitors (for example doxorubicin), 
anti-metabolites (5-fluorouracil) and alkylating agents (carboplatin and cisplatin) (Indovina and 
Giordano 2010). DNA damage evokes cellular responses which results in DNA repair, cell cycle arrest 
and/or apoptosis through DNA damage checkpoint control. These checkpoints consist o f sensors, 
mediators, transducers and effectors (Niida and Nakanishi 2006). Depending on the type o f DNA 
damage, d ifferent signalling pathways are activated. In a nutshell, cell cycle checkpoints at GiS and 
G2 M are activated if the cell sustains DNA damage, stalled replication forks or stress (Bouwman and 
Jonkers 2012). ATM and ATR kinases are signal transducers tha t phosphorylate a large number of 
substrates including Chkl and Chk2 kinases, another type o f signal transducer. In turn, Chkl 
activates effector kinases fo r p53 and W e e l while at the same tim e blocking CDC25 phosphatase 
activity via phosphorylation which results in its direct inhibition, nuclear export or ubiquitination 
followed by its subsequent degradation (Niida and Nakanishi 2006). p53 activation and CDC25 
inhibition are also triggered by Chk2 kinase which receives its activation signal from  ATM. In 
conclusion, the activation o f these DNA damage signalling pathways results in activation o f cell cycle 
checkpoints via inhibition of CDK2-CyclinE activity at GiS and CDKl-CyclinB activity at G2 M 
(Bouwman and Jonkers 2012).
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W ee l's  property as a negative regulator o f the cell cycle has proven to  be an Interesting target fo r 
drug development. Hence MK1775, a W ee l Inhib itor has been In clinical tria l as single and 
combination treatm ent. W e e l Inhibitors \were developed to  provide targeted therapy especially w ith  
cancers tha t are p53-deflclent. In these cells, lack o f p53 Is hypothesized to  make the cells more 
susceptible to  G2M checkpoint abrogation (HIral et al. 2009) and In this context MK1775 can be 
described In this way.
2. MK1775: Synthetic inhibitor ofWeel
2.1 Mechanism of action
Figure 5-15: MK1775 chemical structure (Kreahling et al. 2012).
Cancer patients are typically treated w ith  conventional DNA damaging agents such as Ionizing 
radiation, alkylating agents and platinum compounds. However, these agents possess low specificity 
and are associated w ith considerable side effects. Combinations o f these DNA damaging agents w ith  
more targeted treatm ent may enhance activity and narrow target choice. MK1775 (2-alkyl-6-anlllno- 
1-aryl, 2-dlhydro-3H-pyrazole [3,4-d]pyrlmldln-3-one) originally described by HIral et al. (2010) Is a 
selective and potent small molecule Inhibitor o f W e e l (MIzuaral e t al. 2009). MK1775 Inhibits W e e l 
by competition w ith  ATP fo r Its W ee l binding site, leading to  decreased phosphorylation o f CDKl. 
MK1775 has a >100 fold selectivity over human M y tl,  another W e e l family member tha t also 
Inhibits CDKl (HIral et al. 2009).
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2.2 MK1775 in combination and as a single agent
Combination treatm ent using DNA damaging agent gemcitabine, carboplatin and cisplatin in p53- 
deficient cells promotes apoptosis. In vivo combination treatm ent showed tha t MK1775 enhanced 
tum our growth inhibition and w ith  no evidence o f increased toxicity. MK1775 treatm ent in vitro w ith  
the m icrotubule targeting agent docetaxel and paclitaxel did not enhance the ir cytotoxic effects 
(HIral et al. 2009; Indovina and Giordano 2010). Several other studies also demonstrated 
antltumorlgenic effects o f MK1775 In combination w ith  cytotoxic agents In non-small-cell lung 
carcinoma, breast, prostate, pancreatic, ovarian and colon cancers (reviewed by Kreahling et al. 
2012). In mice, W e e l knockout resulted In mice embryonic lethality, DNA damage and apoptosis. In 
rodents, W e e l downregulation hinders tum our xenograft growth. Synergistic effects to  Inhibit 
cellular proliferation and promoting apoptosis were seen In combination treatm ents using the Chkl 
Inhibitor AR458323. It was also shown tha t cancer cell lines were more prone to  this combination 
compared to  non-cancerous cells (Davies et al. 2011). Another study carried out using the C hkl 
Inhibitor PF00477736 In combination w ith  MK1775 showed tha t regardless o f p53 status, this 
combination acts synerglstlcally In breast, ovarian, colon and prostate cancer cell lines. In vivo 
combination treatm ent In mice results In higher tum our growth suppression In comparison w ith  
single agent treatm ent w ithout any sign o f toxicity (Carrassa et al. 2012). In vivo treatm ent using 
MK1775 alone In animal xenograft models produces lim ited antitum our efficacy In comparison w ith  
another W ee l Inhibitor PD0166285 (HIral et al. 2009). However, MK1775 treatm ent In w ild-type 
p53, mutant p53 and null p53 sarcoma cells produced similar degrees o f cell death as a result o f 
m itotic catastrophe caused by W ee l Inhibition alone (Kreahling et al. 2012). These data suggest that 
MK1775 activity Is based on cancer type and p53 status Is not a definitive way o f determ ining 
treatm ent response towards this agent.
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3. Paclitaxel
3.1 Mechanism of action
AcO r9 OH
10
ÔH
Figure 5-16: Paclitaxel (Taxol ) chemical structure (Orr et al. 2003).
Paclitaxel (Taxol™) is an antim itotic agent derived from  Taxus brevifolia and Taxus yannanensis. 
There are tw o major groups o f antim itotic agents, classified based on the ir action on the tubulin 
polymers/m icrotubule system. Vinca alkaloids are examples o f agents that bind to  a /3-tubu lin  
heterodimers thus inhibit polymer assembly. In contrast, Taxol belongs to  the group o f antim itotic 
agents tha t binds to  polymer and stabilized microtubules. Taxol only binds to  polymerized tubulin, 
specifically the p-tubulin subunit in microtubules and not tubulin dimers themselves. Binding o f 
Taxol to  m icrotubule polymers is reversible and enhances polymerization of tubulin. In the presence 
o f Taxol, microtubules have a higher degree o f stability and resistance towards depolymerisation by 
Ca^\ cold temperature and dilution. Taxol also alters m icrotubule assembly kinetics. Taxol can also 
interfere w ith  m itotic progression by suppressing microtubule dynamics and consequently, produces 
an aneuploid population of cells by means o f forced m itotic exit. Taxol induces several antim itotic 
effects tha t have been shown to be concentration-dependent (Kumar et al. 2010). Taxol was 
approved by FDA (US Food and Drug Administration) fo r treatm ent o f several types o f human 
cancers, including ovarian cancer (Kumar et al. 2010). There are several newer forms o f paclitaxel 
developed by conjugation w ith  other molecules fo r ease o f administration, reducing toxicity and 
improving efficacy. These conjugates include albumin, docosahexaenoic acid, poly-L-glutamic acid 
and brain peptide vector angioprep-2 (Kumar et al. 2010; Yardley 2013).
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3.2 Resistance mechanism to Taxanes
Acquired resistance to  Taxol had been a "stumbling block" in cancer treatm ent. There are several 
known mechanisms o f Taxol resistance. These include overexpression o f the m ultidrug transporter 
p-glycoprotein and alteration in the drug's metabolism. Orr et al. have listed several possible 
mechanisms o f Taxol resistance concentrating on the microtubules. This includes changes to 
microtubule dynamics, altered expression o f (3-tubulin isotypes especially in class III and IV, point 
mutations in tubulin tha t altered m icrotubule dynamics, altered expression or post-translational 
modifications o f tubulin or m icrotubule-regulatory proteins, altered binding o f Taxol to  the 
m icrotubule and alterations in signalling pathway (Orr et al. 2003).
3.3 Taxol and mitotic catastrophe
Taxol as a m icrotubular poison, directly affect mitosis via tubulin stabilization which in turn causes 
m itotic catastrophe. M itotic catastrophe is a poorly defined event. Some researchers classify m itotic 
catastrophe as an event o f cell destruction during or shortly after mitosis as an effect o f abnormal 
chromosome segregation or DNA damage (Bouwman and Jonkers 2012; Galluzzi et al. 2011; Portugal 
et al. 2010). Galluzzi et al. (2011) fu rther defined m itotic catastrophe as a signalling pathway 
triggered by abnormalities in m itotic apparatus sensed during mitosis tha t leads to  m itotic arrest 
followed by cell death. This event can sometimes be accompanied by the release o f pro-apoptotic 
proteins and caspase activation, pointing to  cross-talk between mitosis and another form  o f cell 
death, apoptosis. M ito tic catastrophe had also been defined as the main cause o f cell death by 
ionizing radiation (Portugal et al. 2010). Until recently, there have been no exact biochemical 
features that can define m itotic catastrophe. However, several biochemical events have been 
associated w ith m itotic catastrophe such as caspase- 2  activation, prolonged activation o f spindle- 
assembly checkpoint (SAC), activation o f p53 and aberrant level o f CyclinB (Galluzzi et al. 2011). 
Premature activation or overexpression o f CDKl-CyclinB also leads to  m itotic catastrophe by means
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of early entry into mitosis before the completion o f the G2 phase. Prolonged activation o f CDKl- 
CyclinB via Chk2 inhibition promotes progression towards mitosis followed by m itotic catastrophe 
(Castedo et al. 2004). Some morphological features have been associated w ith  m itotic catastrophe, 
including micronucleation and multinucleation. M icronucleation is an aftermath o f inconsistent 
chromosome and/or chromosome fragments division between tw o daughter cells. Multinucleation 
is a product o f abnormal karyokinesis which generates tw o  or more nuclei w ith  similar or 
heterogeneous sizes (Galluzzi et al. 2011). The fo llow ing table summarizes m itotic catastrophe.
Definitions and characteristic Cell death occurring during or after a faulty mitosis
Can lead to necrosis or apoptosis-like death (p53-independent)
Morphological features Micronucleation 
Multinucleation 
Giant cells
Partially condensed chromatin 
Apoptotic and/or necrotic features
Biochemical features/ 
associated genetic changes
Activation o f caspase-2 
Prolonged SAC signalling 
p53 activation
Abnormal CDKl-CyclinB activation
Stimulated by deficiencies in cell cycle checkpoint proteins and 
m itotic spindle assembly
Can fo llow  caspase-dependent or independent routes 
G2 M accumulation and polyploidy
Inflammatory/immune Poorly defined (might be dependent on the executioner
features mechanism)
Table 5-2: Summary of mitotic catastrophe (Galluzzi et al. 2011; Portugal et al. 2010).
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Aim
\Neel is one o f the genes listed as downregulated in drug-resistant cell lines in comparison w ith 
parental cell lines in the original cDNA microarray analysis. This study aims to  fu rther confirm these 
earlier data and to  try  to  establish if W e e l expression is pivotal in inducing anticancer drug 
resistance.
Hypotheses
•  W ee l, identified as changing its expression levels in several drug resistant cancer cell lines, 
plays a role in mediating the change in drug sensitivity -  particularly in the case o f taxanes
•  Downregulation o f W ee l is due to  epigenetic silencing and this plays a functional role in 
mediating cancer cell responsiveness to  taxanes
•  Conversely, drug resistant cell lines showing marked up regulation o f W e e l may show 
collateral sensitivity to  the W e e l kinase inh ib itor MK-1775
Methods
Methods used in this study as described in Chapter 2 are protein harvest, western blotting, mRNA 
extraction, qPCR analysis, cytotoxicity assay using MTT, DNA harvest, PI staining, Annexin V-FITC, 
flow  cytometric analysis, and siRNA transfection. Cell lines used were A2780 and A2780TaxR Taxol- 
resistant, and SK-OV-3 and SK0V3 Taxol-resistant variant cell lines. Dose-response curves were 
constructed using GraphPAD PRISM. Student's Paired T-Test was performed where applicable and 
result was expressed as p value. All methods have been described in Chapter 2.
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Results
1. Taxol response in cell lines
Taxol treatm ent followed by viability test using M IT  was performed on both A2780 and SK-OV-3 
panel (drug-sensitive and drug-resistant). The dose-response curves were drawn to  acquire IC50 
values o f Taxol fo r each cell lines in the respective panel. All cell lines used in this experiments and 
other subsequent experiments were tested negative fo r mycoplasma.
1.1 Taxol IC50 level in A2780 and SK-OV-3, parental and drug-resistant cell lines
Dose-Response Curve of Taxol in A2780 and A2780TaxR 
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Figure 5-7: Dose-response curve of Taxol treatment to A2780 and Taxol-resistant A2780TaxR. Cells were seeded at 3x10 
cells/mL in 96-well plate and treated with Taxol for 72 hours before termination using MTT reagent. Resistance factor (RF) 
was calculated using formulae (IC50 parental/ICso drug-resistant). RF value for A2780TaxR was 3.189 (n=5).
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Dose-Response Curve of Taxol in SK-OV-3 and SKOV3T6
100
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Taxol ICso (nM ) Resistance factor (RF)
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Figure 5-17: Dose-response curve of Taxol treatment to SK0V3 and Taxol-resistant SKOV3T6. Cells were seeded at 3x10'* 
cells/mL in 96-well plate and treated with Taxol for 72 hours before termination using MTT reagent. RF value for SKOV3T6 
was 20.33 (n=3).
1.2 DNA content analysis of A2780 panel without and with Taxol treatment
A2780 parental and A2780TaxR (Taxol-resistant) was treated w ith  lOnM Taxol and harvested after 
24 and 48 hours treatm ent. Table 5-3 summarized changes seen in DNA content o f both cell lines 
after Taxol treatm ent, as analysed using flow  cytometry. Experiment was conducted to  assess 
differences o f Taxol response (in terms o f cell cycle changes) between Taxol-sensitive and Taxol- 
resistant ovarian cancer cells.
Control Typical DNA content (GiS and G2 M 
peaks)
Typical DNA content (GiS and G2M peaks), 
approximately similar as parental cell line
24 hour post­
trea tm ent
appearance o f debris peaks 
and subGi
reduced Gi peak size 
higher G2 M peak
No significant changes to  DNA profile
48 hour post­
trea tm ent
prominent debris peaks 
maintenance o f G2 M peak
No significant changes to  DNA profile
Table 5-3: Summary of DNA cytogram of A278Q and A2780TaxR treated with Taxol. Taxol induced G2M cell cycle arrest. 
This effect was clearly shown in Taxol-sensitive A2780 but not in Taxol-resistant A2780TaxR. The effect was more 
pronounced with higher Taxol dosage and longer incubation time.
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1.3 DNA cytogram of A2780 panel with different Taxol dose at 48 hours post-treatment
Figure 5-9 shows cytograms of control (untreated) and Taxol-treated (lOnM and 25nM) A2780 and 
A2780TaxR as analysed using flow  cytometry. Experiment was conducted to assess DNA changes 
caused by different Taxol concentration on Taxol-sensltlve and Taxol-resistant ovarian cancer cells.
Untreated
A2780
Gj: 61.5% ±3.29
lOnM  Taxol 25nM  Taxol
Sub-Gj: 47.6% ± 1.60 
G^ : 10.8% ±4.79
GjM: 35.2% ±2.37
Sub-Gji 51.4% ±1.93  
G,: 8.68% ±1.73  
S: 5.2% ±0.98 
G,M :34.8% ± 1.18
JÉâl
A2780
TaxR
Untreated lOnM  Taxol
G jM :31.7% ±0.20
25nM Taxol
Gi: 38.9% ±5.06  
5:14.2% ±2.93  
6 ,M : 31.4% ±1.16
Figure 5-9: DNA cytogram of A2780 and Taxol-resistant A2780TaxR without and with 48 hours of lOnM and 25nM Taxol 
treatment. Longer exposure to Taxol promotes cell death as seen by the appearance of undefined peaks (cell debri) right 
before the actual DNA peaks. However in Taxol-resistant A2780 there were hardly any changes seen in the DNA peaks 
compared to control. This figure is representative o f cytograms obtained during repeated experiments (n=3).
2. Weel mRNA level in A2780 and SK-OV-3 panels
W ee l expression In A2780 and SK-OV-3 panels were measured using qPCR analysis and results were 
presented In Figure 5-10.
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qPCR analysis of W e e l expression in A2780 and SK0V3 
parental and Taxol-resistant counterpart
#> (0 0.4
I  Parental cell line 
I  Taxol-resistant cell line
A2780 SKOV3
Cell lines
Figure 5-18: qPCR analysis of W ee l expression in 2 different parental and Taxol-resistant cell lines (A2780 and SK-OV-3).
Based on qPCR analysis, W ee l expression was significantly downregulated in both Taxol-resistant cell lines compared to  its 
respective parental cell lines. (*p<0.05, **p<0.005) (A2780 pair n=13, SK-OV-3 pair n=6)
Following qPCR, western blotting using an antibody against W ee l was performed in order to  assess 
the protein level in the different cell lines.
3. Weel protein level in A2780 and SK-OV-3 panels
Approx.
85KDa
Approx.
37KDa
A2780 A2780TaxR
# # # #  W ee l
G A P D H
b)
Approx.
85kDa
Approx.
37kDa
SK0V3 SK0V3TaxR
W e e l
G A P D H
Figure 5-19: Western blotting analysis of W ee l level in selected cell lines, a) W ee l protein level in A2780 and Taxol- 
resistant A2780TaxR. in Taxol-resistant cell line, there was clear downregulation of W ee l compared to its parental cell line, 
based on the decreasing size of W ee l protein band in A2780TaxR compared to parental cell line A2780. b) W ee l protein 
expression in SK-OV-3 and SK0V3TaxR Taxol-resistant. W ee l level in Taxol-resistant was higher compared to parental cell 
lines as shown by the increased intensity of the band. (n=3).
The W ee l level in A2780 panel was in agreement w ith qPCR analysis. However, the W ee l protein 
level in SK-OV-3 panel did not reflect its qPCR analysis.
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4. GzM cell cycle control protein level in A2780 panel
Western blotting fo r several G2 M cell cycle proteins was done to  assess and to  compare the ir level in 
A2780 and A2780TaxR. Antibodies used in the experiment were against ATM, ATR, Chkl, Chk2 and 
p53. P-actin and GAPDH acted as positive controls. Experiments were performed on whole cell lysate 
samples.
a)
Approx. 350KDa 
Approx. 250KDa 
Approx. 56KDa
Approx. 62KDa 
Approx. 42KDa
ATM
ATR
Chkl
Chk2
P-Actin
b)
Approx.
53KDa
Approx.
37KDa
A2780 A2780TaxR
GAPDH
Figure 5-12: Western blotting analysis of A2780 and its Taxol-resistant counterpart A2780TaxR. HeLa acted as positive 
control for most of the proteins detected, a) Level o f G2M cell cycle regulator proteins upstream of W ee l in both cell lines. 
Apart from ATM, A2780TaxR Taxol-resistant showed different expression patterns compared to A2780 parental cell line. 
Upregulation was detected in p53 level (b) and massively seen in Chk2 expression. Downregulation was seen in ATR and 
Chkl compared to parental cell line.
Downregulation of W ee l in A2780TaxR might be due to  epigenetic modification of the gene. 
Demethylating treatm ent was done in order to assess this hypothesis.
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5. Demethylating agent treatment in A2780 Taxol-resistant
A2780
A 2780
TaxR
A 2780
TaxR
A 2780
TaxR
5 ’-A za
- - + -
T S A - - -
Approx. 
85 kDa
Approx. 
37 kDa
W eel
GAPDH
Figure 5-13: Treatment with demethylating agents, 5'-aza-cytidine (5-Aza) and Trichostatin A (TSA) to taxol-resistant 
A2780. S'-aza-cytidine treatm ent brings back W ee l expression in this cell line, which is consistent w ith  the cDNA 
microarray analysis.
6. Western blotting of W eel silenced whole cell lysates
W ee l gene silencing was conducted on A2780 and SK-OV-3 to  emulate W ee l downregulation seen 
in their Taxol-resistant counterparts. Western blotting was performed on whole cell lysates 
harvested post silencing treatm ent to  assess silencing efficiency.
6.1A2780
Scramble W e e l-  
Untreated sIRNA silenced
A p p ro x .
B S kD a
A p p ro x .
3 7 k D a
W e e l
G A P D H
A 2 7 8 0
Figure 5-14: W eel silencing experiment in the A2780 cell line. Cells were successfully silenced based on the western 
blotting result above. W ee l protein band can still be seen in samples treated w ith "scramble" siRNA (acted as a negative 
control). Optimal condition for siRNA transfection in A2780 using 6-well plate was achieved at 5x10^ cells/well w ith SOnM 
total siRNA concentration and 6pL transfection reagent per well.
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6.2 SK-OV-3
Scramble W e e l-  
Untreated siRNA silenced
A p p ro x .
8 5 k D a
A p p ro x .
3 7 k D a
W e e l
GAPDH
SK-OV-3
Figure 5-15: W ee l silencing experiment in the SK-OV-3 cell line. Cells were successfully silenced based on the western 
blotting result above. W ee l protein band can still be seen in samples treated w ith scramble (negative control), showing 
that the silencing procedure w ithout the W ee l siRNA did not affect W e i expression significantly.
Based on the western blotting results o f both A2780 (Figure 5-14) and SK-OV-3 (Figure 5-15), W ee l 
silencing was successfully carried out in A2780 and SK-OV-3. Cells were treated w ith Taxol and 
subjected to flow  cytometry analysis to  compare changes o f DNA content and apoptotic cell 
response post-treatment between control and 14/eel-silenced cells.
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7. Weel silencing in A2780 followed by Taxol treatment
7.1 DNA content analysis before and after Taxol treatment using flow cytometry
Comparison between A2780 untreated, scramble and M/eel-siienced 
DNA content before and after Taxol treatment
■  A2780 Untreated control
0  A2780 Untreated lO nM  taxol 
E  A2780 scramble control 
H  A2780 scramble lO nM  taxol
■  A2780 W eel-sllenced control 
[3A2780 W eel-sllenced lO nM  taxol
sub-G l
Figure 5-16: Weel-sllenced A2780 cells were then subjected to Taxol treatment followed by flow cytometry analysis to 
compare the DNA content before and after treatment (n=3).
In drug-sensitive cells, Taxol induced G2 M cell cycle arrest that can be observed as increasing G2 M 
DNA content. Weel silencing in Taxol cells did not alter cell response towards lOnM Taxol treatm ent 
after 48 hours. However sub-Gi population in 14/eel-silenced, Taxol-treated cells were higher 
compared to control and scramble cells treated similarly.
163
7,2 Apoptotic analysis before and after Taxol treatment
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A2780
Untreated
Control
98%
A2780 
Scramble siRNA
A2780
' . - f
Weel siRNA
95%
lOnM
Taxol
82% 83%
Log Annexin V
Figure 5-17: Annexin V-FITC analysis of A2780 control, scramble and Weel-silenced before and after 48 hours of lOnM Taxol 
treatment (n=3). \Neel silencing in A2780 did not affect live cell population (third cytogram from top left, bottom left quadrant) 
similarly as scramble siRNA transfection (second cytogram from top left). There were no significant differences between 
control, scramble and i/l/eel-silenced cells in terms of their response towards Taxol treatment (p value for differences of Taxol- 
treated, IVeel-silenced A2780 versus scramble with similar Taxol treatment is >0.02). Figure is representative of three repeated 
experiments.
Based on the flow cytometric analysis on DNA content and apoptotic analysis, W ee l downregulation in 
A2780 do not give significant influence on Taxol response compared to control cells.
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8. Weel silencing in SK-OV-3 followed by Taxol treatment
8.1 DNA content analysis before and after Taxol treatment
Scramble sIRNA-treated SK-OV-3 cell cycle phases 
before and after Taxol treatment
ra 30
■  Scramble siRNA control
■  Scramble siRNA SOOnM Taxol
sub-Gl
Weel siRNA-treated SK-OV-3 cell cycle phases 
before and after Taxol treatment
TO 30
u
I W e e l siRNA control 
I W e e l siRNA SOOnM Taxoi
sub-Gl
Figure 5-18: M/eel-silenced cells were then subjected to DNA analysis using flow cytometry to compare between DNA 
content before and after treatment. In drug-sensitive cells, Taxol induced G2M cell cycle arrest that can be observed as 
increasing G2M DNA content. In SK-OV-3 scramble siRNA control cells, there was significant increase in G2M peak percentage 
after 48 hour SOOnM taxol treatment (**p  value <0.005). Similar effect was seen in l/l/eel-silenced, Taxol-treated cells. 
However, this effect was much less compared to control. Higher percentage o f sub-G^ peak was also observable in l/l/eel- 
silenced sample compared to control (n=3).
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8.2 Apoptotic analysis before and after Taxol treatment
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Figure 5-19: Annexin V-FITC analysis of SK-OV-3 control, scramble and M/eel-silenced before and after 48 hours of SOOnM 
Taxol treatment. Taxol treatment to control cells (first cytogram from bottom left) reduced live cell's population considerably 
as seen by the emergence of cell population in early (bottom right quadrant) and late-stage apoptosis (top right quadrant). 
Silencing of W eel alone resulted in increased cell apoptosis (third cytogram from top left) but more viable cells seen after Taxol 
treatment (third cytogram from bottom left) in comparison with Taxol-treated scramble cells (second cytogram from bottom 
left). Live cell population in scramble and W eel siRNA cytograms were artificially set to 100% for easier comparison and to 
correct for cell death induced by transfection and W eel silencing (n=3). Figure is representative of three repeated experiments.
Based on the DNA content and the Annexin V-FITC analysis, Weel silencing in SK-OV-3 cells influence 
Taxol response. Weel silencing in SK-OV-3 appears to reduce sensitivity towards Taxol treatment.
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showed by less G2 M cell cycle arrest and higher percentage of live cells in l/l/eel-silenced cells in 
comparison w ith controls (untreated and scramble siRNA).
9. MK1775 effect on viability of A2780 and SK-OV-3, parental and Taxol- 
resistant cell lines
MK1775 is a W ee l inhibitor and was used alternatively to  downregulates W eel expression in selected 
cancer cell lines. A2780 and MCF7 panels were chosen based on the W ee l expression level in 
A2780TaxR and MCF7. Both o f these cell lines exhibits high W ee l expression level in comparison with 
their counterparts. Cells were treated w ith MK1775 followed by a viability assay. Dose-response curves 
were drawn accordingly to derive MK1775 IC50 fo r all cell lines.
9.1 A2780 and A2780TaxR
Dose-Response Curve of MK1775 in A2780 and A2780TaxR 
120
A2780
0  A2780TaxR
A2780 0.35 (±0.0) -
A2780TaxR 3.09 (±0.1) 8.83
■1.0 - 0.5
Log dose ([oM)
Figure 5-20: Dose-response curve of MK1775 treatment to A2780 and A278Q Taxol-resistant cell lines. A2780TaxR has a lower 
W eel expression in comparison with parental cell line A2780 and responds less to MK1775 treatment (n=3).
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9.2 MCF7 and MCF7TaxR
Dose-response curve of MK1775 in MCF7 and MCF7TaxR
Ô 100:
♦  MCF7 
D  MCF7TaxR
K 60
40
MK1775 ICso (nM) Resistance factor (RF)
1.64 (±0.7)MCF7 7.65
1.13 (+0.1)MCF7TaxR
-2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0 1.5
Log dose {[iM)
Figure 5-21: Dose-response curve of MK1775 treatment to MCF7 and MCF7TaxR Taxol-resistant cell lines (n=3). MCF7TaxR 
was more sensitive towards MK1775 treatment compared to MCF7. Of note, MCF7TaxR expresses higher W eel protein level 
compared to its parental cell line MCF7 (see Chapter 4: Key players in cell cycle).
Based on the dose-response curves generated from the viability assay data fo r both A2780 panel (Figure 
5-20) and MCF7 panel (Figure 5-21), cells w ith higher W ee l expression level were more sensitive 
towards MK1775 treatment compared to their counterparts w ith lower W ee l expression. These results 
shows that W ee l plays a role in cell viability and W ee l downregulation gives greater effect on cells w ith 
high W eel expression compared to cells w ith lower W eel expression.
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Discussion
Deregulation of gene expression is a common event in cancer. By doing so, cancer cells acquire growth 
advantage compared to  the surrounding tissues. Weel had been reported as one o f genes 
downregulated in several cancers (refer to  Introduction). The fact that W ee l appears downregulated in 
drug-resistant cancers is also supported by our cDNA microarray analysis (Coley unpublished data 2008).
We examined W eel deregulation in cancer cell cycle particularly in ovarian cancer cell lines A2780 and 
SK-OV-3. These cell lines confer different genetic backgrounds w ith A2780 having a wild-type p53 while 
SK-OV-3 is p53 mutant. Based on the results o f the cytotoxicity assay, we established that drug-resistant 
cells have at least three-fold Taxol resistance in comparison w ith parental cell lines. This level o f 
resistance is clinically relevant according to  Hall et al. (2009). The minimum requirement o f resistance to 
be considered significant is at least two-fold (Hall et al. 2009).
Deregulation of W ee l in cancer has been documented in vitro and in vivo as discussed earlier. cDNA 
microarray analysis that have been done previously also points out W ee l as one of the gene frequently 
downregulated in drug-resistant cancer cell lines w ith possibility of promoter hypermethylation as a 
reason fo r low expression level. Assessment of W ee l mRNA and protein level in A2780 Taxol-resistant 
counterpart versus the parental line shows clear downregulation o f W eel. Even though Weel 
expression was low in SKOV3T6 this was not true for W ee l protein level, which was higher in Taxol- 
resistant SK-OV-3 compared to parental cell line. Discrepancies between mRNA and protein level might 
come from post-translational modification of W ee l protein in SK-OV-3 Taxol-resistant. Defects in W ee l 
regulation, for example in proteosomal degradation might also contribute to higher protein levels. 
Additionally, assessment of the W eel protein level was performed in unsynchronized cells as 
constitutive expression to give the background indication of overall gene expression level. The use of
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synchronized cells or time-point samples might give a clearer understanding o f the state of W ee l 
expression in SK-OV-3 parental and Taxol-resistant cells.
Since the A2780 cell line showed agreement of W ee l downregulation on both mRNA and protein levels, 
this cell line was been chosen as a model to  conduct a study o f W ee l in Taxol resistance. Screening of 
upstream cell cycle components showed that Taxol-resistant A2780TaxR acquired several changes that 
might give advantage to  the cells to tolerate Taxol treatment. In drug-sensitive A2780, there was 
detectable expression of Chkl and W eel. Theoretically, downregulation of W ee l w ill give growth 
advantages to cancer cells through unrestricted CDK activities. However, Chkl and W ee l are essential in 
avoiding replication stress in cells that have acquired other genetic changes that lead to increased 
replication stress via increased CDK activities. Replication stress w ill induce cell death if the burden of 
DNA damage is too high. Thus, W ee l and Chkl expression in A2780 is significant in protecting cells from 
death. It also explains A2780 sensitivity towards MK1775 treatment, since it depends on W ee l to  keep 
control o f CDK activities. This explanation was consistent w ith the hypothesis described by Sorensen and 
Syljuasen (2012). Significant upregulation o f p53 and Chk2 in Taxol-resistant A2780TaxR in comparison 
w ith A2780 might be the effect of Taxol treatment, since Taxol is able to  activate Chk2 which in turn 
phosphorylates p53 at S20 residue, thus promoting its stabilization (Damia et al. 2001). Since p53 is 
downstream of Chk2, it might be that the upregulation of p53 was a response o f elevated Chk2 level. 
High Chk2 expression might also serve as an additional benefit to  these cells. Chk2 expression was 
shown to protect cells from mitotic catastrophe, an event initiated by Taxol (Castedo et al. 2004). 
ATM/ATR are DNA damage sensory proteins. Initiation o f DNA damage will generate signals sensed by 
ATM/ATR which relays it to the downstream effector Chkl/Chk2. These proteins promote activation of 
cell cycle regulatory proteins including W ee l that in turn halt cell cycle progression to allow fo r DNA 
damage repair. Downregulation of ATR and W eel might be as a result o f increased Chk2 and p53 level.
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Both pathways are involved in regulation of CDKl activity and in this cell line, the ATR-Chkl-Weel level 
was preferentially downregulated in order to maintain the cell cycle progression even in the presence of 
Taxol. Since both pathways negatively regulate CDKl activity, complete suppression o f CDKl activity will 
leads to cell cycle arrest and cell death and downregulation of ATR-Chkl-Weel seems to be the only 
way to  keep the cells cycling whilst maintaining the CDKl level in the presence o f Taxol.
Previously in Chapter 3, it was shown that downregulation of pS?' '^’’  ^ in platinum-resistant PEOl was due 
to epigenetic modification, specifically hypermethylation at the gene's promoter site. This event leads to 
downregulation of gene expression and demethylating treatment has been able to  bring the expression 
back. In this study, two types o f chromatin-modifying agents (CMAs) had been utilised to  assess W ee l 
epigenetic changes. 5'-aza belongs to the class of nucleoside analogs of DNA methyltransferase (DNMT) 
inhibitors while TSA is a hydroxamate class o f histone deacetylase (HDAC) inhibitor (HDACi) targeting 
HD AC class I and II. 5'-Aza acts by promoting DNA déméthylation while TSA promotes histone 
acétylation (Seidel et al. 2012; Woo et al. 2007). Both have different mode of action but lead to 
transcriptionally active DNA. Expression of W eel has been re-established in Taxol-resistant A2780TaxR 
after 5'-Aza treatment, showing that hypermethylation of DNA does play a role in W ee l 
downregulation. TSA treatment singly and in combination w ith 5'-Aza (combination result not shown) 
does not significantly restore W ee l expression. It might be due to  the toxic effect o f TSA since TSA- 
treated cells were often died afterwards. TSA has been reported to induce growth inhibition and 
apoptotic cell death in U937 leukaemia cell line in a dose-dependent manner (Woo et at. 2007). 
Additionally, combination treatment using CMAs may result in adverse effects caused by genome-wide 
alterations apart from the lack o f specific targets (Bouwman and Jonkers 2012). Investigation of 
hypermethylation sites on the W ee l gene is currently ongoing. Taxol treatment leads to Gz cell cycle 
arrest via stabilization of microtubules that prevent mitosis (Orr et al. 2003). This effect was clearly seen
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in Taxol-sensitive A2780 by the appearance o f debris (indicating cell death and subGi peaks), reduced Gi 
peak and higher GzM peak as early as post-24 hours Taxol treatment (results not shown). The effect was 
more pronounced after 48 hours treatment and w ith higher Taxol dose. In contrast, the cytotoxic effects 
of Taxol were not seen in Taxol-resistant cells in the same experiments. The DNA profile remains stable 
towards the end o f the treatment, suggesting adaptation in coping w ith DNA damage stress induced by 
Taxol possibly through GzM cell cycle checkpoint modification.
Silencing of W ee l in A2780 was carried out to try  to  emulate the downregulation seen in Taxol-resistant 
A2780TaxR. Unlike SK-OV-3, the A2780 cell line was not yet optimized fo r siRNA transfection using 
DharmaFECT transfection reagent, according to  the manufacturer's protocols. Thus, method 
development to achieve optimal conditions was carried out using GAPDH siRNA in trial experiments. 
Optimization includes assessment of cell density, siRNA concentration and the amount of transfection 
reagent used. Weel silencing was done based on the result o f GAPDH silencing experiments (results not 
shown). Scramble siRNA used as a negative control produced approximately similar cell response as 
untreated control cells after Taxol treatment, proving that the transfection process itself did not initiate 
significant cytotoxic effects to  cells and is less likely to produce high background levels of apoptosis. In 
Weel-silenced cells, Taxol treatment produced significant cell death by appearance of sub-Gi peak, and 
increased GzM peak. A similar effect was seen in control and scramble cells. There were also no 
significant differences in apoptotic readout between non-drug treated control, scramble and W eel 
siRNA-treated cells. Overall, silencing of Weel in A2780 even though successful in downregulating 
W eel, does not give any significant differences in response towards Taxol treatment. This result fits w ith 
the hypothesis that Weel downregulation was a secondary effect o f Chk2 upregulation in Taxol 
resistance developed in wild-type p53 expressing cells. However, it must be noted that the status o f p53
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is not yet verified in A2780TaxR and it might play a role in influencing Taxol response in this Taxol- 
resistant cell line.
W ee l silencing was also carried out in SK-OV-3, an ovarian cancer cell line w ith a significantly different 
genetic background compared to  A2780. SK-OV-3 has been reported to  have mutated p53 and the 
western blotting data in Chapter 4 is in agreement with this. The optimal conditions used fo r Weel 
silencing in A2780 were successfully adopted fo r silencing Weel in SK-OV-3 cells. Taxol induced cell cycle 
arrest in scramble cells, as indicated by a decreased Gi peak percentage showed concomitant higher 
GzM content. Despite differences between control and Taxol-treated GzM being significant in both pairs 
(scramble and W ee l siRNA-treated), data for Weel-silenced SK-OV-3 showed a lower level o f statistical 
significance (<0.05) compared to scramble (<0.005). We believe that this was down to the difficulties in 
determining the exact Taxol dose added with technical issues and financial restriction in performing 
gene silencing experiment itself. Alteration on the Taxol dose could provide a clearer picture but should 
result in the same conclusions. Based on the result obtained, Weel silencing affects DNA content of SK- 
OV-3 cells following Taxol treatment. Instead of causing GzM cell cycle arrest as observed in scramble 
(negative control) cells, Taxol treatment to Weel-silenced SK-OV-3 did not elicit such response. 
Additionally, inhibition o f W ee l expression alone had been reported to reduce cell viability (Garimella et 
al. 2012; Kreahling et al. 2012). This response was also observed following W ee l silencing in SK-OV-3 
control cells. Overall, Weel silencing plays a role in the cellular response to Taxol in p53-deficient SK-OV- 
3 cells. By silencing Weel, the cytotoxic response towards Taxol was abrogated. Even though W ee l 
inhibition has been reported to promote cell death, surviving clones of cancer cells that have acquired 
Weel downregulation may be predisposed to Taxol resistance.
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Another way of downregulating W ee l expression is through the use o f an exogenous inhibitor. The 
W ee l inhibitor MK1775 was used to assess the role o f this checkpoint kinase in Taxol resistance. It is 
tempting to  look at the effect o f MK1775 and Taxol combination treatment and assess whether it will 
reflect the effects we saw with W ee l silencing on Taxol induced apoptosis. W ee l inhibition w ill promote 
early entry into mitosis and Taxol w ill induce cell death via m itotic catastrophe. Hypothetically, 
combinations of both agents will result in higher cell death than a single agent treatment. Simultaneous 
inhibition of W ee l and CDC25 has been shown to promote m itotic collapse, an event described by 
failure to enter and progress through to the m itotic phase (Potapova et al. 2011).
Aside from ovarian cancer, MK1775 treatment was also carried out on MCF7 and its Taxol-resistant 
counterpart MCF7TaxR breast cancer cell lines. In contrast to the ovarian cancer drug resistant models, 
W ee l has been found to be highly expressed in MCF7TaxR in comparison with MCF7 (explained further 
in Chapter 4). In line w ith this, MCF7TaxR was found to be sensitive to MK1775 treatment compared to 
MCF7, showing the importance of W ee l in mediating the drug resistant phenotype in MCF7TaxR. 
Overexpression o f W ee l had been shown to save cells from apoptosis and contributes to efficient DNA 
repair in GzM (de Career et al. 2007; M ir et al. 2010). Being p53-deficient, MCF7TaxR cells rely more on 
GzM checkpoint to be able to  proceed successfully into mitosis w ithout any kind of lethality. W ee l 
overexpression appears to  be a part o f MCF7TaxR adaptation to allow sufficient time fo r DNA damage 
repair. The MCF7 cell line has been reported as being resistant towards W eel inhibitor but W ee l 
inhibition sensitized cells to TRAIL-induced apoptosis (Garimella et al. 2012).
The results presented partially fit the hypotheses. W ee l does play a role in Taxol resistance. Collateral 
sensitivity to  W ee l inhibitor MK1775 was seen in Taxol-resistant cell lines w ith high W ee l expression. 
However, genetic background seems to have an influence towards W ee l and Taxol response.
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Conclusion
W eel deregulation has been reported in a large number o f cancers and was thought to  be caused by 
epigenetic modifications, in p53 wild-type cells, W ee l downregulation does not appear to  influence the 
cytotoxic response to Taxol. Conversely, in p53-deficient cells, W ee l downregulation promotes cell 
death possibly through forced early entry into mitosis w ith subsequent m itotic catastrophe. However in 
p53-deficient cells that have acquired Weel silencing, sensitivity towards Taxol treatment was 
decreased. Based on the data obtained, p53 status o f the cell lines appears to play a role in influencing 
W ee l in relative to cellular Taxol response. Since p53 appears to  be closely related to  W ee l action, 
more studies are needed in order to  establish this relationship that subsequently leads to a firm 
conclusion. Additionally, in a subset o f ovarian cancer w ith Taxol resistance, low W ee l was observed 
coupled w ith resistance towards MK1775 treatment. Therefore the possibility o f Taxol resistance via 
W eel downregulation cannot be dismissed and warrant further analysis, but clearly the picture is 
complex and many factors are closely related and can influence the final outcome o f the treatm ent 
approach.
To date, there are very few reports on W eel silencing effect and Taxol response. This study was 
conducted in hope to shed some light onto this matter.
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Introduction
1.14-3-3 family
14-3-3 family members are highly conserved 30KDa acidic proteins originally discovered as abundantly 
expressed mammalian brain proteins (Ichimura et al. 1988). The characteristic migration pattern on two- 
dimensional DEAE-cellulose chromatography and starch gel electrophoresis plus their elution fraction 
gave rise to the name '14-3-3'. This family consist o f 7 isoforms, named using the Greek letters of a, P, 5, 
8, Ï,, 6 /t  and a according to  their respective positions on HPLC elution, a is phosphoform o f p while Ô is 
phosphoform of 0 is widely expressed in tissues including brain and T cells while o is the only isoform 
that is expressed exclusively in epithelial cells. 14-3-3 family members take part in a variety of cell 
events including cell signalling, cell cycle regulation, intracellular trafficking/targeting, cytoskeletal 
structure and transcription via binding to  their phospho-Ser and phospho-Thr containing ligands (Aitken 
2006; Gardino and Yaffe 2011; Lodygin and Hermeking 2006). They form a dimer and share structural 
similarity amongst family members with some differences in a few regions. 14-3-3 residues were shown 
to be conserved among all isoforms and are important in phosphopeptide binding (Aitken 2006).
2. SFN (14-3-30, HMEl)
2.1 Function
14-3-30 is also known as human mammary epithelial marker 1 (HMEl) or stratifin (SFN). SFN was 
originally discovered via its expression in differentiating epithelial cells and was shown to be under 
direct regulation of p53 (Hermeking et al. 1997). SFN is the only 14-3-3 isoform that is expressed after 
DNA damage, showing its importance in DNA damage checkpoint. SFN was also shown to bind CDKl via 
its nuclear exporting sequence (NES) and promoted CDKl nuclear exclusion into cytoplasm. The NES is 
important in CDK sequestration since mutant NES of SFN was unable to  sequester CDK out from nucleus
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(Laronga et al. 2000). SFN also binds to Gi-specific CDK2 and CDK4. Overexpression o f SFN inhibits CDK2- 
and CDKl-associated kinase activity (Laronga et al. 2000; Lee and Yang 2001; Lodygin and Hermeking 
2006). Apart from that, SFN was reported to interact with Akt (Protein Kinase B-PKB) which in turn 
promotes Akt inhibition and leads to stabilization of CKI p27'^"’  ^via blocking of its Akt-mediated 
ubiquitination and degradation (Gardino and Yaffe 2011; Lodygin and Hermeking 2006). Based on its 
significant role in cell cycle checkpoints, SFN is being defined as a new class of CKI (Laronga et al. 2000; 
Lee and Yang 2001). SFN association w ith CDKl is also important in preventing m itotic catastrophe 
during Gz arrest. Downregulation of SFN after Gz arrest permits CDKl-CyclinB entrance into nucleus thus 
promoting early entry into mitosis which results in m itotic catastrophe (Lee and Yang 2001). Apart from 
the interaction w ith CDKs, SFN also directly interacts w ith W ee l, an important cell cycle regulator that 
has been discussed in Chapter 5. SFN together with Chkl, act as W ee l positive regulators by enhancing 
W eel kinase activity against CDKl (Gardino and Yaffe 2011; Lee and Yang 2001). SFN is vital in 
maintaining genomic stability, since downregulation of SFN leads to  genomic instability characterized by 
loss of telomeric repeat sequences, chromosome end-to-end fusions and non-reciprocal translocations 
(Lee and Yang 2001; Lodygin and Hermeking 2006). SFN also plays a role in the inhibition o f cell 
transformation and inhibits the anchorage-independent growth o f several breast cancer cell lines, 
reducing their transformation potency (Laronga et al. 2000; Lee and Yang 2001). Primary epithelial cells 
can grow indefinitely w ithout stimulation from exogenous oncogenes or oncoviruses in the absence of 
SFN, showing the importance o f SFN in cell transformation (Ren et al. 2010). Despite the fact that SFN 
regulates entry into mitosis, m itotic progression of cells that have already entered mitosis phase is 
promoted by SFN, particularly by enhancing cytokinesis completion via promoting the synthesis of 
m itotic-form CDKll. In normal epithelial cells, binding of SFN to  a transcription factor elF4B (eukaryotic 
initiation factor 4B) impairs its function. This event leads to  the expression o f the m itotic-form o f C D K ll 
(p58-PITSLRE) and completion o f cell division. In the absence of SFN, only the interphase form o f C D K ll
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is synthesized that leads to  incomplete cytokinesis which promotes the development of pre-cancerous 
tetraploid lesions (Gardino and Yaffe 2011; Hynes and Smirnova 2012; Wilker et al. 2007). In 
kératinocytes, SFN has been linked to expression of matrix metalloproteinase 1 (M M Pl) via binding to 
aminopeptidase N (APN), an integral membrane protein that acts as a cell surface receptor (Ghaffari et 
al. 2010). MMPs are proteolytic enzymes w ith functions to  degrade extracellular matrix (ECM) and 
involved in a variety of cellular processes including tum our metastasis. SFN has been shown to promote 
expression of fibroblast associated M M P l, MMP3, MMP8 and MMP24 via the p38 mitogen-activated 
protein kinase (MAPK) signalling pathway (Ghaffari et al. 2010). Another kératinocyte associated plasma 
membrane protein that has shown interaction w ith SFN is BP180 (bullous pemphigoid antigen-2) (Li et 
al. 2007).
2.2 Regulation of SFN
SFN is regulated mainly by the action o f p53 and plays a role in G2M phase by regulating cell cycle 
progression. This was shown by the occurrence of GgM cell cycle arrest and increasing cell size after 
exogenous overexpression o f SFN in cells. A similar event was also seen after DNA damage induced via y 
irradiation or DNA-damaging agent treatment that caused activation o f p53. Since mutant p53 does not 
induce SFN upregulation after DNA damage, it was concluded that SFN was regulated by p53 
(Hermeking et al. 1997; Lodygin and Hermeking 2006). However in p53-negative cells, Tap53 induces 
SFN expression after DNA damage. This serves as evidence of SFN transactivation by other proteins. SFN 
expression was also shown to be induced by TAp73 in breast cancer cell lines while BRCAl can also 
indirectly affect SFN expression via cooperation w ith p53 (Lodygin and Hermeking 2006). TNF-related 
apoptosis-inducing ligand (TRAiL) also causes SFN upregulation in prostate cancer cells. Efp, a target 
gene product of ERa (Oestrogen receptor a) was shown to regulate SFN via ubiquitin-mediated
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degradation. Transfection o f SFN and Efp together in C0S7 cells showed cytoplasmic localization of both 
proteins and their ability to interact and form a complex. Interaction of Efp with SFN was shown to occur 
via the RING finger domain of Efp that acts as an E3 ubiquitin ligase and promotes ubiquitination with 
subsequent degradation of SFN which can then in turn dissociate it from CDK-Cyclin complex, therefore 
promoting cell cycle progression (Urano et al. 2002).
elF4B
(M ito tic  
fo rm )
TAp73 TRAIL TAp53
BP180
CDKl
CDK2
CDK4
Figure 6-1: Function and regulation of SFN. SFN expression is under the control of p53. Apart from p53, other proteins such as 
TAp53, Tap73 and TRAIL can also induce SFN expression. SFN forms a dimer and interacts with various other proteins that result 
in expression of MMPs, regulation of cell cycle control and progression of mitosis. SFN is negatively regulated by Efp that 
promotes its degradation via ubiquitination followed by proteosomal degradation.
2.3 SFN Expression in normal and cancerous tissues
In contrast with other 14-3-3 isoforms, SFN was found to be deregulated in various human cancers 
(reviewed by Hynes and Smirnova 2012). In breast carcinoma, SFN was shown to be downregulated and 
cancer progression from atypical hyperplastic lesions to ductal carcinoma in situ was marked by loss of
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expression. Other than breast cancer, downregulation of SFN was found to be related with loss of 
pl6iNK4a expression in oral and vulval cancers specifically in HPV-negative lesions (Syrjanen et al. 2010). 
Downregulation of SFN was also seen in human hepatocellular carcinoma (Iwata et al. 2000). Other 
cancers that have downregulation of SFN include SV40-transformed human kératinocytes, head and 
neck squamous cell carcinoma lines, primary bladder tumours and colonic polyp specimens (Iwata et al. 
2000; Laronga et al. 2000). A comparison study by Ren et al. (2010) between normal oesophageal 
epithelium and oesophageal squamous cell carcinoma (ESCC) showed that SFN mRNA and protein level 
were markedly downregulated. This observation was supported by immunohistochemistry staining of 
the samples. SFN downregulation was statistically correlated w ith tumour infiltration depth and 
metastasis. A shorter 5-year survival rate of ESCC patients was observed fo r those w ith lower SFN 
expression. Poor prognosis fo r patients with intrahepatic cholangiocarcinoma and prostate cancer was 
also associated w ith lower SFN expression (Ren et al. 2010). In the ErbB2KI transgenic model, loss of 
either one or both copies of SFN allele led to accelerated mammary growth (Hynes and Smirnova 2012). 
SFN downregulation was associated w ith advanced disease in many cancer of epithelial origin including 
stomach and lung. In ovarian cancer, loss of SFN mRNA significantly correlated with progression and 
invasiveness o f tumour (Akahira et al. 2004). Downregulation o f SFN was concomitant w ith the 
progression of glioma and SFN has been shown to be a significant and independent prognostic indicator 
fo r glioma patients (Deng et al. 2011).
In contrast, there are several reports o f SFN upregulation in cancers. In comparison w ith normal cervical 
epithelium, SFN was upregulated in cervical carcinomas (CCs) and cervical intraepithélial neoplasia (CIN) 
lesions, higher grade of CC and CIN shows higher SFN expression in parallel. The mechanism o f SFN 
upregulation in these cases was still unknown (Syrjanen et al. 2010). SFN upregulation is thought to  play
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a role in development and/or progression of pancreatic cancer, papillary or undifferentiated thyroid 
cancer and urinary bladder squamous cell cancer (Ren et al. 2010). A study in lung adenocarcinoma 
revealed high SFN levels associated w ith progression from in situ adenocarcinoma to invasive 
adenocarcinoma by enhancement of tumour cell proliferation. Stimulation of SFN expression in this case 
was found out to  be potentially related to P13K/Akt signalling pathway in a p53-independent manner 
(Shiba-lshii et al. 2011). In certain cancers, there is a difference o f SFN expression and deregulation 
among cancer sub-types. In ovarian cancer, the SFN expression pattern differs based on histological 
type, whereas in small cell lung cancer (SCLC) SFN inactivation also followed in a histological type- 
specific manner (Akahira et al. 2004; Osada et al. 2002).
2.4 SFN gene hypermethylation
SFN downregulation was detected in several types o f cancer as mentioned above. Flowever, silencing of 
SFN was not due to genetic alteration in most cases but due to epigenetic modification specifically via 
CpG méthylation. This was shown by the unmasking of the SFN expression after 5'-Aza treatment. CpG 
méthylation of SFN was detected in cancer of gastric, liver, lung, skin, squamous cells, and endometrium 
w ith higher prevalence in breast, prostate and ovarian cancers. Gradual increase of SFN méthylation was 
observed w ith progression of breast cancer and basal cell carcinoma of the skin. Frequent association 
seen between SFN méthylation status and breast cancer prognosis served as a basis of SFN méthylation 
status being proposed as a marker in diagnosing metaplastic breast carcinomas (reviewed by Lodygin 
and Hermeking 2006). In a study of gene promoter méthylation in Indian breast cancer patients, the 
méthylation status o f ERa and PR (progesterone receptor) was significantly correlated w ith SFN 
méthylation. Overall survival o f patients w ith SFN expression was higher compared to patients w ith 
diminished SFN (Mirza et al. 2010). Even though SFN is a good candidate as a biomarker for breast
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cancer metastasis, a careful approach needs to be taken since a small amount o f SFN méthylation was 
also detected in healthy subjects. These might have been associated w ith occult benign breast disease, 
age, leukocytes and/or benign breast disease (Zurita et al. 2010). Surprisingly, overexpression of SFN 
was found in pancreatic cancer despite SFN promoter hypermethylation and the mechanism is still 
unknown. SFN hypermethylation was also found in normal stromal and lymphoid cells during the 
development stage, showing that downregulation o f SFN was achieved through epigenetic modification 
and was not restricted to  cancer cells only (Lodygin and Hermeking 2006). Additionally, SFN was shown 
to be hypermethylated in both oral squamous cell carcinoma (OSCC) and cancer-free subjects. 
Hypermethylation in these cases was not associated w ith smoking, drinking habits or specific tumour 
characteristic (de Freitas Cordeiro-Silva et al. 2011).
2.5 SFN and drug resistance
In breast cancer cell lines, SFN expression is either positively or negatively associated w ith different drug 
resistant mechanisms (Deng et al. 2011; Hynes and Smirnova 2012). Functional proteomic analysis using 
two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry on MCF7 parental and multidrug-resistant MCF7/AdVp3000 revealed 
that SFN was one o f the protein upregulated in MDR. SFN knock-down in MCF7/AdVp3000 decreased its 
resistance towards mitoxantrone and Adriamycin treatment while SFN overexpression in MCF7 showed 
increased resistance towards both agents. Comparable outcome was also observed in other cell line 
HEK293 (Liu et al. 2006). A similar approach was adopted in the investigation o f multidrug resistant 
MCF7 induced by 5-fluorouracil treatment (MCF7/5-FU). In contrast, SFN was found to  be 
downregulated in MCF7/5-FU along with other genes and overexpression of SFN via transfection 
induced sensitivity towards 5-FU and cisplatin treatment (Zheng et al. 2010).
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Aim
SFN was shown to be downregulated in drug-resistant cancer cells along with other genes in a previous 
cDNA microarray analysis (Coley unpublished data). This study aims to  confirm the changes seen in vitro 
and to attempt to  ascribe a functional role for SFN expression levels in mediating drug responsiveness. 
This study aims to recreate SFN downregulation seen in drug-resistant cancer cells in parental, drug 
sensitive cancers and to provide an insight into SFN regulation in drug-resistant cancers specifically Taxol 
resistance.
Hypothesis
SFN plays a role in anticancer drug resistance and this is likely to be due to epigenetic silencing
Methods
Methods used in this study were, western blotting, mRNA extraction, qPCR analysis, viability assay using 
MTT, DNA harvest, PI staining, Annexin V-FITC, flow  cytometric analysis, and siRNA transfection to 
silence SFN artificially in cancer cell lines. Cell lines used were A2780 and SK-OV-3. Graphs were 
prepared using Microsoft Excel software. Student's Paired T-Test was performed where applicable and 
result was expressed as p value. All methods have been explained in Chapter 2.
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Results
SFN mRNA levels, which represents SFN gene expression in A2780 and SK-OV-3 panels were measured 
using qPCR analysis and results were presented as bar charts (Figure 6-2). Significant downregulation of 
SFN was seen in A2780TaxR compared to its parental. However, SFN expression in SK0V3TaxR was not 
statistically significant compared to SK-OV-3.
1. SFN mRNA level inA2780 and SK-OV-3 panels
qPCR analysis of SFN expression in A2780 and SK0V3 
parental and Taxol-resistant counterpart
to 0.8
U ndetected
I Parental cell line 
I Taxol-resistant cell line
A2780 SK-OV-3
Cell lines
Figure 6-2: Relative SFN mRNA level fold change of Taxol-resistant A2780 and SK-OV-3 in comparison with their parental cell 
line respectively. SFN mRNA level in A2780TaxR Taxol-resistant was undetected compared to A2780 (**p<0.005). Conversely, 
SFN mRNA level in Taxol-resistant SKOVBTaxR was shown to be higher than parental SK-OV-3. However, the difference was not 
statistically significant (p>0.2).
Following qPCR results, western blotting using antibody against SFN was performed in order to assess its 
protein level in the respective cell lines.
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2. SFN protein level in A2780 and SK-OV-3 panels
a) A2780 A2780TaxR b)
SKOV-3 SK0V-3TaxR
Approx. Approx.
Approx.
SFN
GAPDH
Figure 6-3: Western blotting of SFN in A2780 and SK-OV-3 parental and Taxol-resistant cancer cell lines (n=3). a)
Downregulation of SFN was observed in A2780TaxR Taxol-resistant compares to its parental cell line p53 wild-type A2780, 
shown by the disappearance of SFN band in A2780TaxR lane, b) Modest SFN downregulation was seen in Taxol-resistant SK-OV- 
3 compared to its parental, p53-deficient SKOV-3.
Western blotting result of SFN in A2780 panel reflects their qPCR analysis. However, this pattern of SFN 
downregulation was not reflected in SK-OV-3 panel. Higher SFN mRNA level with modest SFN protein 
downregulation was seen in SK0V3TaxR compared to the parental cell line. SFN downregulation was 
postulated as an effect of epigenetic modification. Thus, demethylating treatment was performed on 
A2780TaxR to assess this hypothesis.
3. Demethylating treatment in A2780TaxR Taxol-resistant
A2780
TaxR
A2780
TaxR
A 2780
TaxR
Approx. 
30 kDa
Approx. 
37 kDa
SFN
GAPDH
Figure 6-4: Treatment with demethylating agents, 5' Aza and TSA singly and in combination to Taxol-resistant A2780TaxR.
Treatment with demethylating agents restores SFN expression in A2780TaxR, which is in line with the previous cDNA 
microarray results.
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Following previous results of qPCR analysis and western blotting, silencing of SFN in A2780 and SK-OV-3 
was performed in order to recapitulate its downregulation seen in Taxol-resistant variants and to assess 
its effect on Taxol response of the cells.
4. Western blotting of 5FJV silencing samples
Western blotting was performed on whole cell lysates harvested by the end of the silencing treatment 
to assess silencing efficiency (Figure 6-5). The disappearance of SFN protein band in both SFA/-silenced 
samples showed gene-silencing procedure was carried out successfully.
a)
Scramble 
Untreated siRNA
Approx.
30kDa
Approx.
37kDa
A2780
SFN-
silenced
SFN
GAPDH
b)
Scramble SFN-
Untreated siRNA silenced
Approx.
SOkDa
Approx.
37kDa
SFN
GAPDH
SK-OV-3
Figure 6-5: Western blotting of SFN gene silencing samples in A2780 and SK-OV-3 using siRNA transfection, a) SFN silencing in 
A2780 was carried out successfully based on the disappearance of SFN band in SfA/-silenced sample compared to scramble 
siRNA (negative) and untreated controls, b) SFN silencing in SK-OV-3 was carried out successfully as judged from the 
appearance of the band in SFA/-silenced sample compared to scramble siRNA and untreated controls.
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5. SFN silencing in A2780 followed by Taxol treatment
5.1 DNA content analysis with and without Taxol treatment
Comparison between A2780 untreated, scramble and Sf/V-silenced 
DNA content before and after Taxol treatment
70
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t
■  A2780 Untreated control
□  A 2780 U ntreated 8 n M  taxol 
E3 A 2780 scramble control 
S  A2780 scramble 8nM  Taxol
■  A2780 SFN-sllenced control
a  A2780 SFN-silenced 8nM  taxol
sub-Gl G2/M
Figure 6 -6 : SFA/-silenced cells were subjected to 8 nM Taxol treatment for 48 hours and analyzed using flow cytometry. Taxol 
treatment induces G2M cell cycle arrest, observable by a higher G2M DNA peak. The Taxol effect was seen in all Taxol-treated 
samples. There was no significant difference between untreated, scramble and SFN-silenced cells in Taxol response. (n=3)
SFN silencing in A2780 was then followed by 8 nM Taxol treatment to assess changes of DNA content 
before and after treatment in comparison with controls (untreated and scramble cells). Samples were 
processed for DNA content analysis and Annexin V-FITC analysis using flow cytometry.Based on the DNA 
analysis, SFN silencing does not give significant influence to A2780 response towards Taxol treatment 
(Figure 6 -6 ).
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5.2 Apoptotic analysis with and without Taxol treatment
A 2 7 8 0
Control
U n tre a te d
A 2 7 8 0  
Scramble siRNA
U n tre a te d
= i" ' 2
« - Î
%
10-= . .T i ..
3 • ‘
03S
»
##5%
Ê
: .•
M -=
:
w
o .n
-
95%
l| I I I l l i l l[  1 I I l l l l l[
A 2 7 8 0  
SFN SiRNA
U n tre a te d
A 2 7 8 0
Control
2 5 n M  Taxo l
i L .
2
-
■ ■
,0*
.............. "i_
,0-
y
r ÿ : , . ;
A 2 7 8 0
Scramble siRNA
2 5 n M  Taxo l
I I I m il l  ' I I I  M iiiiI '  I
10* to’ 10*
A 2 7 8 0  
SFN SiRNA
2 5 n M  Taxo l
Log Annexin
Figure 6-7: Annexin V-FITC analysis of A2780 control, scramble and SfA/-silenced cells before and after 48 hours of 25nM 
Taxol treatment. SFN silencing did not affect cell viability significantly. <90% of cell population was still viable after transfection 
(first cytogram from left on second row, bottom left quadrant). Taxol treatment reduced live cell population to approximately 
70% in control cells (first cytogram on top right). Similar effect was seen in scramble and SFW-silenced cells treated with Taxol. P 
value for differences of Taxol-treated, SFW-silenced A2780 versus scramble with similar Taxol treatment is >0.01.This result is a 
representative of repeated experiments (n=3).
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6. SFN silencing in SK-OV-3 followed by Taxol treatment
6.1 Apoptotic analysis with and without Taxol treatment
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Figure 6-8: Annexin V-FITC analysis of SK-OV-3 control, scramble and SFN-silenced cells before and after 48 hours of 25nM 
Taxol treatment. SFN silencing did not affect cell viability significantly. <90% of cell population was still viable after transfection 
(first cytogram from left on second row, bottom left quadrant). Taxol treatment reduced live cell population to approximately 
90% in control cells (first cytogram on top right). Similar effect was seen in scramble and SFN-silenced cells treated with Taxol. P 
value for differences of Taxol-treated, SFN-silenced SK-OV-3 versus scramble with similar Taxol treatment is >0.1). This result is 
a representative of repeated experiments (n=3).
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Annexin V-FITC analysis done on both SFA/-silenced cells o f A2780 and SK-OV-3 showed that SFN status 
does not give any significant influence on apoptotic response after Taxol treatment.
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Discussion
SFN plays an important role in the regulation of G2 M checkpoint following DNA damage and in 
cytokinesis completion during mitosis. It had been shown that SFN downregulation in various cancers 
could promote progression. However, in certain types of cancer SFN was shown to be upregulated (refer 
Introduction). Based on the cDNA microarray analysis results (Coley unpublished data), SFN was among 
the genes downregulated in drug-resistant cancer cells. SFN downregulation was postulated as an effect 
o f genetic modification, particularly gene hypermethylation.
Using qPCR and western blotting, downregulation of SFN in A2780TaxR Taxol-resistant in comparison 
w ith parental cells A2780 was confirmed. However in SK-OV-3 Taxol-resistant cell line, SFN mRNA level 
was not significantly different compared to parental cell line, even though there was downregulation of 
protein level albeit not as low as in A2780TaxR. Discrepancies between mRNA and protein level o f SFN is 
not uncommon, since it had been shown that pancreatic cancer is characterized by SFN overexpression 
despite significant promoter hypermethylation that caused gene silencing (Lodygin and Hermeking 
2006). Apart from promoter méthylation, DNA hypoacetylation is another epigenetic modification that 
can influence the behaviour of gene expression. In this study, treatment with CMAs particularly TSA 
unmasked SFN expression in A2780TaxR cell line. However, 5'-Aza treatment on A2780TaxR, either 
singly or in combination with TSA, did not restore SFN expression to  match parental cell line A2780. The 
result is in line with reports of restored SFN expression by means of CMA treatment (S'-Aza) on SFN- 
silenced breast cancer cells as reviewed by Lodygin and Hermeking (2006). Restored SFN expression in 
A2780TaxR also showed that epigenetic silencing plays a role in SFN downregulation in this cell line. 
Epigenetic silencing has been shown to be the main event that affects SFN expression in cancers. 
Significant downregulation of SFN was linked to hypermethylation and poor survival outcome in a
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number of studies (see Introduction to this chapter). Thus, a number o f studies were conducted to  
assess SFN méthylation as a possible marker fo r tumour progression and cancer prognosis. Based on this 
result, we explored the possibility o f SFN downregulation as a contributor towards Taxol resistance in 
ovarian cancer.
A role played by SFN in drug-resistance has been investigated before (Hynes and Smirnova 2012). In the 
present study, SFN silencing was introduced to  cell lines via siRNA transfection in order to  investigate its 
downregulation in Taxol resistance. Based on our results o f Annexin V-FITC and DNA analysis, SFN 
silencing did not alter Taxol response significantly in ovarian cancer cell lines regardless o f p53 status. 
The G2M blockade seen after Taxol treatment in control non-silenced cells was also seen in SFA/-siIenced 
cells w ithout any significant differences. In a study conducted by Chan et al (1999), m itotic catastrophe 
was seen in SFN-deficient cells w ith wild-type p53 after treatm ent with DNA damaging agent 
(Adriamycin) or ionizing radiation after failure in maintaining G2M blockage. Similar treatm ent o f p53 
wild-type, SFN-expressed cells resulted in increased cell size, nuclear enlargement and DNA content akin 
to G2 M cell cycle arrest (Chan et al. 1999). Even though SFN was seen as a part o f Taxol-resistant 
phenotype in our cell lines, it is possible that the cells acquired SFN downregulation together w ith other 
alterations that brings out the phenotype. Further, we were only looking at the consequences of SFN 
silencing following 48h o f drug challenge and there is the possibility that a longer time frame might have 
revealed a different result. As shown in the previous chapter, A2780TaxR Taxol resistant cell line 
acquired deregulation of several other proteins of G2 M regulators including ATR and W ee l apart from 
SFN. Even though SFN downregulation alone had been shown to be responsible fo r drug-resistance in 
some studies, we did not observe such an effect. Hence, fo r the cell line models used in our study there 
is a likelihood that it is the combination of several genes together that may bring about the drug
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resistant phenotype and for some genes their influence on this process may be obvious when looked at 
in isolation.
Finally, the results presented partially fits the hypothesis. SFN downregulation in A2780TaxR appears 
because of epigenetic silencing. However, SFN appears to  play no role in influencing Taxol response in 
the cell lines studied.
Conclusion
In this study, we have shown that SFN was downregulated in Taxol-resistant ovarian cancer cell lines. 
However, silencing of SFN does appear to  play a role in inducing Taxol resistance in tw o cancer cell lines 
regardless o f the p53 status. Expression of SFN was shown to be varied among cell lines and hence its 
role in mediating drug resistance may be context-dependent.
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Introduction
1. INK4 family of CKIs
INK4 (Inhibitors o f CDK4) is a family of CKIs which consists o f four members. They are 
p^giNK4c pj^ giNK4d^ |NK4 family members specifically inhibit CDK4 and CDK6  and thus play an 
important role in the regulation o f Gi progression into S phase of the cell cycle. These INK4 family are 
able to  bind to  both free and CyclinD-associated CDK4 and CDK6 , consequently forming an inactive 
complex that leads to Gi cell cycle arrest (Lee and Yang 2001; Maddika et al. 2007). Members o f INK4 
are highly conserved among species and shares approximately 40% homology among them (Roussel 
1999).
1.1 pl6'NK4a gen e
Serrano et al. (1993) first isolated human p l 6  complimentary DNA and showed inhibitory effect o f 
p l 6 iNK4a CDK4-CyclinD. The pis" '^ '^^  ^protein is encoded by p l 6  gene and resides in locus 9p21, or the 
INK4a locus (Serrano et al. 1996). Alternative reading frame of INK4o encodes pl4*'^'', a structurally and 
functionally different protein that plays a role in p53 positive regulation via p53 protein stabilization 
(Maddika et al. 2007; Nam and Kim 2008). pio'^^"*® shares similar ankyrin-like repeats w ith other INK4 
members. The ankyrin-like repeats are thought to play a role in protein-protein interaction (Roussel 
1999).
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1.2 p l6 ’NK4a role in cell cycle regulation
p l 6 iNK4a jg pgj.^ o f the pl6-CDK4/6-CyIinD-Rbp pathway controlling cell cycle progression in Gi phase. Rbp 
negatively regulates Gj progression by sequestering the transcription factor E2F while CDK4/6-CyclinD  ^
complexes promote G% progression by inducing phosphorylation of Rbp and the subsequent release of 
E2F (Serrano et al. 1996). CDK4/6 kinase activity is inhibited by which in turn prevents
phosphorylation o f Rbp and consequently halts G% cell cycle progression (Nam and Kim 2008; Roussel 
1999). ETS transcription factors are responsible for p l 6 ‘ '^^ '^  ^expression and its accumulation in the cell is 
induced by the senescence process (Lee and Yang 2001; Massague 2004). Following p l 6 "^ '^ ^^  binding to 
CDK4/6, CyclinD is released. Destabilization o f cyclinD couples w ith redistribution of Cip/Kip CKIs to 
CDK2 promotes Gi arrest (Shapiro 2006; Sherr and Roberts 1999). Apart from senescence, p l 6 "^ '^ '^  ^also 
plays a role in cellular response towards UV damage. Upregulation of p53 and p21*'''^  ^following UV 
exposure is mediated by p l 6 '^ "^^  ^via redistribution o f the RNA binding protein HuR (Hu antigen R) (Al- 
Mohanna et al. 2007). HuR is implicated in the regulation of mRNA stability by antagonizing the mRNA 
degradation pathway (reviewed by Brennan and Steitz 2001). Upon UV exposure, p l 6 "^ '^ '^ ® promotes HuR 
cytoplasmic relocalization from the nucleus which in turn binds to and stabilizes p 2 l ‘^ ''’^and p53 mRNA 
(Al-Mohanna et al. 2007). Hyperactive Ras, Myc and E2F signalling also induces pio'^^'^^ expression which 
subsequently promotes either cell quiescence or senescence (Massague 2004).
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Figure 7-1: roles in cell cycle regulation, is transcribed by ETS and acts as an inhibitor of CDK4/6. also
influences p53 and p2l'"''’  ^stabilization via HuR. As a result of pis'^'^'*^ action, cell cycle progression is halted.
In addition to its role in cell cycle regulation and senescence, was shown to play a role in several
other biological functions such as cell adhesion (anolkis), cell spreading, telomerase activity and in 
angiogenesis via VEGF (vascular endothelial growth factor) regulation as reviewed by Lee and Yang 
(2001). According to Sharpless and Chin (2003), pie"^ "^^ ® is vital in controlling aberrant cellular 
proliferation but plays little or no role in normal development.
1.3 pl6"NK4a in tumours
As a CKI, pie"^ '^ '*® plays a major role in tumour suppression. Studies of pis"^'^'’® relationship with cancers 
have shown that p l 6 '^ '^ '^  ^accumulates following numerous cancer-relevant stimuli, such as passage in 
culture, growth at high density, DNA damage, oncogene activation and advancing age as reviewed by
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Sharpless and Chin (2003). The INK4a locus coding fo r and is frequently mutated in
human cancer cell lines and often altered in human malignancies (Lee and Yang 2001; Serrano et al. 
1996). The observation o f frequent inactivation o f p l 6 '^ '^ '’  ^ in human cancers suggested its importance in 
cancer development. Indeed, Serrano et al. (1996) have shown that INK4a deficiency promotes 
tumorigenesis in mammals via generation of INK4a^' mice. Several mechanisms of p l 6 '^ '^^ ® inactivation 
have been characterized and can be divided into three main mechanisms, which vary according to  the 
cancer type. In cancers such as pancreatic adenocarcinomas, oesophageal carcinomas, biliary tract 
cancers and in families with hereditary predisposition to  melanoma and pancreatic cancer, p l 6 "^ '^ ''^  
inactivation is caused by point mutations and small deletions in the INK4a locus. These mutations can 
affect either p l 6 "^ '^’® exclusively or together w ith pis"^'^''^. The second mechanism of p l 6 "^ '^ '^ ® inactivation 
is large homozygous deletions which eliminate the locus altogether and is commonly found in non-small 
cell lung carcinomas, malignant gliomas, renal cell carcinomas, head and neck tumours, prostate 
tumours, bladder carcinomas and acute lymphoblastic leukaemias. Finally, méthylation of INK4a locus 
leads to gene silencing accounts for p l 6 ‘ '^^ ''^  loss in breast and colon cancers (Lee and Yang 2001; Nam 
and Kim 2008; Serrano et al. 1996). p l 6 "^ '^ '*® inactivation is functionally equivalent to  loss of Rbp function 
(Maddika et al. 2007) which allows for unsupervised cell cycle progression.
Apart from gene inactivation, a growth factor sensor p34^^''^ encoded bySEM (Selected w ith INK4A) 
gene was found to antagonize plO"^ '^ '*  ^ inhibitory action on CDK4-CyclinD complex thus rendering the 
complex resistant to inhibition (Figure 7-1) (Lee and Yang 2001; Sugimoto et al. 1999). Additionally, 
p34^^''^ overexpression promotes fibroblast cell proliferation even under low serum conditions 
(Sugimoto et al. 1999) and the gene is mapped to 19q l3.1-q l3.2 which shows amplification in some 
cancers (Lee and Yang 2001). This suggests the importance o f p34^^''^ in tumorigenesis.
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1.4 pl6i^K4a and melanoma
Melanoma is clinically characterized by aggressive clinical behaviour, tendency of late metastasis and 
high resistance towards therapeutic treatment. Deletion o f INK4a is one o f several genetic events in 
melanoma. INK4a deletion is found in approximately 50% o f primary tumours and in nearly all 
melanoma cell lines (Sharpless and Chin 2003; Walker et al. 1998). According to a review by Sharpless 
and Chin (2003), p l 6 '^ '^ '’  ^ inactivation via deletion and promoter méthylation was found in 30-70% of 
primary melanoma tumours, while germline point mutations o f pie"^'^'’® were associated w ith tumour 
susceptibility in familial melanoma subjects. Thus, pie" '^ '^*^ status serves as an interesting parameter in 
melanoma diagnosis and a rational target for treatment.
Loss or inactivation of CKIs, fo r example pis" '^^^® in melanoma and p57'^'’’  ^in ovarian cancers initiate 
research towards developing synthetic CKIs that would mimic action o f endogenous CKIs and are able to 
influence cancer cell cycle progression. Drug development programs carried out to  search fo r such 
compounds resulted in the development of potent small molecule CDK inhibitors originated from a 
variety of chemical classes. Examples are seliciclib, a purine analog and PD0332991, a pyridopyrimidines 
(Fry et al. 2004). Seliciclib has been discussed earlier in Chapter 3 and PD0332991 is discussed in the 
following paragraph.
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2. PD0332991
HN
Figure 7-2: PD 0332991 chemical structure (Fry e t al. 2004).
PD0332991 is a small, non-ATP competitive CDK inhibitor against CDK4 and CDK6  (Fry et al. 2004; 
Katsumi et al. 2011). PD0332991 treatment inhibits phosphorylation of Rbp as the downstream target of 
CDK4/6-CyclinD in a rapid and reversible manner (Collins and Garrett 2005). In Rbp-positive human 
cancers (breast, colon, lung carcinoma and leukaemias) PD0332991 works by interfering DNA formation 
via inhibition of thymidine incorporation. As a result, PD0332991 produces an exclusive cell cycle Gi 
arrest. PD0332991 has been tested to a panel o f 36 protein kinases and have been found to have 
negative activity. PD0332991 was also shown to have no activity against Rb-negative cells (Fry et al. 
2004). Combination treatment with the proteasome inhibitor bortezomib to a myeloma cell line model 
5T33 resulted in enhancement of cell killing (Menu et al. 2008). Synergistic action was observed when 
PD0332991 was coupled w ith tamoxifen and trastuzumab in ER+ and HER2-amplified human breast 
cancer cell lines respectively (Finn et al. 2009). PD0332991 has been tested in a Phase I study on Rbp- 
positive solid tumours and non-Hodgkin lymphoma and is currently in Phase II clinical trial fo r metastatic 
or advanced liposarcoma (Flaherty et al. 2012; Schwartz et al. 2011). The low level o f pis'^'^''^ has been 
shown to be inversely correlated with PD0332991 sensitivity in malignant rhabdoid tumour (MRT), a 
rare and aggressive form of childhood malignancy. MRT arises from the silencing or mutation o f IN Il 
gene, responsible for transcriptional inhibition of CyclinD, the partner of CDK4 and CDK6 . Since IN Il also
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promotes p l 6 '^ '^ '‘  ^expression, MRT also show a low level o f as a result o f mutation or deletion of
the gene (Katsumi et al. 2011).
PD0332991 therefore is a very promising drug clinically provided the correct patient cohort is selected. 
Nevertheless there is a window of opportunity for cancers to develop resistance to this drug since 
cancers are multifactorial and are able to adapt in order to survive. This forms the rationale fo r this last 
part o f the thesis work by developing a novel PD0332991-resistant cell line, which is important to 
provide an insight into alterations that might hinder the drug's action on cancers.
3. Cell model consideration
Before developing a new drug-resistant cell line, several factors must be considered. Determination of 
tumour type and selecting agent is paramount since there should be a relevant explanation o f choosing 
the said tumour type and agent. Specific molecular characteristics of the tumour might relate to  the 
mode of action o f the selecting agent. Development of the drug-resistant cell line should also aim at 
providing answers to  questions like mechanisms behind the acquired resistance of a developmental 
drug to a specific type of tumour (Coley 2004).
3 .1A 37 5
A375 originated from skin and a malignant melanoma cell line and was chosen as a model to  develop 
PD0332991-resistance based on its specific genetic make-up. The A375 line is plS'^'^'^'^-deleted thus 
lacking pie'^'^'*^ expression, making it a desirable target fo r PD0332991 in line with recent report by 
Katsumi et al. (2011). Therefore, we predicted that A375 should show preferential sensitivity towards
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PD0332991 treatment. However, this tumour might develop acquired resistance towards PD0332991 
treatment over time. Thus, we are interested in investigating the resistance mechanism adopted by 
these PD0332991-resistant cells in order to avoid cell death (Figure 7-3).
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Figure 7-3: a) W ithout p l6   ^in A375 cell line, carcinogenic stimuli promote unrestricted cancer cell growth and proliferation, 
b) PD0332991 inhibits CDK4/6 activity thus promotes cell death via Gj cell cycle arrest. However in time, some of these cells 
treated with PD0332991 may survive and develops PD0332991 resistance.
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Aim
To develop a novel PD0332991-resistant cell line from melanoma cell line A375 and to investigate 
resistance mechanisms adopted by the PD0332991-resistant cells.
Hypothesis
The generation o f a cell line w ith acquired drug resistance to the CDK4/6 inhibitor PD0332991 may help 
to identify biomarkers of response in cancer cells w ith a deficiency in
Materials
A375 cells were grown in RPMI supplemented w ith 10% PCS and Ix  GlutaMAX™. MTT reagent was 
prepared as previously mentioned. Antibodies used were ATM, ATR, CHKl, CHK2, W ee l and GAPDH. 
PD0332991 (Selleck Chemicals, Houston, US) stock was prepared by diluting the drug in DMSO at a 
concentration of lOmM and 20mM. Stocks were stored at -20°C.
Methods
A375 (later designed as parental cell line A375) was seeded at 1:10 ratio. Cytotoxicity assay using MTT 
(spanning over two logs o f concentration) was done on parental cell line to determine the initial dosage 
of PD0332991 (based on its IC50 value) for resistant cell line development. Calculation o f IC50 was carried 
out using Microsoft excel and verified using graphPAD PRISM software. Cells were seeded at 4x10"  ^
cells/mL and treated w ith PD0332991 for 72 hours before the addition of MTT reagent. Based on the
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IC50 value calculated from the results o f MTT, an initial dose o f PD0332991 was chosen, which is 
approximately 10% of the IC50 value, as described in Coley (2004). The dose was increased to lOpM 
based on the overall cell growth characteristic after several passages. Cells were passaged 1:5 ratio and 
treated step-wise w ith increasing dose of PD0332991 fo r every other passage. This was to  ensure that 
only a m inority of cells tolerated the chemical insult. Surviving cells that escape cell death via drug 
treatment were then let to recover in the drug-free passage. Subsequent drug-resistant cells were 
designated as A375PDR and maintained w ith a lOpM dose of PD0332991 fo r every other passage. After 
several passages, A375 and A375PDR cells were subjected to viability assay using MTT to determine the 
level of resistance acquired. Cell count was kept identical fo r both cell lines (4x10^  ^cells/mL) and there 
was no obvious change in the growth rate of A375PDR relative to  the A375 parent line. Cells were also 
harvested for protein as previously stated. Loading o f 30pg/well protein lysates were then subjected to  
SDS-PAGE electrophoresis followed by western blotting to  assess constitutive expression of several 
proteins of interest (ATM, ATR, CHKl, Chk2 and W eel). 24- and 48-hour time-point protein harvest 
following treatment with PD0332991 was carried out to  look at the expression level o f survivin and 
p2 7 K'pi proteins in both cell lines. Cells were seeded in a T25 flask at a cell density of 4x10^  ^cells/mL in 
lOmL. Cells were then treated with lOpM PD0332991. After each time point, cells were harvested fo r 
protein as previously and lysates were run through SDS-PAGE and western blotting. Cells were also 
harvested for DNA content analysis, as previously described in other chapter and then subjected to flow  
cytometry to assess any cell cycle associated changes in DNA content before and after PD0332991 
treatment.
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Results
Viability assay testing on the A375 parental cell line indicated an IC50 of 9.1pM (±0.07pM) (n=3) for 
PD0332991. A375 cells were then treated with increasing PD0332991 concentration for several 
alternative passages before the dose was increased to 8 pM and subsequently to lOpM as a 
maintenance dose.
1. Assessment of resistance
Dose-response curve of PD0332991 in A375 and A375PDR
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Figure 7-4: IC50 analysis of A375 melanoma parental cell line versus PD0332991-resistant derivative A375PDR. Log dose of 
PD0332991 (pM) was plotted against percentage viability of ceils compared to untreated control ceils. Each data point 
represents different drug dosage and its matching comparative ceil viability. A375 parental ceil line was represented by red 
dots while A375PDR was represented by blue square points (n=3).
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The viability assay using MTT was carried out on both cell lines and showed the IC50 value of 22.94pM 
(±0.06pM) for A375PDR. The resistance factor (ratio of IC50 fo r resistant cell line relative to parental cell 
line) was shown to be a 2.5-fold for PD0332991.
2. Assessment of cell cycle regulators and DDR proteins
A375 A375PDR HeLa
Approx. SSOKDa 
Approx. 250KDa
Approx. 56KDa 
Approx. 62KDa 
Approx. 85KDa 
Approx. 42KDa
ATM
ATR
CHKl
CHK2
W eel
Actin
Figure 7-5: Western blotting result of A375 and PD0332991-resistant A375PDR showing the level of cell cycle regulators and 
DDR proteins. HeLa acted as a positive control while Actin as loading control (n=3).
Based on western blotting results, A375PDR showed a minor decrease in ATM and no significant 
difference of Chk2 expression compared to parental cell line. There was also no significant difference of 
ATR expression in both cell lines. However, there was a significant increase of Chkl and a slight increase 
of W eel in A375PDR in comparison to A375. Of note, A375 expressed a wild-type p53 (Min et al. 2005) 
(the p53 western blotting result was not shown) while p53 status in the A375PDR is yet to be assessed.
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3. Western blotting on time-point samples
3.1 Survivin
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Figure 7-6: Expression level of survivin in A375 and A375PDR at 0, 24 and 48 hours, without and with lOpM PD0332991.
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The graph under each western blotting represents the densitometric analysis performed on western blotting results, a) Refers 
to the parental cell line A375. b) Refers to  the PD0332991-resistant A375PDR. Actin acted as a loading control. Both sets of 
western blotting were run simultaneously with each other. (*p<0.05) (n-3)
Based on western blotting results, survivin was expressed by both A375 and A375PDR cell lines. 
However, the quantitative protein expression pattern varied between the cell lines. Survivin expression 
in untreated parental cells was unchanged throughout 48 hours. Treatment with PD0332991 brought 
about significant downregulation o f protein 24 hours post-treatment. However by 48 hours, survivin was 
re-expressed albeit at a lower level compared to control untreated A375. In contrast, survivin expression 
in A375PDR increased over time and interestingly, PD0332991 treatment reduced survivin level as early 
as 24 hours post-treatment. The level was kept approximately similar as in untreated control at 0-hour 
time point w ithout any significant differences.
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3.2 p27«ipi
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Figure 7-7: p27' '^'’  ^protein expression in A375 and PD0332991-resistant A375PDR at 0, 24 and 48 hours, without and with 
lOpM PD0332991.
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The graph under each figure represents densitometric analysis performed on western blotting results.a) Refers to the parental 
cell line A375. b) Refers to  the PD0332991-resistant A375PDR. Actin was used as loading control (n=3). Both sets o f western 
blotting were run simultaneously w ith each other.
Based on the western blotting results, p27' '^'"  ^expression in PD0332991-resistant A375 was higher 
compared to  the parental cell line A375 at 24 and 48 hour. p27'"'^  ^expression was induced by 
PD0332991 treatm ent in A375 as shown by the bands at 24 and 48 hour post-treatment in comparison 
w ith the control at the same time point. However, similar dose of PD0332991 treatment on the 
A375PDR does not give any significant changes to  the level o f p27' '^^  ^at 24 and 48 hours after treatment 
compared to the control.
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4. DNA content before and after PD0332991 treatment
4.1 DNA histograms of A375 (parental cell line) before and after PD0332991 treatment
Control + PD0332991
a) 24h
G,= 58.0% ±0.16
G z M : 31.1% ±0.26
Control
b) 48 h
5
S = 8.4% ± 0.20 
GjM = 25.6% ± 0.45
G i S
G,= 76.6% ± 0.58 
S = 3.4% ±1.37 
G,M= 19.9% ±0.79
GglVI
*0' 10' to' 10'
+ PD0332991
X
G ^S
G,= 68.9% ± 10.18
S =  11.8% ±9.92  ^
G,M = 19.3% ±0 .2 6  !
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Figure 7-8: DNA histogram of parental cell line A375 before and after PD0332991 treatment. Analysis was done using flow 
cytometry, a) DNA content after 24 hours of PD0332991 treatment. Left panel was control cells while right panel was 
PD0332991-treated cells. Changes in peak sizes of both G^ S and G2M peaks can be clearly seen, b) DNA content after 48 hours 
PD0332991 treatment. Left panel was control cells while right panel was PD0332991-treated cells. G2IVI peak was evidently 
smaller. (n=2)
Based on the DNA histograms (Figure 7-8), treatment with PD0332991 considerably reduced the G2M 
peak size, indicating a Gi phase cell cycle arrest in A375 parental cell line compared to the untreated
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control. The effect was evident after 24-hour PD0332991 treatment and prolonged until 48 hours post 
treatment w ithout any significant differences seen between the two values (at 24 and 48 hours).
4.2 DNA histograms of A375PDR before and after PD0332991 treatment
Control + PD0332991
a) 24h
b) 48h
/
G i S G 2 M
G,= 49.4% ±1.78 1 8 = 11.6% ±0.72 1 
G,M = 39.0% ±1.06 1
1 1 HI 1 1 1 1 1 It
Control
G,= 53.9% ± 0.87 
3 = 10.8% ±0.16 
G,M = 35.3% ± 0.71
S
G,= 74.9% ± 0.20
G;M = 22.4% ± 0.09
+ PD0332991
y
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Figure 7-9: DNA histogram of PD0332991-resistant cell line A375PDR before and after PD0332991 treatment. Analysis was 
done using flow cytometry. Similar pattern of response as A375 parental cell line was seen in A375PDR. a) DNA content after 24 
hours of PD0332991 treatment. Left panel was control cells while right panel was PD0332991-treated cells. Changes in the peak 
sizes of both G^ S and G2M peaks can be clearly seen, b) DNA content after 48 hours PD0332991 treatment. Left panel was 
control cells while right panel was PD0332991-treated cells. G2M peak was evidently smaller. (n=2)
Based on the histograms above (Figure 7-9), similar DNA profile as the A375 parental cell line was 
observed in PD0332991-resistant A375PDR, w ithout and with PD0332991 treatment for 24 and 48
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hours. In control cells, a slightly bigger Gi peak was observed in the untreated A375PDR compared to 
the untreated A375 parental cells. The Gj cell cycle arrest was observed in 24 and 48-hour PD0332991- 
treated samples of A375PDR as shown by the evidently smaller G2 M peak relative to  the respective 
controls.
Discussion
Cell cycle deregulation is a common event in cancer development. In normal cells, cell cycle regulation is 
paramount in order to make sure that only unaffected cells survive. This tight regulation comes from 
variety of proteins working together in a concert, involving a very complex web of mechanisms and 
pathways coming together to ensure the survival o f normal cells. Treatment using chemotherapy (either 
single agent or combination of agents) or radiotherapy in most cases provides the means to  stop 
cancerous growth. However, certain types of cancer can develop resistance towards agents used to 
treat them. An example is ovarian cancer, which can develop platinum refractory disease.
Development o f a new class of more targeted therapy has been going on fo r quite some time. The main 
aim of this therapy is to provide treatment that is more effective w ith fewer side effects. There have 
been several success stories of targeted therapy. One o f them is the development of Herceptin to  treat 
breast cancer w ith higher success rate compared to  conventional chemotherapy treatment. Several 
other compounds currently under development show promise as potential new therapeutic agents. This 
has in part been fuelled by the study of drug resistant mechanisms. Since cell cycle is the driving force of 
the cell itself, a lot o f research has been conducted on the deregulation of its components in 
carcinogenesis since it provides many druggable targets. The work described in the present thesis 
emphasizes the close relationship between cell cycle deregulation and anticancer drug resistance.
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In this study, we would like to  look at the probability o f cancer cells acquiring resistance towards 
targeted therapy designed to  treat them effectively. The A375 cell line was chosen based on its specific 
genetic make-up i.e. pls"^'^''*-deletion. is a member of the CKI group INK4 which inhibits CDK4
and CDK6 . Hypothetically, pis'^'^^^-deleted A375 cells should have unchecked GiS phase progression 
that comes from the downregulation of endogenous CKI and unrestrained CDK4/6 activity. Treatment 
w ith the CDK4/6 inhibitor PD0332991 will affect CDK4/6 activity, leading to  the cell cycle arrest at Gi 
phase.
Based on the IC50 analysis, we successfully developed PD0332991-resistant A375 cell line to  achieve 
clinically relevant level o f resistance. In comparison with other established drug-resistant cell lines, 
resistance level acquired was adequate. There might be a possibility to produce a higher level of 
resistance in the future. Additionally, higher resistance level seen in other cell lines may reflect the 
selectivity o f the agents themselves and the genetic make-up of the respective cell line.
Several changes were seen in cell cycle components collaterally w ith acquired drug resistant phenotype 
development. More focus was put on the deregulation of G2M cell cycle components, which are ATM, 
ATR, Chkl, Chk2 and W eel, mainly involved in DNA damage recognition. W ee l negatively regulates 
CDKl activity via inhibitory phosphorylation, reducing active CDKl in the cell thus stalling cell cycle 
progression from G2 to  M phase. ATM and Chk2 were part o f the double strand break (DSB) type of 
damage recognition sensors while ATR, Chkl and W eel were part o f sensors fo r a single strand break 
caused by UV or DNA intercalation agents such as platinum compounds. Higher expression of Chkl and 
W ee l seen in A375PDR cells might have been a part o f the survival mechanism adopted by the cells 
upon PD0332991 treatment. Higher W ee l and Chkl expression in A375PDR might be due to the
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upregulation of CDC25 (as yet not assessed) as a way of compensating fo r lack of CDK4/6 activity. In cell 
cycle, CDC25 promotes CDK4/6 activity by removing inhibitory phosphates (Qu et al. 2003). Hence, 
A375PDR cells might have elevated CDC25 levels, which may increase the possibility o f activating 
CDK4/6 despite the inhibitory action of PD0332991. The level o f activation might not be as high but 
adequate for Rb-phosphorylation, which enables cell cycle progression from Gi to S phase. Elevated 
Chkl and W ee l might be a normal response to higher CDC25 levels, since Chkl negatively regulates 
CDC25 and in turn promotes W ee l expression. However further investigation was not conducted due to 
time constraint.
Survivin, as the name suggests is an inhibitor o f apoptosis protein and a marker fo r cell survival 
(Yamamoto et al. 2008). Cancer cells have higher survivin expression compared to normal cells hence it 
is a good biomarker (Duffy et al. 2007; Jha et al. 2012). p27'^"’  ^conversely is a CKI w ithin CIP/KIP family 
which involves in the regulation o f CDK2-CyclinE activity at the restriction point between the Gi and the 
S phase (Nam and Kim 2008). Based on western blotting results, changes were seen in Survivin and 
p2 7 kipi protein expression level and pattern before and after PD0332991 treatment. A375PDR has a 
lower survivin expression compared to parental A375, however the level did return to  match the 
parental cell line by 48 hours. Even though a similar effect as observed in the parental cell line was also 
seen in A375PDR after PD0332991 treatment, residual survivin expression still can be detected after 48 
hours. This shown that the cells have gained some survival advantages that enables them to withstand 
chemical stress given. Treatment w ith PD0332991 promotes p27' '^’’  ^expression in A375, which is evident 
after 48 hours treatment. This might be due to the p27"^ '"'^  transactivation by p53 following chemical 
stress from PD0332991 treatment. According to literature, A375 express wild-type p53 (Min et al. 2005) 
and the status of p53 expression in A375 cells utilised in this study was assessed previously (data not
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shown). The association of expression with p53 status in cancers have been documented in a 
number of studies (Casalini et al. 2007; Min et al. 2005). Based on the pattern o f p27'"'^  ^expression in 
both cell lines (parent and drug-resistant), p53 might play a role in the p27"^ '"^  ^expression after 
PD0332991 treatm ent in A375, and possibly in A375PDR as well, as part of the stress response.
Flow cytometry results clearly showed the effect o f PD0332991 treatment to cancer cells. However, 
there were no significant differences o f DNA content between A375 and A375PDR control cells. It 
indicated that A375PDR somehow retained a similar DNA content despite changes acquired during 
resistance development. However, PD0332991 treatment caused a specific and prominent Gi arrest on 
both cell lines seen as early as 24 hours post-treatment. There is similar observation o f a specific Gx cell 
cycle arrest reported by other researchers working with different cell lines (Collins and Garrett 2005;
Finn et al. 2009). Despite drug treatment dose was a maintenance dose, PD0332991 still able to evoke 
such response in A375PDR. A possible explanation may be due to the phenotype instability o f the 
resistant cell line.
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Cell cycle perturbation is a common event in carcinogenesis. Changes associated w ith cell cycle are 
diverse and may reflect the tissue o f origin. However, a general pattern of deregulation can be seen in 
several drug-sensitive and drug-resistant cancer types studied particularly concerning the components 
of the G2M cell cycle checkpoint. To consider this further, in the context o f anticancer drug resistance, 
cell cycle regulators such as W ee l and other key cell cycle associated factors such as p53 and Chkl were 
deregulated in several drug resistant cancer cell lines in comparison w ith their drug sensitive 
counterparts. This general trend also shows the importance o f these proteins in regulating cell cycle 
thus makes the case for cell cycle control as being a key factor associated w ith cancer cells in order to 
obtain limitless growth advantage even in the presence o f powerful chemotherapeutic drugs, such as 
Taxol.
Changes in cell cycle regulation in cancer cells are related to their dependence towards genetic 
alteration, a condition known as "oncogene addiction". This is a term coined to  explain the observation 
o f persistent and similar genetic changes seen in cancer cells, including components o f cell cycle. 
Examples of oncogene addiction are high expression of myc in osteogenic sarcoma and cydinDl in 
pancreatic cancer cells (Jain et al. 2002; Nijman 2011; Weinstein 2002). Despite the fact that oncogene 
addiction gives growth advantage to cancer cells, it renders them vulnerable to sudden genetic changes 
introduced, such as inactivation of oncogenes or reactivation o f tum our suppressors. Jain et al. (2002) 
working on transgenic mouse showed that myc overexpression preceded formation o f osteogenic 
sarcoma but also brief loss of this oncogene overexpression prompted sarcoma cells to differentiate into 
normal osteocytes. However, reactivation of myc overexpression in these cells drives them into 
apoptosis, showing the vulnerability of cancer cells toward sudden genetic changes. In the present
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study, oncogene addiction can be seen as a condition to  describe in drug-resistant ovarian cancer cell 
lines. These cell lines showed overexpression of CyclinE, Survivin and E2F1 which are all implicated in cell 
cycle progression.
Molecular changes acquired by drug-resistant cancer cells distinguished them from their wild-type 
counterparts. Apart from gaining growth advantages, these molecular changes also mean genetic 
instability thus presenting a window of opportunity for possible new targeted therapies. In the study of 
pS?' '^'’  ^ in platinum-resistant ovarian cancer, downregulation of p57'^'’^  ^plays a role in platinum 
resistance. However, it is also confers collateral sensitivity towards seliciclib. This might be beneficial as 
a guide for treating ovarian cancer patients that relapsed after platinum treatment. According to  Hall et 
al. (2009), the concept of collateral sensitivity was originally used to explain hypersensitivity o f drug- 
resistant E. co//towards other unrelated agents. It is also used in drug study to  explain a similar 
phenomenon observed in drug-resistant cells (Coley et al. 2012; Hall et al. 2009). An example of 
collateral sensitivity in drug-resistant cells was demonstrated by Nakajima et al. (2010) in human 
ovarian cancer cells PX2 and PX24 and also in MCF-7 cells w ith acquired resistance to  paclitaxel 
(Ajabnoor et al. 2012). These cells acquired paclitaxel resistance w ith cross-resistance to docetaxel, 
another taxane agent. However, all drug resistant cell lines showed collateral sensitivity to platinum 
agent cisplatin (Coley et al. 2012; Nakajima et al. 2010). In this study, cross-resistance was seen in 
platinum-resistant ovarian cancer cell lines PEOlCarbR and PEOlCisR. Both cell lines have shown cross­
resistance to cisplatin and carboplatin respectively even w ith a different genetic background such as the 
difference in the expression level o f p57' '^'’  ^and several other cell cycle proteins. Additionally, more cell 
death was seen in combination treatment compared to single drug treatment in drug-sensitive cancer 
and synergistic action o f the two drugs was confirmed via isobologram analysis. This result might prove
2 2 0
[CHAPTER 8]
to be useful in clinical settings in order to  prevent carboplatin resistance in ovarian cancer patients as 
they have been shown to relapse after treatment with this agent. A subset of cancer patients that have 
gained drug resistance particularly towards Taxol might benefit from the study o f W ee l status. Even 
though the study o f W ee l presented here is still in its early phase, it shows the potential as a biomarker 
or as a treatment guide for a specific subset o f cancer patients.
Drug resistance arises as a consequence of cellular alteration gained during the course of treatment. 
Ovarian cancer is notoriously known fo r its ability to  relapse after chemotherapy after gaining drug 
resistance. Other types o f cancer such as breast cancer are also known to acquire drug resistance. 
Alteration of cell cycle components is one o f the molecular perturbations seen in drug-resistant cancer 
cells. The present study shows that alteration o f cell cycle components as part o f the drug resistance 
phenotype varies depending on the inducing agent and tissue o f origin. p53 status is also believed to 
have an influence in the expression o f other key cell cycle regulator in most cell lines and some o f the 
data obtained in the present study support that. In addition, a general pattern was seen w ith alteration 
in ATR-Chkl-Weel pathway in the majority of cell lines studied. Epigenetic modification was believed to 
be involved in downregulation o f W ee l and SEN in selected drug-resistant cell lines studied. This cellular 
event was also shown to be the cause of p57'^ ''^^  downregulation in drug-resistant ovarian cancer. Studies 
such as this, point to parameters associated w ith cell cycle perturbation such as a source of potential 
biomarker in cancer treatment, choosing the right agent to  use and predicting the outcome of the 
treatment especially for a group of cancer patients with a specific genetic background. In this study, 
p57' '^'"  ^and W ee l was identified as potential candidate biomarkers for use as prognostic indicators. 
p57' '^'"  ^in the formed of its specific methylated DNA, is a possible candidate fo r predicting platinum 
resistance in ovarian cancer and determining seliciclib sensitivity. W ee l also emerges as an interesting
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parameter, particularly in the case of taxane sensitivity. However, this area still requires more 
investigation.
Finally, cell culture is an important in vitro instrument to  study cellular mechanisms behind drug 
resistance and to study drug properties. It is accessible as the study can be conducted in the laboratory. 
Cell culture also provides an environment close enough to mimic in vivo milieu. It is particularly useful in 
the study of acquired drug resistance. Hence, the technique was utilized fo r the development o f drug- 
resistant melanoma in order to study its mechanisms of PD0332991 resistance.
In conclusion, the study of cell cycle regulation has provided more insight into the problem o f anticancer 
drug resistance.
Challenges and future work
Development o f a novel drug-resistant cell lines require a set of trial and errors in order to  determine 
the best culture conditions. It has to be noted that this project is in its early stage and there are 
possibilities of further analysis of the drug resistant phenotype. Development of higher resistance level 
coupled w ith further tests to confirm resistance and phenotype stability could be carried out. As 
explained previously, higher resistance level can be achieved via periodic exposure to increasing level o f 
the drug fo r a certain period. Cancer cells w ith varying levels o f resistance to each other might have 
acquired a different adaptation mechanism. Thus, analysis performed on these cell lines might give 
beneficial information to assist patients during different stages o f cancer treatment using said agent. 
These cells may also possess different sensitivity towards other agents as well. Drug combination
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treatm ent followed by isobologram analysis on these cells might yield additional information. However, 
it must be kept in mind that drug resistance achieved in vitro must correlates with the actual level of 
drug resistance acquired by patients in clinical settings. Nevertheless, cancer cell lines with higher drug 
resistance level might reveals other cellular mechanisms that can be an interesting subject to study.
Data presented in this study will benefit from more supporting data such as mRNA level fo r proteins of 
interest, and screening and assessment of other regulatory proteins involved in the pathway for 
instance CDC25, p53, Rbp and CDK4/6. Additionally, survivin as an inhibitor of apoptosis shows potential 
as an interesting target for a marker of PD0332991 resistance in melanoma thus requires further 
investigation on its exact role in acquired drug resistance mechanisms. Survivin might play a major role 
as part of an adaptation mechanism acquired by cancer cells to  withstand chemical insults. However, 
another key player (p53) which is upstream o f survivin might also influences cellular response towards 
drugs. Thus, establishing the role of p53 is vital in building the case o f survivin role in PD0332991- 
resistant melanoma. This is also the case for W ee l and SFN in Taxol resistance. Since they are 
downstream targets of p53 and p53 status might influence cellular response to Taxol as well. 
Consideration o f the genetic background is also important in choosing the suitable model to  study drug 
resistance.
Finally, knock-in experiment followed by drug treatment may be helpful in determining the role of 
protein of interest in a specific drug-resistance mechanism, for example W ee l in Taxol resistance. It has 
been shown in this study that W ee l downregulation was seen in a certain Taxol-resistant cancer cells 
and Weel silencing influences cellular Taxol response. Additionally, works carried out by Mariam and 
Coley (unpublished data, 2013) on MCF7TaxR (higher W ee l expression compared to parental cell line
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MCF7) shown that W ee l knock-out re-sensitized Taxol-resistant breast cancer to  Taxol trea tm ent Thus, 
W ee l knock-in experiment on the parental cell line MCF7 might give a clue on W ee l role in Taxol 
resistance acquired by MCF7TaxR. Furthermore, this might also applicable to other cell lines w ith similar 
genetic background as well.
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